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Xiaoting Wang 
NEURAL REPAIR BY ENHANCING ENDOGENOUS HIPPOCAMPAL 
NEUROGENESIS FOLLOWING TRAUMATIC BRAIN INJURY 
Traumatic brain injury (TBI) is a critical public health issue in the United 
States, affecting about 2.8 million people annually. Extensive cell death and 
neural degeneration directly and diffusively caused by the initial mechanical insult 
results in a wide range of neurological complications post-trauma. Learning and 
memory dysfunction is one of the most common complains. Hippocampal 
neuronal loss, together with other mechanisms, largely contributes to learning 
and memory impairment as well as other cognitive dysfunctions post-trauma. To 
date, no FDA-approved drug is available to target cell death or improve learning 
and memory following TBI. It is of great interest to develop alternative 
approaches targeting neural repair instead. 
Neural stem/progenitor cells (NSCs) in the adult hippocampus undergo 
life-long neurogenesis supporting learning and memory functions, thus hold great 
promise for post-traumatic neuronal replacement. The previous studies 
demonstrated that TBI transiently increase NSC proliferation. However, it is 
debated on whether TBI affects neurogenesis. The mechanism of TBI-enhanced 
NSC proliferation remains elusive. In the current studies, I have investigated 
post-traumatic neurogenesis after different injury severities, evaluated integration 
of post-injury born neurons, illustrated a molecular mechanism mediating TBI-
enhanced NSC proliferation, proposed a de novo state of NSCs, and tested 
vii 
 
effects of a pharmacological approach on spatial learning and memory function 
recovery.  
My results demonstrated that post-traumatic neurogenesis is affected by 
injury severities, partially explained the pre-existing inconsistency among works 
from different groups. Post-injury born neurons integrate in neural network and 
receive local and distal inputs. TBI promotes functional recruitment of post-injury 
born neurons into neural circuits. Mechanistically, mechanistic target of 
rapamycin (mTOR) pathway is required primarily for TBI-enhanced NSC 
proliferation; NSCs feature a de novo alert state, in which NSCs are reversibly 
released from quiescence and primed for proliferation. Furthermore, my data 
demonstrated a beneficial role of ketamine in improving post-traumatic spatial 
learning possibly by activating mTOR signal in NSCs and/or promoting neuronal 
activity of post-injury born neurons. Together, my data support the feasibility of 
neurogenesis mediated neuronal replacement, provide a target for enhancing 
post-traumatic NSC proliferation and subsequent neurogenesis, and prove a 
potential pharmacological approach benefiting post-traumatic functional recovery 
in learning and memory. 
Xiao-Ming Xu, Ph.D., Chair 
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CHAPTER 1 
INTRODUCTION 
 
Background 
As one of the most impactful socio-economic issues, traumatic brain injury (TBI) 
is rising in public awareness and attention on its high prevalence and serious 
sequelae. According to published data from the Centers for Disease Control and 
Prevention (CDC), about 2.5 million TBI-associated hospital visits are reported 
each year (Thomas R. Frieden, 2013). Death occurs in nearly 52,000 patients, 
while survivors are subjected to physical disabilities and a wide range of 
neurological complications including cognitive deficits, post-traumatic seizure, 
Alzheimer’s disease, Parkinson’s disease and various psychiatric diseases as 
well (Prigatano, 2005, Salmond and Sahakian, 2005, Vespa et al., 2010, 
Sivanandam and Thakur, 2012, Marras et al., 2014, Perry et al., 2015). 
Consequently, quality of life after TBI is largely compromised, especially for 
pediatric TBI cases (McCarthy et al., 2005, Hung et al., 2014). Although multiple 
pathological changes have been observed after TBI in both human subjects (by 
multiple neuroimaging techniques (Bodanapally et al., 2015)), and in animal 
models (by histological analysis (McIntosh et al., 1998)), effective therapy against 
TBI is an unmet clinical need.  
Diffuse axonal injury, dendritic damage, and neuronal cell loss together 
directly cause neurodegeneration and disrupt intrinsic connectivity network in the 
brain (Sharp et al., 2014, Lu et al., 2005, Hall et al., 2008, Saatman et al., 2006), 
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accompanied by indirect impacts, such as neuroinflammation and neurovascular 
destruction (Nortje and Menon, 2004), which further deteriorates the brain injury. 
Cell death that affects a large number of areas in the brain is one of the most 
detrimental events following TBI (Saatman et al., 2006, Lu et al., 2005, Hall et al., 
2008). Depending on the compromised region, neuronal loss can contribute to 
disconnection in neurocircuitries regulating body movement, cognitive and/or 
emotion functions. Thus, approaches aimed at neuroprotection or neural repair 
against cell death are urgently desired. Although numerous attempts and 
investigations have been conducted on neuroprotection reagent development 
(Alzheimer and Werner, 2002, Xiong et al., 2008, Xiong et al., 2007, Xiong et al., 
2009, Wu et al., 2014, Chen et al., 2015), there have been no successes as of 
yet in the clinic. As an alternative approach, enhancement of neural repair 
following TBI is of great interest in the field.  
Stem cells, a powerful tool for regenerative medicine, no doubt hold great 
promise in the area of neural repair. Several types of non-neural human stem 
cells, such as umbilical cord blood stem cells, mesenchymal stem cells, and 
marrow stromal stem cells, have been transplanted into rodent TBI models. 
Although there was improvement in functional outcomes, it was only related to 
the neuroprotective effects through structural and/or nutritional support rather 
than direct neural repair (Mastro-Martinez et al., 2015, Mahmood et al., 2005, 
Sykova and Jendelova, 2005). The discovery of neural stem/progenitor cells 
(NSC) in adult animals and humans provides ideal resources and hope for 
authentic network replenishment and restoration (Ming and Song, 2005). Both 
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transplantation of in vitro expanded NSCs and intervention on endogenous NSCs 
are considered as potential therapeutics. Several groups have demonstrated that 
NSC proliferation in the adult brain is promoted by TBI (Dash et al., 2001, Kernie 
et al., 2001, Ramaswamy et al., 2005, Rice et al., 2003, Rola et al., 2006, Sun et 
al., 2005, Sun et al., 2007, Yu et al., 2008, Gao et al., 2009a, Gao and Chen, 
2013, Chirumamilla et al., 2002), indicating an innate repair mechanism and 
suggesting interventions on endogenous NSC-mediated neurogenesis as a 
promising approach for neuronal replacement. Indeed, enhanced neurogenesis 
has shown correlation with improved cognitive function recovery post-trauma (Lu 
et al., 2005, Lu et al., 2007, Kleindienst et al., 2005, Lu et al., 2003, Sun et al., 
2009, Xiong et al., 2009, Xiong et al., 2008), thus further illustrating the feasibility 
of repairing neuronal loss and restoring damaged behavioral functions by 
enhancing endogenous neurogenesis. However, there is still a discrepancy on 
neurogenesis level alteration after TBI, inquiries into properties of post-injury 
born neurons, demand on mechanistic studies of TBI-mediated NSC activities, 
and the urgent need for therapeutics targeting neurogenesis and cognitive 
function improvement after TBI. This body of work would focus on these gaps in 
the knowledge base and provide new perspectives and insight into a number of 
TBI related issues: (1) depict a baseline of TBI reshaped neurogenesis, (2) 
demonstrate the anatomical and functional integration of post-injury born 
neurons, (3) illustrate a mechanism of mammalian target of rapamycin (mTOR) 
signaling mediated TBI-enhanced NSC proliferation, and (4) investigate a 
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pharmacological approach focused on endogenous neurogenesis and cognitive 
functional improvement.  
 
Hippocampal cell death and cognitive function deficits following TBI 
As a complicated disease process, TBI is composed of initial insult caused 
primary injury, which is followed by prolonged secondary injury. Thus, damage is 
not restricted to focal site, but diffusively and progressively impacts a much larger 
area of the brain parenchyma (McIntosh et al., 1998). To reproduce pathological 
alterations in humans, several animal TBI models were developed. Although 
many of them were developed to induce TBI in medium-sized animals, like cats 
and ferrets, they were subsequently remodeled to fit rodents later. Although each 
TBI animal model replicates some of the different pathophysiological events 
observed in human cases, neuronal loss is one of the common features shared 
by all the models studied to date (Morales et al., 2005). Following injury, diffusive 
cell death occurs in various cortical and subcortical regions, among which the 
hippocampus is noteworthily vulnerable.  
In 1989, Cortez and colleagues observed rapid neuronal counts loss in the 
CA2-CA3 region of the ipsilateral hippocampus within 24 h of lateral fluid 
percussion (FPI) injury. The effects lasted for at least 4 weeks when less residual 
neurons were detected (Cortez et al., 1989). Later on, hilar neuron death was 
selectively identified, and consequent granule neuron hyperactivity was recorded 
in the same injury model (Lowenstein et al., 1992). In 1993, hippocampal neuron 
loss was first associated with cognitive deficits after TBI, where a positive 
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correlation was demonstrated between hilar neuron survival after FPI and 
performances in Morris Water Maze test (Hicks et al., 1993). The temporal and 
spatial profile of hippocampal neuronal loss was then characterized in great 
detail for FPI-induced trauma (Hicks et al., 1996, Sato et al., 2001). 
Although different from diffusive injury caused by FPI model, the focal 
injury induced by controlled cortical impact (CCI) model displays hippocampal 
cell loss in a similar pattern. In 1995, McIntosh group customized a CCI model for 
study in mice and observed damaged neurons at 48 h after injury in hippocampal 
CA2-CA3, CA3, and dentate gyrus regions. These injuries corresponded to 
memory deficits (Smith et al., 1995). The research was further expanded on to a 
longer temporal profile with neuronal dystrophy and necrotic and/or apoptotic 
dentate granule neuron death detected up to 4 weeks post-trauma (Colicos et al., 
1996, Chen et al., 2003, Lu et al., 2005, Hall et al., 2008, Colicos and Dash, 
1996). My colleagues pinpointed predominant death of immature but not mature 
neurons in the dentate gyrus and proved strong evidence that a necrotic but not 
apoptotic cell death was the underlying mechanism of immature neuron death. 
My colleagues previously found that the necrotic immature neuron death occurs 
intensively and promptly within 24 h after moderate CCI injury (Gao et al., 2008, 
Zhou et al., 2012). Although detailed spatial-temporal and mechanistic 
characterizations are not exactly the same among the different studies published 
in this area, the fact that a significant neuronal loss happens in the hippocampus 
and the loss is correlated with cognitive functions deficits, especially learning and 
memory dysfunction, after TBI is consistent across all the studies. Additionally, it 
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is relatively clear that the therapeutic window for preventing cell death is narrow 
for therapy must be received within 24 h of injury.  
So far, around 30 clinical trials have been conducted on neuroprotective 
reagents to minimize neuronal death. However, none of them has yet to succeed 
(Kabadi and Faden, 2014). Alternatively, regenerative medicine, specifically stem 
cell therapy, provides a new route to promote neural repair instead. Current 
efforts have been largely focused on stem cell transplantation, and some 
promising studies have shown improved motor and/or learning functions in 
rodents. However, a few concerns regarding cell source, dosage, and delivery 
have greatly restricted clinical translation (Gennai et al., 2015). It is possible that 
utilization of endogenous NSCs could achieve neural repair and restore the 
injured hippocampus and at the same time bypass the barriers mentioned above.  
 
Neurogenesis in the adult brain 
Conventionally, the adult brain was considered as a non-regenerative organ. 
Neurogenesis was traditionally deemed to only occur during embryogenesis and 
postnatal development. It was in the early 1960s when cell proliferation was first 
detected in the adult mouse brain by [H3]-thymidine labeling (Smart, 1961). Then 
a series of investigations proved that new neurons were also detected in adult rat 
brain (Altman and Das, 1965, Altman and Das, 1966, Altman, 1969). The 
Nottebohm group was the first to publish a series of papers that proved the 
functional involvement of adult neurogenesis in songbirds’ learning capacity 
(Nottebohm, 2002). Thereafter, the significance of adult neurogenesis was finally 
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recognized and accepted. Currently, NSCs are widely studied in adult canaries 
(Alvarez-Buylla et al., 1998), rodents (Reynolds and Weiss, 1992), primates 
(Kornack and Rakic, 1999), and humans (Kukekov et al., 1999, Roy et al., 2000). 
Investigators in the areas of NSC research agree that adult neurogenesis is 
mainly restricted to two neurogenic niches: the subventricular zone (SVZ) of the 
lateral ventricle and the subgranular zone (SGZ) of the hippocampal dentate 
gyrus (Figure 1.1). NSCs in the adult SVZ continuously generate precursors, 
which differentiate to neuroblasts, migrate via the rostral migratory stream, 
eventually arrive at the olfactory bulb, and become interneurons there (Doetsch 
et al., 1999, Ming and Song, 2005). NSCs in the adult SGZ also generate 
precursors, which commit mainly to neuronal differentiation and subsequently 
produce immature neurons. Newborn immature neurons migrate shortly from 
SGZ to granule cell layer, grow an extensive dendritic arborization, and become 
mature granule neurons, which eventually integrate into pre-existing neural 
circuits (Figure 1.2 A) (Zhao et al., 2006, van Praag et al., 2002, Ming and Song, 
2005, Cameron and McKay, 2001).  
 
Functions of adult neurogenesis 
The function of adult neurogenesis in both regions has been extensively studied 
via stimulatory or inhibitory interventions. In the SVZ, inhibition studies have 
suppressed adult neurogenesis using anti-mitotic reagents, focal irradiation, and 
genetic modifications respectively, and consequently odor discrimination deficits, 
short-term and long-term olfactory memory dysfunctions have been discovered   
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Figure 1.1: Neural stem cells (NSCs) in the adult mouse subventricular zone 
(SVZ) and subgranular zone (SGZ).  
Coronal sections from adult Nestin-GFP transgenic mouse. (A) GFP staining 
(green) shows NSCs locate in the SVZ. (B) Enlarged image of A (indicated by 
white box) to show GFP positive NSCs in the SVZ in higher magnification. (C) 
GFP staining (green) shows NSCs locate in the SGZ. (D) Single cell image to 
show GFP positive NSCs in the SGZ in higher magnification. 4’,6-diamidino-2-
phenylindole (DAPI) staining of nuclei shows brain structure. CC: corpus 
callosum; GCL: granule cell layer; HDG: hippocampal dentate gyrus; LV: lateral 
ventricle; SGZ: subgranular zone; SVZ: subventricular zone. Adapted from 
Figure 29.1 of Chen and Wang et al. (Chen, 2018). 
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Figure 1.2: Adult NSCs and neurogenesis in the normal hippocampus and after 
TBI. 
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(A) Adult NSCs in the hippocampus support neurogenesis. 1: Radial-glial like 
NSC mainly remain quiescence in the SGZ, 2: Small proportion of RGL NSC 
constantly under activation to proliferate, 3: Active RGL NSCs generate neuronal 
lineage committed immediate progenitor cell, 4: immediate progenitor cell 
differentiate to neuroblast, 5: neuroblast become immature neuron in the SGZ, 6: 
immature neuron migrated from SGZ to inner GCL, extend dendrites towards ML 
and axons towards CA3, 7: after prolonged morphological and 
electrophysiological maturation, mature neurons integrate in pre-existing circuits. 
LPP: lateral perforant path; MPP: medial perforant path. (B) TBI alters 
neurogenesis at multiple steps, including increasing NSC proliferation and induce 
ectopic migration of post-injury born neurons. It is not agreed on if TBI increases 
neurogenesis, and it is not thoroughly studied if TBI alters post-injury born 
neuron integration. 
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correspondingly (Gheusi et al., 2000, Breton-Provencher et al., 2009, Arruda-
Carvalho et al., 2014). In contrast, odor enrichment paradigm enhanced adult 
neurogenesis in the OB and promoted odor memory (Rochefort et al., 2002). 
Recent application of optogenetics further makes it possible to selectively excite 
adult-born OB neurons, and directly demonstrate their roles in facilitating learning 
and memory of odor discrimination in mice. Taken together, adult neurogenesis 
in the SVZ primarily participates in olfactory-associative functions. 
In the SGZ, adult neurogenesis is considered essential for long-lasting 
learning and memory capacity, in line with the fundamental role of the 
hippocampus. Enriched environment similarly increased adult hippocampal 
neurogenesis and improved spatial memory performances correspondingly in 
Morris Water Maze test (Kempermann et al., 1997, Nilsson et al., 1999).  An anti-
mitotic reagent induced defective neurogenesis in the hippocampus resulted in 
trace memory formation deficits in a mouse model (Shors et al., 2001). Similarly, 
when adult hippocampus neurogenesis was ablated in focal irradiated mice or 
transgenic mice with neural precursor elimination, these mice displayed 
impairments in contextual fear conditioning behavior but with spatial memory 
remained intact (Saxe et al., 2006, Kitamura et al., 2009). Additionally, with 
compromised adult hippocampal neurogenesis, fear memory extended the period 
of hippocampus dependency before it was transferred to cortical structures for 
permanent storage (Kitamura et al., 2009). Likewise, it is suggested that adult 
hippocampal neurogenesis is required for memory clearance instead of 
formation, since memory retention was negatively correlated with adult 
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neurogenesis in mice (Feng et al., 2001, Akers et al., 2014). Together, adult 
hippocampal neurogenesis plays critical roles in learning and memory functions 
in the adulthood, presumably by facilitating the formation of new memory and 
clearance of old memory.  
In an organism, adult neurogenesis is dynamically regulated by the 
physiological conditions and external stimuli. Aforesaid an enriched environment 
paradigm has been proven and is commonly used to increase neurogenesis in 
adult animals, similarly used methods include training with learning protocol and 
physical exercises such as running (Gould et al., 1999, van Praag et al., 1999, 
Kempermann et al., 1997, Nilsson et al., 1999, Rochefort et al., 2002). In 
contrast, age and stress were revealed to negatively modulate neurogenesis 
(Kuhn et al., 1996, Gould et al., 1997). These daily events together alter 
neurogenesis level dynamically, which coordinates with and determines animal 
behaviors. Likewise, under pathological conditions, the neurogenesis level is 
affected in a context-dependent manner. Brain injuries, such as stroke, epilepsy 
and TBI, have been reported to stimulate NSC proliferation and subsequently 
influence neurogenesis (Parent et al., 1997, Yagita et al., 2001, Parent et al., 
2002, Yamashita et al., 2006, Kernie et al., 2001, Rice et al., 2003, Braun et al., 
2002, Chirumamilla et al., 2002, Dash et al., 2001, Gao et al., 2009a). These 
observations suggest endogenous attempts of neuronal replacement mediated 
by NSCs. This innate repair machinery reveals a potential therapeutic target for 
clinical interferences and offers great promise for functional improvement. 
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TBI reshapes adult hippocampal neurogenesis  
In the case of TBI, cell proliferation, including NSC proliferation, is widely 
observed to increase in rodent hippocampus (Dash et al., 2001, Chirumamilla et 
al., 2002, Braun et al., 2002, Ramaswamy et al., 2005, Rice et al., 2003, Rola et 
al., 2006, Sun et al., 2005, Kernie et al., 2001). A study from human hippocampal 
tissues validated the increase of NSC proliferation (Zheng et al., 2013). My 
colleagues further pinpointed that it is quiescent NSCs but not their progeny, the 
active (neural progenitor cells) NPCs, who were mainly activated by TBI in mice 
(Gao et al., 2009a). These observations demonstrated an innate repair attempt 
for neuronal replacement, mediated by NSCs in the damaged adult 
hippocampus. Nevertheless, NSC proliferation is just the starting point of 
neurogenesis. The increase of NSC proliferation does not necessarily guarantee 
an increase of neurogenesis or functional improvement. There is indeed a 
controversy in the published literature regarding how TBI affects the generation 
of mature granule neurons, in which increased, decreased, or unchanged 
neurogenesis have all been reported by individual groups (Braun et al., 2002, 
Rola et al., 2006, Sun et al., 2005, Sun et al., 2007, Gao and Chen, 2013, Bye et 
al., 2011, Dash et al., 2001, Kernie et al., 2001, Rice et al., 2003). To better 
understand the effects of TBI on neurogenesis, it is necessary to carefully 
evaluate not only the NSC proliferation but also the status of every step during 
neurogenesis. This is critical since the injury environment may also affect 
newborn neuron survival, migration, maturation, morphology development, as 
well as anatomical and functional integration (Figure 1.2 B).  
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Newborn neuron survival after TBI 
Under physiological conditions, less than 25% adult-born granule neurons can 
survive the first three weeks after birth (Sierra et al., 2010, Christian et al., 2014, 
Tashiro et al., 2006). After trauma, how the injured environment impacts the 
survival rate of post-injury born neurons remains elusive. My colleagues 
previously reported rapid and dramatic cell death in the injured hippocampal 
dentate gyrus within 24 h after a moderate CCI injury. The cell death was 
revealed as selective loss of doublecortin-positive immature newborn neurons 
(Gao et al., 2008). The number of immature neurons returns to the level 
comparable to sham animals 2 weeks later, roughly the time it takes for the injury 
stimulated NSCs to undergo differentiation and turn to post-mitotic immature 
neurons (Wang et al., 2016a, Zhao et al., 2016). Although the increased NSC 
proliferation helps compensate for the cell loss, it is unknown whether the 
survival of post-injury born neurons is altered, which may also promote neuronal 
replacement. A few studies evaluated cell survival by labeling cell proliferation 
with 5-bromo-2'-deoxyuridine (BrdU) and then as a measure of survival, 
assessed the presence of BrdU-positive cells 2 weeks after TBI. Cell survival 
was unchanged in the SGZ (Rice et al., 2003, Bye et al., 2011). However, the 
identities of the cells that survived were not validated by specific cell type 
markers, thus the BrdU-positive cells that survived were not necessarily neurons. 
More investigations are needed to clarify if the survival rate of newborn neurons 
is altered by TBI.  
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Properties of post-injury born mature neurons 
Once the cells survive, a short migration from the SGZ to inner granule cell layer 
(GCL) is also critical for newborn neurons to mature, properly integrate into local 
circuits, and establish synapses with appropriate axonal terminals. Recently, a 
study illustrated the aberrant localization of neurons newly born about 5 days 
post-injury, indicating ectopic migration in the injured environment (Villasana et 
al., 2015). My colleagues also revealed the migration issue of newborn neurons 
in moderate and severe CCI. They have observed that a large proportion of 
newborn neurons were misplaced in outer GCL or even mismigrated further to 
the border between GCL and molecular layer. These neurons stay misplaced 
after they fully mature (Wang et al., 2016a, Ibrahim et al., 2016). Adult-born 
granule neurons generally locate in the inner GCL. Thus the ectopic migration of 
newborn neurons may cause circuit disorganization and potentially contribute to 
post-traumatic epilepsy (Hunt et al., 2013).  
Besides the aberrant migration issue, post-injury born neurons were also 
subjected to morphological alterations. Neurons born after CCI extended more 
proximal and less distal branches from their somas, and their dendritic 
arborizations showed more widespread morphologies. This morphology indicates 
a shift from synapses on distal inputs to synapses on proximal inputs, thus 
potentially disturbing original information flow. Whereas, the post-injury born 
neurons still maintained comparable electrophysiological properties compared to 
newborn neurons in sham animals (Villasana et al., 2015). The post-injury born 
neurons are able to fire action potentials responding to perforant path stimulation 
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and uptake retrograde tracer from CA3 pyramidal neurons. These observations 
demonstrated that post-injury born neurons extended their dendrites and formed 
synapses on perforant path and spread their axons to and formed synapses on 
CA3 pyramidal neurons (Sun et al., 2007, Villasana et al., 2015, Emery et al., 
2005). Together, both similarities and differences were detected in neurons born 
after injury compared with newborn neurons in sham animals. However, more 
questions remain unanswered. Do the post-injury born neurons receive input 
signals from other brain regions besides perforant path like their counterparts in 
uninjured animals? Do they change the ratio of innervation from different 
regions? If so, will this alteration affect behavior outcomes? Do the post-injury 
born neurons exert neuronal activities? If so, how are they contributing to post-
traumatic functional recovery? Further investigations are urgently needed to 
thoroughly elucidate the integration of post-injury born neurons and illustrate the 
functional relevance of post-traumatic neurogenesis to behavioral performances.  
 
Post-traumatic neurogenesis level 
Morphological and electrophysiological studies on individual post-injury born 
neurons elucidated some of their functional properties, however, it is still 
controversial of how TBI affects the production of mature neurons on a 
population level (Braun et al., 2002, Rola et al., 2006, Sun et al., 2005, Sun et al., 
2007, Gao and Chen, 2013, Bye et al., 2011, Rice et al., 2003, Dash et al., 2001, 
Kernie et al., 2001). A few variables were identified in the contradictory studies 
after a thorough review of the specific approaches used by individual groups to 
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evaluate post-traumatic neurogenesis. These variations included injury model, 
time point post-injury, and cell fate tracing method, which collectively might 
together contribute to the existing discrepancy (Table 1). The first studies on 
post-traumatic neurogenesis were published in 2001 independently by two 
groups. Kernie and colleagues evaluated post-traumatic neurogenesis by a CCI 
model in adult mice. They traced cell proliferation by BrdU in the first week post 
injury, followed by the fate identification of the BrdU positive cells (i.e. cells that 
proliferated) at 60 days after injury. Their results demonstrated a 5-fold increase 
of BrdU-labeled cell proliferation in the injured hippocampus, and revealed co-
labeling of BrdU with calbindin, proving mature neuron generation post-trauma 
(Kernie et al., 2001). In the meantime, Dash and colleagues reported similar 
results in adult rats. They induced TBI by CCI model and labeled proliferation for 
9 days after injury. In their study, BrdU-positive cells were assessed acutely at 1 
day after the last BrdU injection, which similarly exhibited a dramatic increase in 
dentate gyrus. Identities of BrdU-positive cells were determined at 3 weeks later 
by calbindin expression, and BrdU/calbindin double-labeled cells were also 
detected (Dash et al., 2001). Kernie and Dash demonstrated similar phenomena, 
including cell proliferation and neurogenesis induced by CCI. Whereas, the 
number of BrdU and calbindin double-labeled cells was not quantified or 
compared between injured and sham animals, so the question of how TBI 
remodels neurogenesis was not answered. In 2002, Braun and colleagues 
studied neurogenic cells by III-tubulin expression in adult rats after a weight 
drop injury. They observed an increase of the neurogenic cells at 3 and 7 days
 
 
Table 1: Summary of major studies on post-traumatic neurogenesis. 
Post-traumatic 
Neurogenesis 
Level 
Injury 
Model 
Experiment 
Parameters 
Species Cell Label Strategy 
Tissue Collection 
Time 
Neurogenesis 
Markers 
References 
No 
quantification 
CCI 
4.4m/s, 
1.0mm 
deformation 
mouse 
BrdU labeled for 1 
week after injury 
60 days post-injury BrdU/Calbindin 
Kernie et 
al., 2001 
6m/s, 2.75mm 
deformation 
rat 
BrdU labeled for 9 
days after injury 
30 days post-injury BrdU/Calbindin 
Dash et al., 
2001 
weight 
drop 
20g, 9cm not labeled 7 days post-injury βIII tubulin 
Braun et al., 
2002 
Increase FPI 
2.1 ± 0.08 atm 
rat 
BrdU labeled at 2 
days after injury 
4 weeks post-injury BrdU/NeuN 
Sun et al., 
2005 
2.2 ± 0.02 atm 
BrdU labeled from 2 
days to 5 days after 
injury 
10 weeks post-injury BrdU/FluoroGold 
Sun et al., 
2007 
Unchanged 
FPI 
2.16 ± 0.06 
atm 
rat 
BrdU labeled at 18h 
and 20h after injury 
15 days post-injury BrdU/βIII tubulin 
Rice et al., 
2003 
CCI 
3.0m/s, 
1.0mm 
deformation 
mouse 
BrdU labeled for 1 
week after injury 
5 weeks post-injury BrdU/NeuN 
Gao et al., 
2013 
weight 
drop 
450g, 2m, 
3.6m/s 
rat 
BrdU labeled from 
24h to 4days after 
injury 
8 weeks post-injury BrdU/NeuN 
Bye et al., 
2013 
Decreased CCI 
4.5m/s, 1mm 
deformation 
mouse 
BrdU labeled for 1 
week after injury 
4 weeks post-injury BrdU/NeuN 
Rola et al., 
2006 
Adapted from Table 29.1 of Chen and Wang et al. (Chen, 2018).
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post-trauma in the dentate gyrus (Braun et al., 2002). Collectively, these early 
investigations set the foundation for TBI-enhanced NSC proliferation. Although 
the proliferated NSCs can produce mature neurons after injury, how TBI changes 
the level of neurogenesis still remained elusive. To address this question, several 
other groups have followed up this work. Sun and colleagues reported increased 
neurogenesis in adult rats after FPI injury. They demonstrated increased 
neurogenesis by BrdU injection at 2 days after trauma and by assessing cell fate 
via neuronal nuclei (NeuN) double-labeling at 4 weeks after TBI (Sun et al., 
2005). Their follow-up work further validated the increased neurogenesis at a 
long-term time point, 10 weeks after TBI (Sun et al., 2007). On the contrary, in a 
CCI injury study in adult mice, Rola et al reported decreased neurogenesis by 
BrdU labeling in the first week and fate tracing via BrdU and NeuN co-staining at 
4 weeks post-trauma (Rola et al., 2006). Whereas using a similar paradigm, my 
colleagues instead detected unchanged neurogenesis following trauma by BrdU 
labeling in the first week, and cell fate determination with BrdU and NeuN co-
labeling at 5 weeks after a moderate CCI in adult mice (Gao and Chen, 2013). 
Bye et al demonstrated in an adult rat traumatic axonal injury (TAI) model similar 
unchanged neurogenesis by BrdU labeling for the first 5 days and BrdU NeuN 
double positive cell quantification at 8 weeks post-trauma (Bye et al., 2011). 
Moreover, Rice et al studied neurogenesis by BrdU injection acutely at 18 h and 
20 h after FPI induced TBI in adult rats, and co-labeling of BrdU with III-tubulin 
at 15 days later. Similarly, they did not observe any apparent difference in the 
injured SGZ compared to sham cohorts, while increased neurogenesis was 
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observed in the SVZ (Rice et al., 2003). Collectively, key factors that varied 
among different studies consisted of animal species, injury models, injury 
parameters, labeling strategies, and assessment time points (Table 1). Each of 
the individual variants by itself or the combination of any might contribute to the 
existed discrepancy in proving TBI-remodeled neurogenesis. The first part of 
chapter 2 in this body of work helped settle the controversy by pinpointing injury 
severity as a factor that can determine neurogenesis level following trauma. I 
illustrated that although post-traumatic NSC proliferation increases as injury 
severity elevates, only severe but not mild or moderate CCI increases 
neurogenesis in adult mice (Wang et al., 2016a). Further investigations are in 
need to determine how the other factors influence post-traumatic neurogenesis 
and to help elucidate a more detailed profile of how TBI reshapes neurogenesis. 
 
Function of post-traumatic neurogenesis 
Learning and memory dysfunction is one of the most common complaints by TBI 
patients. This is largely resulted from neurocircuitry disconnection in the 
hippocampus caused by neuronal loss and degeneration. Meanwhile, 
spontaneous recovery was observed in both humans and rodents, although by 
different degrees, indicating activation of the intrinsic neuroplasticity post-trauma 
(Schmidt et al., 1999, Prigatano, 1987). Post-traumatic neurogenesis represents 
one of the neuroplasticity mechanisms by taking the place of dead neurons and 
reconnecting the damaged circuits. In animal models, increase of post-traumatic 
neurogenesis by neurotrophic factors was positively correlated with cognitive 
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function improvement (Kleindienst et al., 2005, Lu et al., 2005, Lu et al., 2003, 
Wu et al., 2008, Lu et al., 2007, Sun et al., 2009). By loss-of-function method, 
other studies proved the participation of post-traumatic neurogenesis in the 
functional improvement. Approaches used include genetic ablation of neurogenic 
cells and systemic inhibition of cell proliferation, by which diminishment of 
spontaneous recovery was observed (Blaiss et al., 2011, Sun et al., 2015).  
Additionally, investigations on individual post-injury born neurons have 
suggested their integration into the neural network, supporting the hypothesis 
that post-traumatic neurons can exert neuronal function and post-traumatic 
neurogenesis is beneficial for functional improvements (Sun et al., 2007, Emery 
et al., 2005, Villasana et al., 2015). However, although integration of post-injury 
born neurons was observed, more information is needed to determine the exact 
identities of pre- and post-synaptic neurons the post-injury born neurons connect 
with. As mentioned in the prior session, the ectopic migration and abnormal 
dendritic arborization were observed in post-injury born neurons, and aberrant 
neurogenesis is also considered a contributor of post-traumatic epilepsy 
(Villasana et al., 2015). It is essential to investigate if the post-injury born neurons 
are synapsing on proper targets and rebuilding a functional network that follows 
the intrinsic pattern or instead, misrepair the circuits and further disrupt the 
damaged organizations. With the recent invention of monosynaptic pseudorabies 
virus tracing system, the pre-synaptic inputs onto post-injury born neurons can 
be investigated, and thus help assess if the post-injury born neurons rewire the 
damaged circuits and/or disrupt the pre-existing network. In the second part of 
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chapter 2, I used this method and exhibited that post-injury born neurons are 
innervated by a variety of neurons, both locally within the hippocampus and 
distally from cortical and subcortical regions. More quantitative studies would 
help to understand if there is any alteration regarding the innervation pattern.  
Moreover, the approaches used to study the function of post-traumatic 
neurogenesis have been either correlative analysis or ablation a population of 
cells, but not direct and selective demonstration of a cause-and-effect 
relationship between post-traumatic neurogenesis and functional outcomes. So 
far, there is a lack of direct evidence showing the functional recruitment of post-
injury born neurons. No studies have displayed if specific inhibition of post-injury 
born neuron activity can block post-traumatic functional recovery or not. Thus the 
beneficial and/or maladaptive effects of post-traumatic neurogenesis need to be 
further validated. Recent development of the DREADD (designed receptors 
exclusively activated by designed drugs) and optogenetic systems are powerful 
tools for selective investigations on newly born neurons (Lee et al., 2014, 
Boyden, 2015). By assessing behavioral performances with exclusive excitation 
or silence of post-injury born neurons, it is possible to directly evaluate the 
beneficial and/or maladaptive functions of post-traumatic neurogenesis. Only 
when comprehensive evaluation on the functions of post-injury neurogenesis is 
achieved, can translational studies on endogenous NSCs and post-traumatic 
neurogenesis realistically be worth pursuing. This is a critical prerequisite for any 
potential clinical applications of and/or interventions on post-traumatic 
endogenous neurogenesis as a therapeutic treatment for TBI. 
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Mechanisms of TBI-induced neurogenesis  
In normal conditions, NSC activity and neurogenesis is regulated by extracellular 
signals in the NSC niche of the hippocampal SGZ. Various cell types, blood 
vessels and extracellular matrix in the niche together regulate NSC activity 
through releasing neurotransmitters, secreting growth/neurotrophic factors and 
cytokines, providing direct cell-cell contact, and/or offering systemic factors 
(Figure 1.3 A). For instance, parvalbumin interneurons are critical for NSCs to 
maintain quiescent by tonic releasing GABA (Song et al., 2012). NPCs express 
delta-like 1 to activate Notch signal in NSCs and maintain NSC quiescence 
(Kawaguchi et al., 2013). Astrocytes can secrete IL-1  and IL-6 to promote 
neuronal differentiation (Barkho et al., 2006). Microglia are known to shape 
neurogenesis by cleaning non-survived newborn neurons via phagocytosis 
(Sierra et al., 2010). The expression and secretion of various growth/neurotrophic 
factors and cytokines locally from cells within the niche or distally from the 
system and released from blood vessels plays critical roles in NSC quiescence 
maintenance, proliferation, neuronal differentiation, survival, and morphological 
development (Faigle and Song, 2013). After TBI, there are dramatic alterations in 
the cellular components, like immature neuron death, astrocyte reactivation, and 
microglia reactivation, which can alter signal profiles in the niche (Figure 1.3 B). It 
is still unclear which ones are primarily responsible for injury-enhanced NSC 
proliferation and differentiation. 
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Figure 1.3: NSC niche in the normal hippocampus and after TBI.  
(A) NSC niche in the normal hippocampus consist of their progenies, the 
immediate progenitor cells, immature and mature granule cells. Parvalbumin 
interneurons (light purple), astrocytes (grey-blue), and microglia (blue) around 
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NSCs (green) participate in NSC activity and neurogenesis regulation. Blood 
vessels (red) and extracellular matrix (yellow) provide systemic factors and other 
extracellular signals, respectively. Growth/neurotrophic factors and cytokines 
provided by multiple cell sources modulate neurogenesis. Modified from Figure 2 
(Bond et al., 2015). (B) After TBI, a series of alterations in the NSC niche were 
reported, included but not limited to granule neuron death, astrocyte and 
microglia reactivation, and changes of a few growth/neurotrophic factors and 
cytokines. 
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Extracellular signals in NSC niche after TBI 
All four classical pathways in stem cell biology have been reported to be involved 
in post-traumatic NSC activities and neurogenesis. Notch pathway, a main 
contributor to adult NSC maintenance and expansion (Ables et al., 2010, Ehm et 
al., 2010), was studied after TBI. Inhibitor of Notch1 pathway signaling, -
secretase inhibitor, has been introduced to TBI animals and decreased NSC 
proliferation after injury (Kishimoto et al., 2012). On the contrary, Notch1 
downstream target Hes1 has been reported to negatively regulate NSC 
proliferation and neurogenesis after TBI (Zhang et al., 2014). The role of Notch 
pathway in TBI-induced neurogenesis still needs to be clarified. The implications 
on other pathways are relatively limited. Wnt/β-catenin pathway normally 
enhances NSC proliferation and neuronal differentiation (Lie et al., 2005). After 
TBI, increased expression of Wnt/β-catenin pathway downstream target, survivin, 
has been observed in the hippocampus, which indicated the potential 
involvement of Wnt//β-catenin pathway in TBI-induced NSC proliferation (Zhang 
et al., 2013a). However, change of β-catenin itself or how Wnt/β-catenin 
signaling influences NSC proliferation after TBI has not been studied yet. 
Moreover, Sonic hedgehog (Shh) is another pathway normally regulating NSC 
proliferation and changed after TBI (Lai et al., 2003). Shh-responsive cells in the 
SVZ after CCI were increased in the ipsilateral brain, consistent with its role in 
enhancing NSC proliferation under normal conditions (Ahn and Joyner, 2005), 
while the correlation with NSC proliferation has not been determined (Mierzwa et 
al., 2014). Additionally, bone morphogenetic proteins (BMPs) are known to 
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promote gliogenesis and suppress neuronal fate specification, their mRNA 
expression was increased in SVZ and SGZ after TBI, but no functional relevance 
to neurogenesis after TBI has been evaluated (Logan et al., 2013, Lim et al., 
2000). There are still a series of studies that need to be done to determine the 
dominant contributor to TBI-induced NSC proliferation or to unravel the 
combinational roles of each pathway.  
Besides the extrinsic signals, neurotrophic factors and growth factors are 
another group of regulators of neurogenesis after TBI. They normally come from 
multiple cell sources and act on multiple steps of adult neurogenesis. A member 
of the neurotrophic factor family, brain-derived neurotrophic factor (BDNF), has 
been widely studied in the development of the nervous system, and is the most 
important factor involved in adult neurogenesis. Ablation of either BDNF or its 
receptor in hippocampal NSCs impaired NSC proliferation and reduced granule 
cell layer volume (Li et al., 2008). Meanwhile, BDNF plays an important role in 
promoting survival of the immature and mature neurons, and it is required for 
dendritic arborization development of new granule cells (Ghosh et al., 1994, 
Kirschenbaum and Goldman, 1995, Gao and Chen, 2009, Gao et al., 2009b). 
After TBI, both protein and mRNA levels of BDNF increase in the cortex and 
hippocampus (Grundy et al., 2000, Yang et al., 1996, Griesbach et al., 2004), 
indicating the involvement of BDNF in TBI pathophysiology. Previous study from 
my colleagues confirmed the administration of a BDNF receptor agonist 
successfully increased immature neuron survival post trauma, suggesting that 
BDNF plays a positive role in neuroplasticity after injury (Zhao et al., 2015b). 
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Beneficial effects of delayed exercises on increasing neurogenesis and functional 
recovery post trauma also correlated with BDNF up-regulation in the 
hippocampus (Griesbach et al., 2004).  
Other than neurotrophic factors, growth factors, i.e. insulin-like growth 
factor-1 (IGF-1), vascular endothelial growth factor (VEGF) and fibroblast growth 
factor-2 (FGF-2), are also crucial for NSC regulation and neurogenesis. IGF-1 
positively regulates NSC proliferation and neurogenesis in vitro and in vivo in the 
adult hippocampus (Aberg et al., 2000, Arsenijevic and Weiss, 1998). IGF-1 and 
its receptor have exhibited increased expression in TBI animals in both the cortex 
and hippocampus (Madathil et al., 2010, Schober et al., 2010). Conditional 
overexpression of IGF-1 can enhance neurogenesis in the hippocampus after 
TBI and rescue dendritic impairments as well (Carlson et al., 2014). VEGF, 
secreted by astrocytes, microglia, neurons, and NSCs, is a potent angiogenic 
and neurogenic factor (Mosher et al., 2012). VEGF treatment can enhance NSC 
proliferation and neurogenesis in the adult hippocampus and improve 
hippocampus-dependent contextual fear conditioning (Segi-Nishida et al., 2008, 
Licht et al., 2011, Kirby et al., 2015). Post injury, VEGF expression is increased 
in the cortex and hippocampus. VEGF antisense oligonucleotide treatment 
impaired injury-induced neurogenesis, while administration of exogenous VEGF 
after TBI promoted neurogenesis in the DG and SVZ (Skold et al., 2005, Lu et 
al., 2011, Lee and Agoston, 2010, Thau-Zuchman et al., 2010). FGF-2 functions 
as another important regulator of adult neurogenesis (Woodbury and Ikezu, 
2014). FGF-2 infusion increased cell proliferation and neurogenesis in the SVZ 
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and adult hippocampus; inducible FGF-2 receptor knockout in the adulthood, on 
the contrary, reduced neurogenesis in the hippocampus and compromised short-
term memory (Kuhn et al., 1997, Stevens et al., 2012). After TBI, FGF-2 is also 
required for post-traumatic neurogenesis. FGF-2 deficient animals displayed 
decreased hippocampal neurogenesis and dentate gyrus volume post-trauma. 
Oppositely, FGF-2 overexpression and infusion increased hippocampal 
neurogenesis after TBI, respectively, which correlated to improved cognitive 
function recovery (Yoshimura et al., 2003, Sun et al., 2009). In Summary, BDNF, 
IGF-1, VEGF, and FGF-2, as neurogenic factors, all positively regulate 
neurogenesis in the normal and also injury environments. Investigations on direct 
administration of the above factors in TBI animals for functional recovery is 
strong evidence that their receptors are good targets for the development of 
small molecule analogs to achieve similar beneficial effects. However, 
interventions on any of these receptors has yet to succeed in clinical trials.  
 
Intracellular signals in NSCs after TBI 
With all the extracellular factors regulating NSC activity, it is extremely 
complicated to coordinate their alterations after TBI. The combination of their 
effects on post-traumatic neurogenesis and/or the dominant contributors to post-
traumatic neurogenesis largely remain elusive. Therefore, the development of an 
optimal approach maximizing therapeutic effects is impeded. Thus, it might be 
more feasible to study the induction of an intracellular signaling pathway instead, 
since most of the neurotrophic and growth factors share the same pathways, 
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such as PI3K/Akt (Phosphoinositide 3 kinase/Protein kinase B), MAPK/ERK 
(Mitogen-activated protein kinase/Extracellular signal-activated kinase) for signal 
transduction (Huang and Reichardt, 2003, Dailey et al., 2005, Kowanetz and 
Ferrara, 2006, Chitnis et al., 2008). These involved signaling pathways, mainly 
responsible for cell survival and proliferation, are possible shortcuts to 
therapeutic augmentation of endogenous neurogenesis. Alterations of the 
PI3K/Akt pathway after TBI in the adult brain have been reported, as well as its 
involvement in treatment enhanced neuronal survival, neurogenesis, histological 
and behavioral outcome improvements (Chen et al., 2012, Wu et al., 2008, Wu et 
al., 2014). In terms of neurogenesis, administration of a cholesterol-lowering 
medication, simvastatin, exhibited a correlation between the up-regulation in 
PI3K/Akt pathway and increased neurogenesis (Wu et al., 2008). However, more 
investigation is needed to distinguish if there is a cause-and-effect relationship or 
is these are simply independent events. MAPK/ERK pathway activation has also 
been implicated in reducing apoptosis and increasing neurogenesis when 
activated after injury (Ma et al., 2011, Lu et al., 2011).  
Since PI3K/Akt and MAPK/ERK converge on the mTOR (mammalian 
target of rapamycin, or mechanistic target of rapamycin) pathway downstream, it 
is of great interest to study mTOR signaling after TBI (Mendoza et al., 2011). 
Generally, mTOR pathway is a cellular hub controlling multiple events, including 
cell metabolism, growth, proliferation, survival, migration, etc. The mTOR 
pathway consists of the mTOR complex 1 (mTORC1), involved in most of the 
mTOR activities, and mTOR complex 2 (mTORC2), mainly controlling cell 
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survival and cytoskeleton. It responds to diverse extracellular signals, like 
nutrients, amino acids, growth factors, cytokines, and energy. Intracellularly, 
mTOR senses cellular energy status, oxidative states, and DNA damage (Meng 
et al., 2018). Its activation depends on PI3K/Akt signaling, and it is negatively 
regulated by PTEN (Figure 1.4 A). Its roles have been extensively studied in 
various diseases, such as cancers, diabetes, and neurodegenerative diseases 
(Laplante and Sabatini, 2012). Recently, mTOR has also gained attention in stem 
cell studies and neuroregeneration fields (Meng et al., 2018, Park et al., 2008, 
Liu et al., 2010, Liu et al., 2017).  
 
mTOR signaling in TBI 
After TBI, increased mTOR activation has been detected in the cortex and 
hippocampus in a mouse model (Chen et al., 2007). Most studies of mTOR in 
TBI focus on its negative role in neuronal survival within hours of initial injury 
(Ding et al., 2015). Genetically constitutive mTOR activation worsened 
neurological scores, while inhibition by rapamycin benefits acute cognitive 
function improvement (Rozas et al., 2015, Nikolaeva et al., 2015, Park et al., 
2012). However, the conclusion is debatable, since another study proved 
rapamycin, on the contrary, worsens cognitive function (Zhu et al., 2014). My 
current study also observed increased mTOR activation in the hippocampus after 
TBI, while by combining specific cell type markers, I identified mTOR activation 
not only in the mature neurons, astrocytes, and microglia but also in the NSCs, 
all at different time points (Figure 1.4 B). In chapter 3, I demonstrated that  
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Figure 1.4: Signaling pathway of mTOR and mTORC1 activation in different cell 
types in the hippocampus after TBI. 
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(A) Signaling pathways regulate mTOR activities and roles of mTORC1 and 
mTORC2. Modified from Figure 2 (Laplante and Sabatini, 2012) and Figure 2 
(Meng et al., 2018). (B) Activation of mTORC1 in different cell types at different 
time points after TBI. 
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rapamycin administration abolished NSC proliferation promoted by the injury, 
indicating besides neuronal survival, mTOR is also important in the innate repair 
mechanism activation (Wang et al., 2016b). It is speculated that mTOR activation 
in different cell types correlates with different functional relevance, which peaks 
at different time points as well. Thus, careful characterization of mTOR functions 
and identification of a time course of mTOR activation in individual cell types may 
provide more detailed information on whether mTOR activation as well as when 
and where mTOR activation is beneficial for functional recovery from TBI.  
Taken together, agreements and debates co-exist in the mechanistic 
studies of neurogenesis after TBI, while some insights still be can obtained on 
the development of potential therapeutic approach from current knowledge. 
Although neurotrophic and growth factors have proven to be beneficial to 
enhance endogenous neurogenesis and improve functional recovery, the 
administration of polypeptide is either invasive or blocked by blood-brain-barrier. 
More issues include potential immune response to exogenous polypeptide and 
high cost for polypeptide production and storage. Development of small 
molecules mimicking neurotrophic and growth factor effects is an alternative and 
already has some promising results published. Other options include targeting 
primary pathways involved in neurogenesis in the injury environment. In chapter 
4, I tested a small molecule targeting mTOR signaling and showed improved 
spatial learning function. Nevertheless, more investigations are needed to fully 
understand the molecular mechanism regulating the functional outcomes before 
it can provide feasible avenues for clinical applications. 
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Current therapeutic interventions and potential clinical applications 
Based on current knowledge of various mechanisms mediating TBI induced 
neurogenesis, several reagents have been tested in animal models to gain 
information on their therapeutic potential and rationale for clinical trial testing. 
Erythropoietin (EPO), as a kidney originated cytokine, classically is considered 
as modulator of red blood cell production. Recently, it is found in the brain and 
exhibits neuroprotective roles (Nguyen et al., 2014). The administration of EPO in 
TBI animals increased neurogenesis and improved neurobehavioral outcomes 
(Lu et al., 2005, Xiong et al., 2009). EPO-mediated effects are linked to VEGF 
expression and VEGF receptor type 2 activation (Xiong et al., 2011b). Since EPO 
is already an FDA-approved and commercialized drug against anemia, Dr. 
Roberson’s group conducted a randomized phase 2 trial in 200 closed head TBI 
patients. They found that an EPO regimen (500 IU/kg, intravenous infusion within 
6 hours of initial injury with/without 2 additional doses every 24 h) failed to 
improve neurological outcomes by 20% and demonstrated the futility of 
conducting a further phase 3 trial with this regimen (Robertson et al., 2014). In 
addition, a recent multicenter trial of a different regimen (40,000 IU, 
subcutaneously, once per week up to 3 doses) failed to improve functional 
recovery again (Nichol et al., 2015). Failure of these individual regimens does not 
necessarily indicate the end of EPO application in TBI. Although species 
difference between human and rodents may impede the translation of results 
from animal experiments, treatment time, dose, and duration can be finely 
modified to achieve better outcomes in clinical trials in the future. Besides EPO, 
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no other reagent has been tested in TBI clinical trials in terms of enhancing 
neurogenesis. However, there are a few candidates available.  
Cerebrolysin, a mixer of neuropeptides derived from purified brain 
proteins, has also displayed neurogenic effects in rodents by increasing mature 
neuron production and cognitive function improvement after TBI (Zhang et al., 
2013b, Zhang et al., 2015b). Additionally, it has been tested in several clinical 
trials against stroke, Alzheimer’s disease and TBI, most of which exhibited 
beneficial outcomes and stable safety in human subjects (Heiss et al., 2012, 
Chen et al., 2013, Gauthier et al., 2015, Thome and Doppler, 2012). Current 
phase 2 trial results suggest the necessity of phase 3 trial to step forward 
towards an effective treatment for TBI.  
Statin, a cholesterol-lowering agent widely used in cardiovascular 
diseases, recently has been applied after TBI in mice as well. Its beneficial 
effects showed in various respects including increased neurogenesis in the 
dentate gyrus, reduced neuronal death in the hippocampal CA3 region, 
decreased glial response and pro-inflammatory cytokine in the lesion site, up-
regulated VEGF and BDNF expression and improved neurological outcomes (Li 
et al., 2009, Wu et al., 2012, Wu et al., 2008, Lu et al., 2007). Imipramine, an 
antidepressant, has also shown to increase neurogenesis in the hippocampus 
and enhance cognitive function in mice model (Han et al., 2011). Recombinant 
tissue plasminogen activator (tPA) is an effective reagent against ischemic 
stroke, as it mainly resolves blood clots. Its application in TBI at subacute but not 
acute phase in rodents has led to increased generation of post-injury born 
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mature neurons along with cognitive functional recovery (Meng et al., 2014). 
These above reagents, as FDA-approved drugs, are all good candidates for 
clinical trials in human patients, since no more safety tests are required. Fine-
tuning design of the regimen still needs further development and testing. For 
instance, the adverse effect of tPA on blood coagulation restricts its application 
only after hemorrhaging stops. The precise time point of drug administration in 
potential clinical trials should be designed accurately according to human TBI 
pathophysiological characteristics. 
Some other novel molecule treatments aimed at neurogenesis tested in 
animal models include LM11A-31, thymosin 4 (T4), 7,8-dihydroxyflacvone 
(DHF), angiotensin receptor 2 (AT2) agonists, mesenchymal stromal cells (MSC)-
derived exosomes, MLC901 and P7C3-A20. LM11A-31 is a small molecule of 
p75 neurotrophic receptor agonist, which was developed by Dr. Longo in 2006 
and succeeded phase 1 safety trial conducted by PharmatrophiX in human 
subjects (Massa et al., 2006). Although initially designed for Alzheimer’s disease, 
LM11A-31 has shown therapeutic effects in spinal cord injury, as well as in TBI. 
In TBI animals, LM11A-31 administration decreased cell death, increased 
proliferation of progenitors, enhanced neurogenesis, and improved spatial 
learning and memory impairments (Shi et al., 2013). T4 is an actin-sequester 
protein, but also holds multiple other biological properties and has been applied 
to clinical trials in healthy volunteers to test safety and against venous ulcers 
(Crockford et al., 2010, Guarnera et al., 2007, Ruff et al., 2010). Treatment with 
T4 in TBI mice reduced tissue lesion volume, increased neurogenesis in the 
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hippocampus and improved functional recovery, which indicated potential 
application of T4 in TBI trials (Xiong et al., 2011a, Ye et al., 2013). These two 
reagents are candidates developed by biomedical companies. If proven to be 
effective in clinical trials, they are close to be commercialized in the field of brain 
trauma. 
DHF is a natural small molecule activating TrkB receptor and mimicking 
BDNF effects. My colleagues and others reported neuroprotective functions of 
DHF treatment after TBI in animal models shown as decreasing neuronal death, 
reducing tissue lesion, and ameliorating dendritic degeneration (Wu et al., 2014, 
Chen et al., 2015, Zhao et al., 2015a, Agrawal et al., 2015). My colleagues also 
demonstrated beneficial effect of DHF on neurogenesis in the hippocampus after 
TBI, indicating DHF is a promising therapeutics aimed at neuroprotection and 
neuroregeneration at the same time (Zhao et al., 2016). Angiotensin, a hormone 
mainly controlling blood pressure through vasoconstriction, also has receptors 
expression in the brain. Activation of AT2 mediated effects are called protective 
arm in brain injuries (Namsolleck et al., 2014). Thus, a small molecule AT2 
agonist, CPG42112A has been introduced in TBI mice, and neurogenesis was 
elevated at 35 days after a 3-day treatment, as well as improved neurobehavioral 
outcome (Umschweif et al., 2014).  
Exosomes are tiny membrane vesicles secreted by several cell types to 
the body fluids, and normally contain proteins, mRNAs, and miRNAs from parent 
cells (Ching and Kingham, 2015). Their applications as diagnostic markers and 
therapeutic targets have been widely studied in cancer biology and emerged in 
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the field of neuroregeneration (Tominaga et al., 2015, Ching and Kingham, 
2015). MSC-derived exosomes delivery to TBI rats has improved functional 
recovery, increased angiogenesis and neurogenesis as well as deceased 
gliogenesis and inflammation (Zhang et al., 2015a). 
MLC901, the active component in a traditional Chinese medicine, showed 
neuroprotective effects when applied at 2 h after injury and enhanced 
neurogenesis if introduced in drinking water during the first week of injury 
(Quintard et al., 2014). P7C3-A20 is a compound related to latrepirdine, a drug 
that failed in Pfizer and Medivation conducted phase 3 clinical trials against 
Alzheimer’s disease and Huntington’s disease. The new compound exhibits 
neuroprotective potential, so it was applied to TBI rats to test whether benefits in 
functional outcomes can be achieved. By an initial dose at 30 min after FPI with 
concessive doses twice per day for 7 days, P7C3-A20 successfully reduced 
contusion volume, increased cell proliferation in the first week, enhanced 
generation of mature neurons, and improved spatial learning and memory 
performance in Morris Water Maze test (Blaya et al., 2014). These novel 
approaches are still in the early phases of development and lack of 
pharmacokinetics and toxicity analysis. In addition, more animal studies are in 
need to validate these potentially exciting therapeutic approaches. 
Although it seems that more than enough promising candidates for TBI 
treatment exit, none of them have succeeded in clinical trials. Before an authentic 
cure is translated from animal experiments to patients’ bedside, well-designed 
investigations should be conducted on the molecular mechanisms of the effective 
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reagent. To establish clinical relevance, a detailed comparison between animal 
and human pharmacokinetics should be assessed. If these details can be 
analyzed thoroughly, fine-tuning strategies can be developed to achieve high 
efficacy and strong potency and to maximize therapeutic benefits for TBI 
patients. 
 
Summary 
As a promising therapeutic target for TBI patients, great efforts have been spent 
on endogenous hippocampal NSC mediated post-traumatic neurogenesis. 
Extensive information has been obtained regarding the phenomenon of TBI-
enhanced NSC proliferation, properties of post-injury born neurons, and 
functional correlation between post-traumatic neurogenesis and functional 
recovery. A few clinical trials are undergoing and targeting post-traumatic 
neurogenesis with the hope of achieving better cognitive functional outcomes. 
Whereas, more questions are yet to be answered.  
The following chapters will describe my work in assessing if TBI severity 
affects the neurogenesis level and if post-injury born neurons can integrate 
anatomically and functionally. The molecular mechanism of TBI-enhanced NSC 
proliferation was investigated. In addition, a pharmacological approach was 
applied to target the mechanism, and spatial learning and memory function was 
examined.  
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CHAPTER 2 
CHARACTERIZATIONS ON TBI RESHAPED NEUROGENESIS REGARDING 
POST-TRAUMATIC NSC PROLIFERATION, POST-INJURY BORN IMMARUTE 
NEURON PRODUCTION, AND POST-INJURY BORN MATURE NEURON 
GENERATION AND INTEGRATION 
 
Hypotheses 
1) TBI reshapes neurogenesis by affecting NSC proliferation, post-injury born 
immature neuron production, and post-injury born mature neuron generation in a 
severity-dependent manner, and 2) TBI alters post-injury born neurons’ 
anatomical integration in the neural network, and promotes their functional 
recruitment in standard housing environment and upon hippocampus-dependent 
behavior recruitment. 
 
Introduction 
TBI causes a wide range of complicated pathological changes, among which 
neuronal death and degeneration directly contribute to functional deficits (Lu et 
al., 2005, Hall et al., 2008). Diffusive injury after trauma affects much larger brain 
regions than the initial impact site, and the hippocampus is among the most 
vulnerable areas to neuronal death (McIntosh et al., 1998, Ariza et al., 2006). 
Consequently, learning and memory deficit is one of the most commonly 
complained symptoms among TBI patients (Wolf and Koch, 2016). Since no 
FDA-approved drug is available to stop cell death, it is urgently desired to 
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develop an alternative approach aiming to generate new neurons and 
compensate for cell loss. 
Neurogenesis has been widely detected in the adult hippocampus in 
songbirds, rodents, primates, and humans (Cameron and McKay, 2001, Eriksson 
et al., 1998, Kempermann and Gage, 2000, Kornack and Rakic, 1999, Kuhn et 
al., 1996, Leuner et al., 2007, Burd and Nottebohm, 1985). NSCs in the SGZ 
undergo constant activation, proliferation, neuronal differentiation, and 
maturation, which eventually generate new functional granule neurons (Christian 
et al., 2014, Shapiro and Ribak, 2005, Zhao et al., 2006). Adult NSC-derived 
neurogenesis provides a potential resource for neuronal replenishment to the 
injured hippocampus following TBI. Post-traumatic neurogenesis has been 
reported responsible for spontaneous recovery (Schmidt et al., 1999, Blaiss et 
al., 2011, Sun et al., 2015), since enhanced endogenous neurogenesis achieved 
by introduction of neurogenic agents is positively correlated with functional 
improvements in the injured animals (Lu et al., 2003, Kleindienst et al., 2005, Lu 
et al., 2005, Wu et al., 2008). Together, it is feasible to promote compensation on 
neuronal loss by enhancing NSC-mediated endogenous neurogenesis, and 
consequently to rebuild damaged circuits and restore cognitive functions.  
Enormous studies have reported TBI induced cell proliferation, which 
includes NSC proliferation (Braun et al., 2002, Chirumamilla et al., 2002, Dash et 
al., 2001, Kernie et al., 2001, Ramaswamy et al., 2005, Rice et al., 2003, Rola et 
al., 2006, Sun et al., 2005, Sun et al., 2007, Yoshimura et al., 2003, Gao and 
Chen, 2013, Gao et al., 2009a, Bye et al., 2011), however, the results on post-
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traumatic neurogenesis are controversial. Increased (Sun et al., 2005, Sun et al., 
2007, Braun et al., 2002), unchanged (Chirumamilla et al., 2002, Bye et al., 2011, 
Gao and Chen, 2013), and decreased (Rola et al., 2006) post-traumatic 
neurogenesis have all been described. Since different TBI models were used in 
individual studies: fluid percussion injury (FPI) model (Chirumamilla et al., 2002, 
Rice et al., 2003, Sun et al., 2005, Sun et al., 2007), controlled cortical injury 
(CCI) model (Braun et al., 2002, Rola et al., 2006, Gao and Chen, 2013), cortical 
contusion model (Braun et al., 2002), and impact-acceleration model (Bye et al., 
2011), severities of the injuries were not comparable. Thus, I speculated that 
injury severity is the key variable that causes the contradictory results and 
hypothesized that TBI severity affects neurogenesis level. To test my hypothesis, 
I introduced mild, moderate, and severe injuries to adult mice by a CCI model, 
and evaluated NSC proliferation, immature neuron number, and post-injury born 
mature neuron number. These findings are the first to elucidate that TBI 
reshapes post-traumatic neurogenesis in a severity-dependent manner and 
partially explains the pre-existing controversy. 
Besides compensating the amount of cell loss on a population level, post-
injury born neurons are supposed to undergo morphological and functional 
maturation before they can contribute to neurological behaviors. Although 
individual post-injury born neurons have shown comparable electrophysiological 
properties with counterparts in sham animals, they have morphologically shown 
altered dendritic arborization and ectopic migration (Villasana et al., 2015, 
Ibrahim et al., 2016), indicating possible circuit integration alteration. Moreover, 
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previous studies using retrograde tracer Fluorogold labeling showed tracer 
uptake by post-injury born neurons from the injection site in the CA3 region. 
However, this phenomenon only proves axonal extension to CA3, but is not 
sufficient to prove functional synapse formation between post-injury born neuron 
and CA3 neurons (Emery et al., 2005, Sun et al., 2007). Together, it is not clearly 
studied if TBI affects the pattern of anatomical integration of post-injury born 
neurons, and if they were exerting neuronal activity in standard housing 
environment and upon behavioral recruitment. I hypothesized that TBI alters 
anatomical integration of post-injury born neurons and promotes their functional 
integration. To test the hypothesis, I utilized a dual-virus pseudotyped rabies 
virus monosynaptic tracing system to label pre-synaptic targets of post-injury 
born neurons, and used c-fos, an immediate early gene (IEG) (Ramirez et al., 
2013, Garner et al., 2012), as a neuronal activation marker to evaluate functional 
integration of post-injury born neurons in standard housing environment and 
upon behavior task. My results proved that post-injury born neurons form 
synapses with their normal distal (LEC/PRH) and local (granule neurons) targets. 
However, they are also innervated by the medial habenular nucleus and 
retrosplenial granular cortex neurons and CA1 neurons, which has not been 
reported before. TBI promotes functional recruitment of post-injury born neurons 
in both standard housing environment and upon spatial learning and memory 
task. To my knowledge, these findings are the first to describe the influences of 
TBI on post-injury born neuron integration pattern. 
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Materials and methods 
Animal care 
Male C57 BL/6 mice were purchased from Envigo and Jackson Laboratories and 
housed in a 12/12-hr light/dark environment. Food and water were given ad 
libitum. Nestin-GFP (green fluorescent protein) transgenic mice were a kind gift 
of Dr. Enikolopov at Cold Spring Harbor Laboratories (Mignone et al., 2004). All 
procedures were performed under protocols upon approval from Indiana 
University's Animal Care and Use Committee. 
 
Controlled cortical impact traumatic brain injury 
Male C57 BL/6 mice were used at the age of 8 to 10 weeks (n=76). In the 
studies, mice were subjected to CCI injury like previously described (Gao and 
Chen, 2013, Gao and Chen, 2011). Briefly, mice were anesthetized using a 
solution of 2.5% Avertin (Sigma, St. Louis, MO) followed by fixation in a 
stereotaxic frame (Kopf Instruments,Tujunga, CA). Under sterile procedures, the 
skin was retracted to expose the skull. A 4 mm craniotomy was performed 
laterally midway between the central suture and the temporalis muscle, 
posteriorly midway between the bregma and lamda sutures. The skullcap was 
carefully removed, leaving dura undisrupted. The impactor tip used in the 
experiment has a diameter of 3.5 mm. The tip was angled perpendicular to the 
exposed cortical surface when performing injury.  
The mouse CCI injury impactor was controlled electromagnetically, which 
allows independent adjustments of contact velocity, contact duration, and 
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deformation depth, respectively. In the severity experiments, contact velocity was 
constantly set at 3.5 m/s, impact duration was constantly set at 0.1 s, and 
deformation depth was the parameter that determines injury severity. It was set 
at 0.2 mm, 1.0 mm, and 1.2 mm to generate mild, moderate, and severe TBI, 
respectively. In the presynaptic neuron tracing studies and the functional 
integration studies, the parameters were set as 3.5 m/s, 0.1 s, and 1.0 mm. The 
injury site was sutured after bleeding stops. The animals were put on a heating 
pad set at 36–37 °C to maintain body temperature the whole time during surgery 
and recovery. 
 
BrdU injection 
To evaluate cell proliferation, BrdU was delivered at 44 h following TBI (100 
mg/kg in saline, intraperitoneally [i.p.]; Sigma, St. Louis, MO). To quantify post-
injury born mature neurons, BrdU was injected daily in the first week following 
TBI (50 mg/kg in saline, i.p.). To label post-injury born neurons and study their 
neuronal activity, BrdU was injected daily for the first two weeks after TBI (50 
mg/kg in saline, i.p.). 
 
Virus production and injection 
To trace pre-synaptic neurons innervating post-injury born neurons, a dual-virus 
pseudotyped rabies virus monosynaptic tracing system was used (Callaway and 
Luo, 2015). Briefly, the genome of rabies virus was engineered by replacing its 
own glycoprotein gene with a fluorescent protein gene. The engineered rabies 
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virus was then pseudotyped with envelope protein A (EnvA) from avian sarcoma 
and leukosis virus (ASLV), which specifically binds and infects cells expressing a 
TVA (tumor virus A) receptor. A helper virus was used to express TVA receptor 
and rabies glycoprotein for the pseudotyped rabies virus infection, and its 
packaging and retrograde trans-synaptic tracing, respectively. In my studies, 
EnvA G-Deleted Rabies-dsRedExpress pseudotyped rabies virus was purchased 
from the GT3 Core Facility of the Salk Institute for Biological Studies (La Jolla, 
CA). The helper virus constructs were RV-Syn-GTRgp (a retrovirus construct), a 
kind gift of Dr. Fred Gage from the Salk Institute of Biological Studies (Vivar et 
al., 2012). The retroviral helper virus was packaged with plasmids expressing 
vesicular stomatitis virus G glycoprotein (VSVG), Gal, and Pol. Virus packaging 
was conducted by Eric Lee Thompson in the Department of Pharmacology and 
Toxicology at Indiana University School of Medicine.  
To trace the pre-synaptic target of post-injury born neurons, intracranial 
injections were performed at two sites with retroviral helper virus at the following 
coordinates: AP -1.8 mm, LM -1.5 mm, depth -1.6 mm, and AP -2.4 mm, LM -1.8 
mm, depth -1.6 mm. Each site was injected with 1 ul retrovirus. Pseudotyped 
rabies virus was then injected at the same sites with 1 ul for each site.  
 
Tissue processing 
Animals in each experiment were sacrificed at time points specified in figures. 
Briefly, the animals were deeply anesthetized a solution of 2.5% avertin. 
Transcardial perfusion was performed with cold saline first, followed by 4% 
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paraformaldehyde (PFA) in PBS. The brains were harvested and post-fixed 
overnight in PFA at 4°C. Then the brains were transferred to 30% sucrose for 
48h at 4°C for cryoprotection. Serial coronal sections were cut at 30 um thick 
using a cryostat (LeicaCM 1950), followed by storage at -20 °C. For pre-synaptic 
neuron tracing studies, serial horizontal sections were cut at 30um thick using the 
cryostat, followed by storage at -20°C. 
 
Histology and immunohistochemistry 
Nissl staining was used to analyze anatomical changes. Briefly, sections were 
successively incubated in a solution of 0.1% cresyl violet (Sigma) for 20 min, 
quickly rinsed in distilled water, differentiated in 95% ethanol for 3 min, 
dehydrated in 100% ethanol for 5 min twice, cleared in xylene for 5 min twice, air-
dried, and mounted with DPX (Sigma).  
FJB staining was used to detect dying neurons. Briefly, brain sections 
were hydrated in distilled water for 5 min, followed by 20 min incubation in a 
solution containing 0.06% potassium permanganate (Sigma) at room 
temperature. The sections were successively washed in distilled water for 5 min 
twice, incubated in a 0.0004% solution of FJB (Sigma) for 20 min, washed again 
in distilled water for 3 times, incubated in a solution of 0.01% 4′,6-diamidino-2-
phenylindole (DAPI) (Sigma) for 10 min, air-dried, and mounted with DPX.  
Immunostaining was performed to specify target cells. Briefly, free-floating 
sections were washed at room temperature in PBS for 3 times, incubated with 
blocking buffer containing 1% bovine serum albumin, 0.1% Triton X-100, 5% 
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normal goat serum in PBS at room temperature for 1 h. Then they were 
incubated in primary antibody at 4 °C overnight. Then sections were washed in 
PBS for 3 times, incubated with secondary antibody for 2 h at room temperature, 
and followed by DAPI treatment for 2 min. The sections were washed in PBS for 
3 times and mounted with Fluoromount-G solution (SouthernBiotech). For BrdU 
detection, HCl pretreatment was performed prior to standard staining protocol. 
Briefly, sections were treated with 2N HCl for 1 h at room temperature, 
neutralized with 0.1M borate buffer (pH 8.4) for 10 min, washed in PBS 3 times, 
and processed to standard blocking protocol. The primary antibodies and final 
concentrations used were listed in Table 2. Jackson ImmunoResearch 
Laboratories, Inc. secondary antibodies were applied in a dilution of 1:1000. 
 
Cortical cavity volume measurement 
Series of every sixth sections (30 μm thick, 180 μm apart) were processed to 
Nissl staining to show the spared cortex. Images were acquired with a Zeiss 
microspore. The contours of the contralateral and ipsilateral spared cortices were 
drawn in the sections that cover the injured cortex, and contours enclosed 
volume was measured in AxioVision Rel 4.8 software (Zeiss). The percentage 
cortex of the cavity was calculated by the following formula: percentage of the 
cortical cavity = (contralateral cortex volume – ipsilateral spared cortex volume) / 
contralateral cortex volume × 100%. 
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Table 2: Antibodies used in the studies. 
Antibody Company Catalog Number Dilution 
Mouse anti- β-actin Abcam ab8226 1:10000 
Rat anti-BrdU Abcam ab6326 1:200 
Rabbit anti-c-fos Santa Cruz sc52 1:200 
Rabbit anti-CD11b Abcam ab133357 1:200 
Guinea pig anti-DCX Millipore AB2253 1:500 
Chicken anti-GFP Abcam ab13970 1:1000 
Mouse anti-GFAP Sigma G3893 1:800 
Goat anti-MCM2 Santa Cruz sc-9839 1:200 
Mouse anti-NeuN Millipore MAB377 1:500 
Rabbit anti-NG2 Millipore AB5320 1:200 
Rabbit anti-pS6 Cell Signaling 4858 1:200 
Rabbit anti-RFP Invitrogen R10367 1:1000 
Goat anti-Sox2 R&D AF2018 1:1000 
Rabbit anti-Sox2 Abcam ab97959 1:1000 
Rabbit anti-S6 Cell Signaling 2217 1:1000 
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Cell counting 
An inverted fluorescent microscope system (Zeiss Axiovert 200 M) was used to 
analyze immunostained sections. The total number of target cells was 
determined by counting every individual positive cell (even partial positive cell at 
the borders of sections) in multiplanes throughout the entire interested region in 
every section, and the number from each section analyzed was added together. 
For BrdU labeled cell proliferation, cell fate tracing, and post-injury born neuron 
activity, a series of every sixth section (30 μm thick, 180 μm apart, 12 to 16 
sections for each animal) covering the whole hippocampus were processed with 
immunostaining. To quantify immature neurons, 3 epicenter sections (30 μm 
thick, 180 μm apart) were processed with immunostaining. To analyze pre-
synaptic neurons of post-injury born neurons, sections covering the whole brain 
were processed to immunostaining.  
To calculate the cell density of target cells, the volume of the granule cell 
layer of the dentate gyrus area was measured by creating contours by Zeiss 
software (AxioVision v4.8). To evaluate NSC proliferation, cell density was 
calculated by dividing the total cell number by the volume of the granule cell 
layer. For surviving proliferated cells and newly generated mature neurons 
assessment, cell density was calculated by dividing the total number by the 
volume of the dentate gyrus. For immature neuron quantification, cell density was 
calculated by dividing the total number by the volume of the granule cell layer.  
In order to assess ratios of mature neurons versus reactive glia in 
surviving proliferated cells, epicentral sections from each animal were stained 
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with antibodies against BrdU and GFAP or NG2 or CD11b, respectively. BrdU 
single positive cells and target double positive cells were counted. The 
percentage of target cell type was respectively calculated. The ratio of each cell 
type in the BrdU positive population was then normalized to match 100% in total. 
 
Microscopy 
The inverted microscope system (Zeiss Axiovert 200 M) used in the experiments 
was equipped with an apotome for optical sectioning and a motorized stage for 
stitched images and interfaced with a digital camera (Zeiss Axio Cam MRc5). 
After image acquisition, the images were assembled and labeled by Photoshop 
7.0 (Adobe System). 
 
Statistical analysis 
Quantitative data were displayed as average ± standard deviation. Results were 
analyzed by one-way ANOVA. The post hoc analysis was done via Tukey’s 
honest significance test using SPSS software. Functional integration data was 
analyzed via two-tailed student’s t-test. Significance was set at p<0.05. 
 
Results 
CCI model induced different severities of TBI 
TBI, as a complex disease, ranges from mild to severe levels. To generate 
different injury severities in mice, a CCI model was used as previously described 
(Gao and Chen, 2013, Gao and Chen, 2011) and injury levels were managed by 
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deformation depths set at 0.2 mm, 1.0 mm, and 1.2 mm, corresponding to mild, 
moderate, and severe injury, respectively. Injury severity was further confirmed 
by histological examination (Figure 2.1). Consistent with previous reports from 
my colleagues, mild injury caused limited cortical disruptions without obvious 
cavity formation (lesion volume at 0.2% ± 5.4%, p=1, Figure 2.1 B and E) (Gao 
and Chen, 2011). Moderate TBI induced a cortical cavity (cavity volume is 14.3% 
± 1.0%, p=0.001, Figure 2.1 C and E) with an intact corpus callosum (Gao et al., 
2008), while severe TBI dramatically increased cavity volume ( 26.2% ± 1.8%, 
p<0.001, Figure 2.1 D and E), further destroyed the corpus callosum and even 
deformed the hippocampal structure.  
At the cellular level, I evaluated cell death in the hippocampal dentate 
gyrus (HDG), where the NSCs reside, with Fluoro-Jade B (FJB) staining. FJB-
positive cells were hardly observed in the HDG of the mouse brain that received 
sham (Figure 2.2 A) or mild CCI injury (Figure 2.2 B). FJB-positive cells were 
vastly detectable in the HDG of mouse brain that received moderate CCI injury 
(Figure 2.2 C), mainly at the inner 1/3 of the granular cell layer, where the 
immature neurons locate. My colleagues previously reported that most of the 
dead cells in the HDG following moderate CCI-injury are immature neurons (Gao 
et al., 2008). As the injury severity escalated to the severe level, the FJB-positive 
cells not only located at the inner 1/3 of the granular cell layer, they also were 
observed in the outer granular cell layer and hilus (Figure 2.2 D), where mature 
granular neurons and interneurons respectively locate. Immunostaining results 
confirmed that the majority of cells dying in severe TBI were co-stained with   
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Figure 2.1: TBI severities shown by Nissl staining. 
Brain tissues collected at 48 h after traumatic brain injury (TBI). (A-D) Nissl 
staining of serial coronal sections of sham (A), mild (B), moderate (C), and 
severe TBI (D) mice shows the characteristic structures in different severities of 
TBI. (E) Quantification of cortical cavity volume in different severities. (* p<0.05, 
** p<0.01, *** p<0.001, n.s. not significant, n=3 for each group).   
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Figure 2.2: Severe TBI mainly causes mature neuron death. 
Brain tissues collected at 24 h after traumatic brain injury (TBI). (A-D) Fluoro-
Jade B (FJB) staining shows dying cells in the hippocampal dentate gyrus (HDG) 
of sham (A), mild (B), moderate (C), and severe TBI (D) mice. (E, F) 
Immunostaining against NeuN (red) for mature neurons followed by FJB staining 
(green) for dying cells. (G, H) Immunostaining against doublecortin (DCX; red) for 
immature neurons followed by FJB staining (green) for dying cells. 4′,6-
diamidino-2-phenylindole (DAPI) staining of nuclei shows HDG structure. (F, H) 
Enlarged images of E, G (indicated by white boxes) to show co-staining of NeuN 
and FJB (F, indicated by white arrows) and co-staining of DCX and FJB (H, 
indicated by white arrows).  
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Neuronal Nuclei (NeuN) positive mature neurons (Figure 2.2 E and F, indicated 
by white arrows) and a small proportion were co-labeled with doublecortin (DCX) 
positive immature neurons (Figure 2.2 G and H, indicated by white arrows). 
 
TBI severity affects the survival of proliferated cells in the HDG 
The effect of TBI on overall cell proliferation in the HDG during the first week 
post-trauma has been investigated widely in different models by BrdU 
incorporation (Braun et al., 2002, Chirumamilla et al., 2002, Dash et al., 2001, 
Kernie et al., 2001, Ramaswamy et al., 2005, Rola et al., 2006, Sun et al., 2005, 
Sun et al., 2007, Yoshimura et al., 2003, Gao and Chen, 2013, Gao et al., 2009a, 
Bye et al., 2011). Whether the severity of injury affects cell proliferation and the 
subsequent survival is unclear. To address this question, I injected animals with 
BrdU (50 mg/kg) intraperitoneally (i.p.) once per day for the first week following 
surgery to label the proliferating cells and collected tissues at 4 weeks after TBI 
(Figure 2.3 A). A series of every sixth section (12 to 16 sections in total for each 
animal), which covered the whole hippocampus, were stained for BrdU.  
BrdU-positive cells in the HDG were quantified. Sham animals displayed 
the baseline of surviving proliferated cells in the HDG at 969 ± 175/mm3 (Figure 
2.3 B and F); mild injury animals had a similar level at 1267 ± 161/mm3 (p=0.985, 
Figure 2.3 C and F). In moderate injury animals, the density of surviving 
proliferated cells was dramatically elevated to 3739 ± 1250/mm3 (p=0.039, Figure 
2.3 D and F). The number was further elevated to 5406 ± 1611/mm3 (p=0.001, 
Figure 2.3 E and F) in severely injured animals. Collectively, moderate and 
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Figure 2.3: TBI severity affects surviving proliferated cells. 
(A) Schematic shows experimental strategy. (B-E) Immunostaining with 5-bromo-
2’-deoxyuridine (BrdU; green) to identify surviving proliferated cells in the 
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hippocampal dentate gyrus (HDG) in sham (B), mild traumatic brain injury (TBI) 
(C), moderate TBI (D), and severe TBI (E) mice. 4′,6-diamidino-2-phenylindole 
(DAPI) staining of nuclei shows the HDG structure. (F) Quantification of BrdU-
positive surviving proliferated cells in the HDG of mice after sham surgery and 
different TBI severities. (G) Ratio of BrdU-positive surviving proliferated cells in 
individual HDG subregions, molecular layer (ML), granule cell layer (GCL), and 
hilus, after sham surgery and different TBI severities. Pie chart sizes indicate the 
scale of total BrdU-positive cell numbers in different groups. (H-J) Quantification 
of BrdU-positive surviving proliferated cells in the ML, GCL, and hilus, 
respectively. (* p<0.05, ** p<0.01, *** p<0.001, n.s. not significant, n=3 for sham 
group, n=4 for mild and moderate TBI groups, and n=5 for severe TBI group). 
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severe, but not mild TBI, promoted the number of surviving proliferated cells at 4 
weeks after injury. 
 
TBI severity affects NSC proliferation 
Various types of cells proliferate post-trauma in the HDG, including NSCs and 
reactive glia (Braun et al., 2002, Chirumamilla et al., 2002, Dash et al., 2001, 
Kernie et al., 2001, Ramaswamy et al., 2005, Rice et al., 2003, Rola et al., 2006, 
Sun et al., 2005, Sun et al., 2007, Yoshimura et al., 2003, Gao and Chen, 2013, 
Gao et al., 2009a). A previous study of my colleagues’ in moderate TBI showed 
that injury transiently enhanced NSC proliferation, peaking at 44-48 h after initial 
injury (Gao et al., 2009a). To examine NSC proliferation after different levels of 
injuries, proliferating cells were pulse-labeled by BrdU (i.p., 100 mg/kg) at 44 h, 
and the brains were collected at 48 h. The cells that proliferated between 44-48 h 
following surgery were quantified (Figure 2.4 A). In the HDG of sham animals, a 
small number of cells undergoing proliferation were mainly observed in the SGZ, 
where the NSCs reside (Figure 2.4 B). Mild injured animals showed a similar 
number and distribution of BrdU-positive cells in the HDG (Figure 2.4 C). 
Moderate and severe TBI animals exhibited an obvious increase of BrdU-positive 
cells and also a dispersed distribution into the molecular layer and hilus (Figure 
2.4 D and E).  
It is known that post-traumatic cell proliferation also contains glial 
reactivation (Laird et al., 2008). To further discern NSC proliferation, I performed 
double immunostaining with antibodies against BrdU and transcription factor   
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Figure 2.4: TBI severity affects NSC proliferation. 
(A) Schematic shows experimental strategy. (B-E) Immunostaining with 5-bromo-
2’-deoxyuridine (BrdU; green) to detect proliferating cells in sham (B), mild (C), 
moderate (D), and severe TBI (E) animals between 44-48 h after injury. 4′,6-
diamidino-2-phenylindole (DAPI) staining of nuclei shows hippocampal dentate 
gyrus (HDG) structure. (F-I) Double immunostaining against BrdU (green) and 
transcription factor Sox2 (red) to identify neural stem cell (NSC) proliferation in 
the subgranular zone (SGZ) of sham (F), mild (G), moderate (H), and severe TBI 
(I) mice. (J-M) 3-dimensional reconstruction of proliferating NSCs in F-I (indicated 
in white boxes) to show BrdU and Sox2 co-label. (N) Quantification of BrdU and 
Sox2 double-positive NSC proliferation in SGZ in sham and different TBI 
severities. (* p<0.05, ** p<0.01, *** p<0.001, n.s. not significant, n=5 for each 
group) 
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Sox2, since Sox2 is required for NSC self-renewal and widely used as an NSC 
marker (Graham et al., 2003, Favaro et al., 2009). Because hippocampal NSCs 
exclusively reside in the SGZ, proliferating NSCs were quantified based on their 
specific location within the SGZ and co-staining with Sox2 (Figure 2.4 F-M). In 
sham animals, I observed the baseline of NSC proliferation to be 1038 ± 
135/mm3 (Figure 2.4 F, J, and N), which represents normal adult neurogenesis in 
physiological conditions. In mild injury animals, NSC proliferation was not altered 
compared with sham animals (1096 ± 105 /mm3, p=0.998, Figure 2.4 G, K, and 
N). After moderate TBI, NSC proliferation showed a significant 2.2-fold increase 
(2332 ± 540/mm3, p=0.001, Figure 2.4 H, L, and N). This result is consistent with 
previous data (Gao and Chen, 2013). In severe injury animals, NSC proliferation 
was further boosted by 3.2-fold compared with sham animals (3352 ± 714/mm3, 
p<0.001, Figure 2.4 I, M, and N).  
Sox2 is also expressed in some of the reactive glia. Therefore, to rule out 
the possible interference from the reactive glia adjacent to the SGZ, I took 
advantage of a Nestin-GFP (green fluorescent protein) transgenic mouse line, in 
which GFP expression is driven by Nestin promoter and is observed in the NSCs 
but not in reactive glia (Mignone et al., 2004). With this unique mouse line, I 
validated that more than 83% of BrdU and Sox2 double-positive cells in the SGZ 
were GFP-positive NSCs following a moderate level of CCI-injury (Figure 2.5).  
 
TBI severity affects immature neuron number 
Previously, my colleagues have demonstrated that immature neurons are the 
most vulnerable cell type in the HDG following moderate TBI (Gao et al., 2008).   
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Figure 2.5: Validation of NSC proliferation following TBI with Nestin-GFP 
transgenic mice. 
Brain was collected at 48 h after moderate traumatic brain injury (TBI) in Nestin-
GFP mouse. (A-D) Immunostaining with green fluorescent protein (GFP), 5-
bromo-2’-deoxyuridine (BrdU), and Sox2 confirms that majority of BrdU and Sox2 
double-positive cells in the subgranular zone (SGZ) (indicated by white arrows) 
are GFP-positive neural stem cells. (E-H) 3-dimensional reconstruction of D 
(indicated in white box) shows co-label of Sox 2 and GFP in SGZ. A Sox2, GFP, 
and BrdU triple positive proliferating NSC in the SGZ was indicated by a white 
arrowhead. A Sox2 solely positive reactive glia in the hilus was indicated by a 
white arrow. 
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To assess the effects of injury severity on immature neuron number, I collected 
brains at 2 weeks post-injury at different severities and counted Doublecortin 
(DCX)-positive immature neurons in the HDG (Figure 2.6 A). Two weeks is the 
critical time point for a newly born and immature neuron to survive and 
differentiate into a mature neuron (Christian et al., 2014). In all the groups, DCX-
positive cells resided primarily in the inner 1/3 of the granule cell layer (GCL) with 
their neurites growing towards the molecular layer (ML) (Figure 2.6 B-E). I then 
quantified DCX- positive cell numbers in each group (Figure 2.6 F-J). In sham 
animals, there were 23,432 ± 3,861/mm3 DCX-positive cells residing in the GCL 
(Figure 2.6 F and J). No significant alteration was detected in the number of 
DCX-positive cells in the HDG following mild TBI (30,528 ± 6,495/mm3, p=0.738, 
Figure 2.6 G and J) and moderate TBI (31,640 ± 5,778/mm3, p=0.681, Figure 2.6 
H and J). However, in severe injury animals, the number of DCX-positive cells 
was dramatically elevated by 2.2-fold to 51,586 ± 15,426/mm3 (p=0.003, Figure 
2.6 I and J). These results indicated that severe, but not mild or moderate injury, 
increases immature neuron number within the HDG at 2 weeks post-trauma.  
 
TBI severity affects the generation of new mature neurons 
To examine the number of post-injury newly born mature neurons after different 
severities of TBI, BrdU staining was combined with NeuN, a specific cell type 
marker for mature neurons, to detect adult-born mature neurons post-trauma 
(Figure 2.7 A). In the sham HDG, BrdU-positive cells mainly located in the GCL, 
where newly generated granule neurons are supposed to be (Figure 2.7 B). Mild  
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Figure 2.6: TBI severity affects immature neuron number. 
(A) Schematic shows the experimental strategy. (B-I) Immunostaining against 
doublecortin (DCX) (red) to identify immature neurons in the hippocampal 
dentate gyrus (HDG) in sham (B, F), mild (C, G), moderate (D, H), and severe 
TBI (E, I) mice. 4′,6-diamidino-2-phenylindole (DAPI) staining of nuclei shows the 
HDG structure. (F-I) Enlarged images of B-E (indicated in white boxes) to show 
DCX-positive immature neurons in the granule cell layer (GCL) in higher 
magnification. (J) Quantification of DCX-positive immature neurons after sham 
surgery and different TBI severities. (* p<0.05, ** p<0.01, *** p<0.001, n.s. not 
significant, n=4 for sham and moderate TBI groups, n=5 for mild TBI group, and 
n=7 for severe TBI group). 
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Figure 2.7: TBI severity affects mature neuron generation. 
(A) Schematic shows experimental strategy. (B-M) Double immunostaining with 
5-bromo-2’-deoxyuridine (BrdU) (green) and Neuronal Nuclei (NeuN) (red) to 
identify newly generated mature neurons in the hippocampal dentate gyrus 
(HDG) of sham (B, F, J), mild (C, G, K), moderate (D, H, L), and severe TBI (E, I, 
M) animals. (F-I) Enlarged images from B-E (indicated in white boxes) to show 
BrdU and NeuN double-positive cells in the granular cell layer (GCL). (J-M) 3-
dimensional reconstruction of newly generated mature neurons in F-I (indicated 
in white boxes) to show BrdU and NeuN co-staining. (N) Quantification of BrdU 
and NeuN double-positive cells in HDG after sham surgery and different TBI 
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severities. (O) Percentage of BrdU and NeuN double-positive cells in the 
individual HDG subregions, molecular layer (ML), GCL, and hilus, after sham 
surgery and different TBI severities. Pie chart sizes indicate the ratio of total 
BrdU and NeuN double-positive cell number in different groups. (* p<0.05, ** 
p<0.01, *** p<0.001, n.s. not significant, n=3 for sham group, n=4 for mild and 
moderate TBI groups, and n=5 for severe TBI group) 
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TBI animals showed a similar pattern of BrdU-positive cells localization, mostly in 
the GCL (Figure 2.7 C). While in the HDG of moderately and severely injured 
animals, a large ratio of BrdU-positive cells also distributed in the ML and hilus 
(Figure 2.7 D and E), conferring robust gliogenesis. I further quantified BrdU and 
NeuN double-positive cells in different groups (Figure 2.7 F-N). In sham animals, 
a baseline of 108 ± 11/mm3 new neurons were generated in the HDG (Figure 2.7 
F, J, and N). The number was not significantly increased in mild TBI (145 ± 
66/mm3, p=0.935, Figure 2.7 G, K, and N) or moderate TBI (223 ± 118/mm3, 
p=0.316, Figure 2.7 H, L, and N). However, severe TBI dramatically promoted 
newly produced neurons by 3-fold (329 ± 84/mm3, p=0.016, Figure 2.7 I, M and 
N). Regardless of injury severities, the vast majority of newly generated mature 
neurons (more than 91%) located in the GCL with few in the ML and hilus, and 
there was no significant difference for the distribution among four groups (Figure 
2.7 O). Taken together, the generation of adult-born mature neurons was 
promoted only in animals with severe, but not mild or moderate TBI. This 
conclusion agrees with my colleagues’ previous report that demonstrated 
moderate CCI-induced injury does not increase neurogenesis (Gao and Chen, 
2013). 
 
TBI severity affects gliogenesis 
Glial response after TBI is another source of cell proliferation besides NSC 
proliferation. As shown in Figure 2.3, the number of proliferated cells in the HDG 
increased as the severity of injury increased. Furthermore, the localization of the  
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proliferated cells was different following different severities of TBI. In sham or 
mildly injured mice, the proliferated cells primarily resided in the SGZ. In contrast, 
after moderate or severe TBI, proliferated cells widely dispersed to other regions 
in the HDG. Since the location of cells can partially indicate their identities, I first 
divided surviving proliferated cells into different subregions of the HDG (Figure 
2.3 G-J). Compared with sham animals, mildly injured mice showed a similar 
pattern of BrdU-positive cells distribution in the hilus, the granule cell layer 
(GCL), and the molecular layer (ML). In moderate and severe TBI animals, the 
distribution of BrdU-positive cells shifted slightly away from the GCL (43.5% in 
sham and 41.1% in mild TBI compared with 31.5% in moderate and 33% in 
severe TBI animals in the GCL, Figure 2.3 G). When each subregion was 
separately examined, mild TBI did not change the number of BrdU-positive cells 
in any of the subregions, while moderate and severe injury increased the cell 
number in both the GCL and the ML, but not in the hilus. Specifically, moderate 
TBI resulted in a 4.6-fold and a 2.8-fold promotion of BrdU-positive cell number in 
the ML and the GCL, respectively. Severe TBI further elevated the number to a 
5.5-fold in the ML and a 4.2-fold in the GCL (Figure 2.3 H-J). Since the majority 
of cells in the ML are glia, and neurons mainly reside in the GCL, adult-born 
mature granule neurons only account for a small part of those BrdU labeled cells. 
The rest of the BrdU-positive cells are likely reactive glia. 
To further confirm glial cell identities, I double-stained BrdU-positive cells 
with different types of glial cell markers: glial fibrillary acid proteins (GFAP) for 
astrocytes (Figure 2.8 A-C), NG2 for oligodendrocyte precursors (Figure 2.8 D-  
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Figure 2.8: Gliogenesis accounts for the rest of surviving proliferated cells. 
Brain tissues were collected as the procedure shown in Figure 2.3; tissues from 
moderate traumatic brain injury (TBI) mice shown as an example. (A-C) Double 
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immunostaining against 5-bromo-2’-deoxyuridine (BrdU, green) and glial fibrillary 
acid proteins (GFAP, red) to identify astrocytes in proliferated cell population in 
the ipsilateral side of the injured brain. (D-F) Double immunostaining against 
BrdU (green) and NG2 (red) to identify the oligodendrocyte lineage in proliferated 
cell population in the ipsilateral side of the injured brain. (G-I) Double 
immunostaining against BrdU (green) and CD11b (red) to identify microglia in 
proliferated cell population in the ipsilateral side of the injured brain. 4′,6-
diamidino-2-phenylindole (DAPI) staining of nuclei shows the hippocampal 
dentate gyrus (HDG) structure. (B, E, H) Enlarged images of A, D, G (indicated in 
white boxes) to show gliogenesis in higher magnification. (C, F, I) 3-dimensional 
reconstruction of proliferated glial cells in B, E, H (indicated in white boxes) to 
confirm their cell types. (J) Percentage of different cell types in BrdU-positive 
surviving proliferated cell population in individual HDG subregions, molecular 
layer (ML), granule cell layer (GCL), and hilus, in sham and different TBI 
severities. Pie chart sizes indicate ratios of total BrdU-positive cell number in 
different groups. (* p<0.05, ** p<0.01, *** p<0.001, n.s. not significant, n=3 for 
sham group, n=4 for mild and moderate TBI groups, and n=5 for severe TBI 
group) 
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F), or CD11b for microglia (Figure 2.8 G-I). I quantified the proportion of each cell 
type in the BrdU-positive cell population in each subregion (Figure 2.8 J). Despite 
no significant alteration was detected in the cellular compositions in any of the 
subregions, some subtle changes were observed. In the ML, the composition of 
each cell type did not significantly change among different groups (Figure 2.8 J, 
top panel). In the GCL, the generation of mature neurons accounted for a similar 
ratio in the BrdU-positive cell population of all groups (52.9% in sham, 61.3% in 
mild, 52.3% in moderate, and 52.8% in severe TBI animals, Figure 2.8 J, middle 
panel), despite the absolute number of newly generated neurons increased in 
severe injured mice. Whereas, an increase in proliferated NG2-positive cell ratio 
was observed in moderate and severe injured mice (5.8% in sham, 3.8% in mild, 
11.6% in moderate, and 14.1% in severe TBI, Figure 2.8 J, middle panel). On the 
contrary, an interesting elevation of proliferated CD11b-positive microglia ratio 
instead was noticed in the hilus (0 in sham, 9.4% in mild, 26.0% in moderate and 
26.3% in severe TBI, Figure 2.8 J, bottom panel).  
 
Anatomical integration of post-injury born neurons 
Although I demonstrated that, in terms of number of neurons born after injury, 
neurogenesis level is affected by injury severities, it is not clearly studied if they 
function as mature neurons comparable to their counterparts born and developed 
in a non-injured environment or not. I wondered whether they form proper 
connections with appropriate presynaptic neurons or form aberrant connections 
and disrupt information flow. Thus, I assessed if the injury environment alters the 
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anatomical integration pattern of post-injury born neurons, which might affect 
their functions.  
I used a pseudotyped rabies virus based dual-virus retrograde 
monosynaptic tracing system to identify the pre-synaptic neurons innervating 
post-injury born neurons (Figure 2.9 A). I first used a retrovirus-based helper 
virus to specifically infect proliferating cell, including proliferating NSCs. Once an 
infected cell becomes a neuron and express synapsin, a histone-tagged GFP, 
TVA receptor, and rabies glycoprotein are expressed under the synapsin 
promoter. This strategy ensures that only post-injury born neurons express the 
elements and are labeled by histone-GFP (Figure 2.9 B). Then EnvA 
pseudotyped engineered rabies virus was introduced, and would only infect cells 
expressing TVA receptors, which would be pre-infected post-injury born neurons. 
With the rabies glycoprotein expressed by the helper virus, the rabies virus 
conducts self-package and retrogradely infects pre-synaptic neurons. Within the 
infected pre-synaptic neurons, rabies virus expresses DsRed by its engineered 
genome and would not further infect second order pre-synaptic neurons because 
of its glycoprotein gene removal. Together, any post-injury born neurons infected 
by two viruses would be labeled by histone-GFP and DsRed, while their pre-
synaptic neurons would only be labeled by DsRed (Figure 2.9 C) (Callaway and 
Luo, 2015, Vivar et al., 2012). By this method, I was able to evaluate connections 
made by post-injury born neurons, which might indicate their functions. 
At 4 weeks after injury, I was able to detect post-injury born neurons 
labeled by hGFP and DsRed in the injured GCL (Figure 2.10). I have observed  
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Figure 2.9: Dual-virus pseudorabies virus system of monosynaptic retrograde 
tracing is used to identify pre-synaptic neurons innervating post-injury born 
neurons. 
(A) A schematic illustrates the dual-virus pseudorabies virus mediated 
monosynaptic retrograde tracing system. The RNA genome of rabies virus was 
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engineered by deleting its glycoprotein gene and replacing it with the DsRed 
gene. Then the engineered rabies virus genome was pseudotyped with envelop 
protein A (EnvA) of avian sarcoma and leukosis virus (ASLV) and named EnvA-
G-DsRed. EnvA drives virus infection specifically on cells expressing tumor 
virus A receptor (TVA). Thus, the pseudorabies virus was used together with a 
helper virus, which express TVA, histone tagged green fluorescent protein 
(hGFP), and rabies virus glycoprotein (Rgp) under a synapsin promoter. The 
helper virus was packaged in a retrovirus form and named it RV-HTB. Modified 
from Figure 1 C (Wickersham et al., 2007). (B) To trace pre-synaptic innervation 
of post-injury born neurons, RV-HTB was intracranially injected into the dentate 
granule cell layer after TBI. Retrovirus specifically infects proliferating cells, which 
include proliferating NSCs after TBI. Once the proliferated cells differentiate and 
become mature neurons, they express TVA on cell surface, Rgp, and hGFP in 
nuclei. (C) A week before assessing the innervation, EnvA-G-DsRed was 
intracranially injected into the dentate granule cell layer at the same coordinates. 
EnvA-G-DsRed only infects cells expressing TVA, which are post-injury born 
neurons that have been pre-infected by RV-HTB. These double infected cells are 
termed starter cells. Then the pseudorabies virus gets packaged by Rgp 
expressed in the starter cell, which then retrograde label its pre-synaptic 
neurons.   
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Figure 2.10: Post-injury born neurons infected by dual viruses. 
(A) A schematic shows the experimental design. (B-G) Immunostaining with GFP 
(green) and DsRed (red) to identify post-injury born neurons as starter cells 
(indicated by white arrowhead) in the granule cell layer. 4′,6-diamidino-2-
phenylindole (DAPI) staining of nuclei shows the hippocampal dentate granule 
cell layer structure. 
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pre-synaptic neurons locally in the ipsilateral granule cell layer, dentate molecular 
layer, hilus, and CA1 regions, matching connections locally in the hippocampus 
(Figure 2.11), and distally in the contralateral perirhinal cortex (PRH), ipsilateral 
retrosplenial granular cortex (RSG), and ipsilateral medial habenular nucleus 
(MHb, Figure 2.12). These results proved that post-injury born neurons are able 
to integrate into neural networks. The connections suggest that post-injury born 
neurons’ activity is possibly regulated under local feedback circuit, and they are 
highly likely participating in memory functions and integrating sensory, spatial, 
and emotional information. 
 
Functional integration of post-injury born neurons 
With the dual-virus system, I illustrated the anatomical integration of post-injury 
born neurons. I further wondered if they are able to exert neuronal activity to 
support functional outcomes. Previous studies have widely used expression of 
immediate early gene, c-fos, as a marker to visualize functional integration of 
neurons (Kee et al., 2007, Garner et al., 2012, Ramirez et al., 2013). Thus, in the 
current study, I similarly used the expression of c-fos as an indicator of functional 
integration of post-injury born neurons. I labeled cells born in the first 2 weeks 
after injury by BrdU incorporation and collected brain tissues after 6 weeks of TBI 
(Figure 2.13 A). By the BrdU, NeuN, and c-fos triple labeling strategy, I evaluated 
functional integration of post-injury born neurons at their age of 4 weeks to 6 
weeks, the time point when newborn neurons have been proved able to 
functionally integrate into network (Kee et al., 2007). I was not able to detect 
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Figure 2.11: Local pre-synaptic neurons within the hippocampus innervating 
post-injury born neurons labeled by DsRed. 
(A-I) Immunostaining with GFP (green) and DsRed (red) to identify pre-synaptic 
neurons (indicated by white arrowheads) in the hippocampal granule cell layer 
(A-C), hippocampal dentate molecular layer (D-F), and hippocampal CA1 (G-I) 
that innervates post-injury born neurons. 4′,6-diamidino-2-phenylindole (DAPI) 
staining of nuclei shows the hippocampal dentate granule cell layer structure.  
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Figure 2.12: Distal pre-synaptic neurons in cortical and subcortical regions 
innervating post-injury born neurons labeled by DsRed. 
(A-I) Immunostaining with GFP (green) and DsRed (red) to identify pre-synaptic 
neurons (indicated by white arrowheads) in the retrosplenial granular cortex (A-
C), medial habenular nucleus (D-F), and perirhinal cortex (G-I) that innervates 
post-injury born neurons. 4′,6-diamidino-2-phenylindole (DAPI) staining of nuclei 
shows the brain structure. MHb: medial habenular nucleus; PRH: perirhinal 
cortex; RSGa: retrosplenial cortex a). 
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Figure 2.13: Functional recruitment of post-injury born neurons in a standard 
housing environment. 
(A) A schematic shows the experimental design. (B-J) Immunostaining with BrdU 
(green), c-fos (red), and NeuN (cyan) to identify neuronal activity in post-injury 
born neurons (indicated by white arrowheads, all from TBI animals). Scale bar 
indicates 5 m. (K) Quantification of active post-injury born neurons in sham and 
TBI animals (n=4 for each group). 
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triple positive cells in sham animals (0 triple positive cells in 1,809  893 BrdU 
and NeuN double positive post-surgery born neurons). On rare occasions, I was 
able to observe active post-injury born neurons in TBI animals (13  6 triple 
positive cells in 5,732  1,964 BrdU and NeuN double positive post-injury born 
neurons) (Figure 2.13 B-K). Although rare, this quantification suggested that 
post-injury born neurons were able to exert functional activities in a standard 
housing environment.  
Furthermore, I asked if the post-injury born neurons are able to respond to 
behavior task. To answer the question, I challenged mice with standard Morris 
water maze (MWM) test at 7 weeks after TBI and sacrificed mice 45 min after 
MWM probe test (Figure 2.14 A). After MWM test, I was able to detect triple 
positive cells in both sham and TBI animals (Figure 2.14 E-G), and there was a 
slight but not significant increase of number of triple positive cells in TBI than 
sham cohorts (13  7 triple positive cells in sham compared to 20  7 in TBI, 
p=0.13, Figure 2.14 H). Further studies are needed to validate if TBI promotes 
functional recruitment of newborn neurons or not. 
 
Discussion 
NSCs support adult neurogenesis in a lifetime and resemble the regenerative 
potential of the adult brain. NSC proliferation in the hippocampus after TBI sheds 
light on the possibility of injury repair by endogenous neurogenesis. Whereas, 
whether the NSC proliferation supports neurogenesis after injury is argued. 
Current contradictory studies were conducted in different injury models, mostly in   
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Figure 2.14: Functional recruitment of post-injury born neurons upon Morris 
water maze test. 
A) A schematic shows the experimental design. (B-G) Immunostaining with BrdU 
(green), c-fos (red), and NeuN (cyan) to identify neuronal activity in post-injury 
born neurons (indicated by white arrowheads) in sham (B-D) and TBI (E-G) 
animals. (H) Quantification of active post-injury born neurons in sham and TBI 
animals after Morris water maze test (n=5 for each group). 
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rodents. Comparing reported works, CCI injury induced in adult mice (Gao and 
Chen, 2013, Rola et al., 2006) and cortical contusion injury induced in adult rats 
(Braun et al., 2002) both recapture focal injury characteristics in human TBI. 
Whereas impact acceleration model performed in adult rats (Bye et al., 2011) 
mainly mimics diffused axonal injury in patients, and lateral FPI injury induced in 
adult rats (Chirumamilla et al., 2002, Sun et al., 2005, Sun et al., 2007) exhibits 
mixed focal and diffuse injury in the clinical setting (Morales et al., 2005). Diffuse 
injury, i.e. impact acceleration and FPI, tends to affect a larger brain area than 
focal injury, i.e. cortical contusion model and CCI, so diffuse models generally 
produce injury with greater severity regarding the whole brain network. Overall, 
neural activity, neurotrophic factors, and metabolism level in the hippocampus 
may all be altered by various injury models and resulting in injury severity 
differences. Since all the signals above are essential for adult neurogenesis 
regulation (Faigle and Song, 2013), injury severity is considered as one of the 
most crucial variations in previous discrepancies. Besides injury severity, the 
time when neurogenesis was examined is also critical, as TBI pathogenesis and 
adult neurogenesis are both dynamic processes. Current studies that evaluated 
neurogenesis at as early as 2 days after injury to as late as 10 weeks after injury 
might reflect different single points on the dynamic curve. Here, I assessed 
neurogenesis at three crucial stages after different severities of TBI in a 
consistent system, to attain a better understanding of how NSCs respond to 
trauma. 
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By combining BrdU labeling and immunostaining of specific cell type 
markers, I evaluated the effects of injury severity on NSC proliferation, immature 
neuron number, and maturation of adult-born neurons (Figure 2.15). In my study, 
I observed that mild TBI hardly causes alteration of NSC proliferation, immature 
neuron number, or generation of mature neurons, implying low NSC or glial 
responses. Previously, my colleague reported that mild TBI causes limited cell 
death in the cortex but not in the HDG (Gao and Chen, 2011), and this may 
explain why mild TBI does not trigger cell proliferation and following processes.  
Moderate TBI results in increased NSC proliferation without dramatic 
change in immature neuron number or mature neuron production. My colleagues 
have reported that immature neurons are the most vulnerable cells in the 
hippocampus, leading to a dramatic decrease of the immature neuron number in 
the hippocampus at 24 h after injury (Gao et al., 2008). Although moderate injury 
promotes NSC proliferation, it only makes up for the loss of immature neurons in 
the early acute phase. The slight but not significant increase of immature neuron 
number is likely compensating effect.  
In contrast, severe CCI injury induced a much more severe cortical tissue 
lesion and increased cell death, primarily mature neuron death, in the dentate 
gyrus. Severe CCI significantly promoted NSC proliferation and mature neuron 
generation compared with moderate TBI, corresponding to the drastic mature 
neuron death when injury severity increased. This result indicates that NSCs can 
sense the environmental changes and respond to different intensities of stimuli.  
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Figure 2.15: Summary of post-traumatic neurogenesis in a severity-dependent 
manner. 
A schematic summarizes the severity-dependent post-traumatic neurogenesis. 
Sham animals have a baseline of NSC proliferation, immature neuron number, 
and mature neuron generation. Mild TBI does not change any of the stages. 
Moderate TBI increases NSC proliferation, which makes up for the immature 
neuron loss. Thus, immature neuron number returns to a comparable level of 
sham animals, and generation of mature neurons is not changed. Severe TBI 
further increases NSC proliferation, increases immature neurons, and increases 
the generation of mature neurons. 
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Subtle changes in gliogenesis were also detected in different subregions 
of the HDG. Cellular composition was comparable among all groups in the ML. 
Moderate and severe CCI caused an increased percentage of proliferated NG2 
cells in the GCL. The proliferated microglia ratio was elevated in all TBI groups 
instead in the hilus. It is interesting to observe these trends, since glial cells play 
crucial roles in regulating neuronal activity and adult neurogenesis. Traditionally 
considered solely as oligodendrocyte precursors, NG2 cells have currently been 
shown to have population heterogeneity. Some subgroups of NG2 cells can 
respond to neuronal stimulation in the adult hippocampus by elevating 
intracellular calcium. They are considered as modulators of synaptic activity 
(Trotter et al., 2010). NG2 cells in the GCL after injury predominantly located 
close to the inner or outer border of the GCL, thus indicating their potential 
involvement in modulating neuronal activity in spared or newly formed neural 
circuitry post injury. Microglia have been reported to play bidirectional roles in 
adult neurogenesis. Classic activation of microglia was reported to inhibit 
neurogenesis by expressing pro-inflammatory cytokines, such as IL-6 and TNF α, 
while with alternative activation, microglia release anti-inflammatory cytokines, i.e. 
IL-4, IGF-1 and TGF β, and promote neurogenesis (Belarbi and Rosi, 2013). In 
my case, microglia subtype identification was not performed. Although the 
elevated microglia proportion in the hilus is likely one of the mechanisms 
regulating neurogenesis, no clear clue refers to their supportive or detrimental 
involvements to post-traumatic neurogenesis. 
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Taken together, my results demonstrate that TBI severity affects post-
traumatic neurogenesis. Mild TBI does not affect post-traumatic neurogenesis. 
Moderate TBI promotes post-traumatic NSC proliferation without increasing 
neurogenesis. Severe TBI enhances post-traumatic NSC proliferation, immature 
neuron number, and mature neuron generation (Figure 2.15). By illustrating the 
phenomenon above, I may partially explain the existing dispute among different 
groups regarding post-traumatic neurogenesis. Moreover, this effect on post-
traumatic neurogenesis indicates that in the adult brain, NSCs have the potential 
to compensate for cell loss following injury. By further studying the mechanism 
that regulates this inner neuroplasticity, I might provide insights into a potential 
therapeutic application of endogenous NSCs against cell loss post-trauma.  
Previous studies on individual post-injury born neurons have shown that 
they have both similarities and differences compared to their counterparts in 
sham animals regarding their morphologies, electrophysiological properties, and 
their location. Neurons born after TBI showed similar membrane potential, 
excitability, spine density, and response to perforant pathway stimuli compared to 
their counterparts in sham animals (Villasana et al., 2015). However, they 
exhibited altered dendritic arborization by branching closer to soma, growing 
more apical dendrites, and/or spreading branches to a larger angle (Villasana et 
al., 2015). Additionally, adult-born neurons normally migrate slightly from SGZ to 
inner GCL (Zhao et al., 2006), but post-injury born neurons showed ectopic 
migration and misplaced in the outer GCL or even in the ML (Villasana et al., 
2015, Ibrahim et al., 2016). Together, these observations indicate the possibility 
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of post-injury born neurons forming synapses with neurons that they might not 
connect in a non-injured environment, which might disrupt network and perform 
maladaptive functions. Indeed, aberrant neurogenesis has been widely proposed 
as a mechanism for epilepsy (Jessberger and Parent, 2015). Thus, it is critical to 
investigate the anatomical integration pattern of post-injury born neurons to 
illustrate their beneficial and/or maladaptive functions. 
In normal conditions, developmentally-born granule neurons are 
classically studied and known to primarily receive glutamatergic signals from the 
perforant path of entorhinal cortex (EC) layer II neurons. Additionally, they 
receive cholinergic projections from the medial septal nucleus (MS) and the 
nucleus of the diagonal band of Broca (NDB), and projection from the 
supramammilary nuclei, which are likely excitatory via glutamate. Locally, their 
dendrites also form synapses with Mossy cells, basket cells, and other hilar 
interneurons. They relay signals to CA3 pyramidal neurons through the mossy 
fiber pathway (Andersen and Oxford University Press., 2007). Separately, adult-
born neurons have been specifically studied with the dual-virus system and have 
shown some similar but also unique connections compared to the developmental 
counterparts. They successively receive the classic inputs from local mossy cells 
and interneurons, followed by distal inputs from LEC, MS and NDB, but also 
uniquely receive inputs from local mature granule neurons, CA3 pyramidal 
neurons, subiculum, and distal perirhinal cortex (Vivar et al., 2012, Deshpande et 
al., 2013). The temporal shift of input connections is considered critical for 
regulating adult-born granule neuron survival and functional maturation.  
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In my study, I observed the innervation of post-injury born neurons from 
PRH, local granule neurons, and hilar neurons, consistent with their integration 
pattern in the non-injured environment, indicating normal functions they may 
serve. Novel inputs from the medial habenular nuclei (MHb) and retrosplenial 
granular cortex (RSG) were also discovered in the injured animals. However, 
studies of pre-synaptic tracing on adult-born granule neurons are limited, it is too 
early to conclude if these novel inputs represent undiscovered connections 
specific to adult-born granule neurons or misconnections made by post-injury 
born neurons. Additionally, MHb is known to participate in anxiety and fear 
memory formation (Viswanath et al., 2013), while the RSG is involved in episodic 
memory, navigation, and learning (Vann et al., 2009). These novel connections 
are highly consistent with the proposed roles of post-injury born neurons in 
cognitive functions, especially learning and memory, supporting the beneficial 
roles of post-traumatic neurogenesis. Further investigations on anatomical 
integration of post-injury born neurons at more and longer time points after TBI 
would help understand the temporal shift of signals that post-injury born neurons 
receive, provide more detailed evaluations on the anatomical integration of post-
injury born neurons. This will shed light on the normal and/or maladaptive 
functions of post-injury born neurons. 
Functionally, adult-born neurons were studied for their integration by their 
expression of IEGs, such as c-fos, Arc, Zif268, and Homer1A. Adult-born 
neurons were able to express IEGs in animals housed in home cage and 
respond to environment exploration behavior, MWM test, and drugs-induced 
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seizures (Carlen et al., 2002, Jessberger and Kempermann, 2003, Ramirez-
Amaya et al., 2006). Compared to their developmentally born counterparts, using 
c-fos as an indication of functional integration, adult-born neurons were proved to 
be preferentially recruited into spatial memory network by the age of 4 weeks or 
more (Kee et al., 2007). Besides spatial learning and memory in MWM test, 
adult-born neurons’ roles were studied in contextual fear memory and spatial 
pattern separation by fear conditioning test and the touchscreen system, 
respectively (Nakashiba et al., 2012, Vivar et al., 2012, Gu et al., 2012). By 
ablating different populations of adult-born neurons at specific ages, non-
reversibly silencing subgroups of adult-born neurons by tetanus toxin, or 
optogenetically silencing adult-born neurons, they were learned to be specifically 
required at the age of 3 to 4 weeks for spatial memory retrieval, long-term 
memory retention, and contextual discrimination (Gu et al., 2012, Nakashiba et 
al., 2012, Deng et al., 2009). Together, adult-born neurons are able to 
functionally contribute to behaviors at least after 4 weeks of their birth (Kee et al., 
2007).  
In current studies, I also used c-fos as a marker to investigate the 
functional integration of post-injury born neurons. In a home caged standard 
environment, I did not detect c-fos expression in newborn neurons aged 3-4 
weeks in sham animals or TBI injured animals, possibly due to their early 
maturation stage and/or limited stimuli in standard home caged environment. 
While for post-injury newborn neurons aged 4-6 weeks, I detected c-fos 
expression in these cells in TBI injured animals but not in sham animals in home 
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caged standard environment, indicating possible accelerated maturation of post-
injury born neurons by TBI. Moreover, I detected c-fos expression in newborn 
neurons aged 5-7 weeks after MWM spatial memory test in both sham and TBI 
animals, supporting functional integration of post-injury newborn into spatial 
neural networks. The number of c-fos positive post-injury born neurons observed 
in my studies are relatively limited, consistent with the sparse coding activity 
pattern of HDG granule cells (Jung and McNaughton, 1993). Noteworthily, I 
again observed a slight increase of post-injury newborn neurons’ integration in 
TBI compared to sham animals, indicating potential accelerated maturation of 
neurons born in the injured environment. Further investigations on potential 
mechanisms of this phenomenon would enhance the current understanding of 
the functional contributions of post-injury born neurons to the neurobehavioral 
improvements. 
Collectively, the body of my works in chapter 2 profiled the way of how TBI 
reshapes neurogenesis in terms of specific stages of neurogenesis affected by 
different injury severities, demonstrated that post-injury born neurons are able to 
integrate into neural network by receiving major inputs locally from neurons 
within hippocampus and distally from neurons in MHb, PRH, and RSG, and be 
functionally recruited especially upon behavior task. These conclusions serve as 
the foundations to investigate and test new functional improvements, especially 
learning and memory function restoration after TBI, by enhancing endogenous 
neurogenesis.  
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With the baseline of how TBI reshapes neurogenesis profiled, an 
approach to enhance post-traumatic neurogenesis is an urgent need. Although 
great efforts have already been devoted to clinical trials, to date, no treatment is 
clinically available to target post-traumatic neurogenesis. The lack of 
understanding molecular mechanisms governing post-traumatic neurogenesis is 
a major obstacle. In the following studies, I sought to investigate the molecular 
mechanism of TBI-enhanced NSC proliferation in hopes of providing a target for 
enhancing post-traumatic neurogenesis potentially by pharmacological 
interventions.  
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CHAPTER 3 
IDENTIFICATION OF MTORC1 AS A MOLECULAR TARGET TO PROMOTE 
TBI-ENHANCED NSC PROLIFERATION 
 
Hypotheses 
1) mTORC1 is required for TBI-enhanced NSC proliferation, 2) TBI primarily 
promotes proliferation of radial-glial like (RGL) NSCs but not neural progenitor 
cells (NPCs) through activating mTORC1 signaling, and 3) mTORC1 promotes 
RGL NSC proliferation by priming quiescent NSCs to a de novo alert state. 
 
Introduction 
NSCs in the adult hippocampus have been observed to increase proliferation in 
response to TBI in both human patients and experimental models (Dash et al., 
2001, Kernie et al., 2001, Braun et al., 2002, Chirumamilla et al., 2002, Rice et 
al., 2003, Ramaswamy et al., 2005, Gao et al., 2009a, Zheng et al., 2013, Sun et 
al., 2005). However, the spontaneous response of the adult NSCs is frequently 
inadequate for full compensation on the cell loss. Thus cognitive function deficits 
commonly persist in TBI patients (Prigatano, 1987, Cicerone et al., 2005). 
Although it holds great promise for utilizing the innate neurogenic machinery for 
injury repair, the lack of mechanistic studies on TBI-enhanced NSC proliferation 
impedes the development of therapeutic approaches targeting this regenerative 
machinery. 
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Hippocampal NSCs reside in a niche consists of various cell types and 
extracellular matrix. Multiple extracellular signals, such as parvalbumin 
interneuron activity, local granule neuron activity, Notch signal from progeny 
cells, and several others (Sierra et al., 2015, Song et al., 2012, Breunig et al., 
2007, Jang et al., 2013), work together to regulate NSC activity in normal 
conditions. After TBI, multiple signals from the NSC niche are greatly disrupted, 
and it is possible that it is not a single signal alteration but rather a combination of 
alterations that stimulates the transient NSC proliferation increase. Instead of 
isolating extracellular mediators, I targeted the intracellular signaling pathway 
that integrate and transduce extracellular signals and modulate NSC activity 
post-trauma.  
One of the critical intracellular signaling pathways governing cell 
proliferation is the mammalian target of rapamycin (mTOR) or mechanistic target 
of rapamycin (mTOR) pathway. The mTOR pathway is capable of orchestrating 
extracellular signals and regulating cell growth, proliferation, and survival through 
regulating protein synthesis, energy metabolism, and autophagy (Laplante and 
Sabatini, 2012). Dysregulated mTORC1 activity in embryonic and neonatal mice 
leads to imbalanced proliferation and differentiation of their NSCs (Magri et al., 
2011, Hartman et al., 2013).  In adult and aging rodent SVZ, mTORC1 is 
required for the neural progenitor pool maintenance (Paliouras et al., 2012). 
Decrease of mTORC1 activity in the aging mouse hippocampus contributes to 
NSC proliferation decline, and pharmacological activation of mTORC1 rescued 
the decline and increased neurogenesis (Romine et al., 2015). Taken together, 
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mTORC1 plays essential roles in NSC activity regulation. After trauma, mTORC1 
activation was reported in the hippocampus, presumably in neurons, microglia, 
and astrocytes (Chen et al., 2007, Park et al., 2012). Thus, I hypothesized that 
mTORC1 is required for TBI-enhanced NSC proliferation. To test the hypothesis, 
I examined the spatial-temporal profile of mTORC1 activation in the injured 
hippocampus, specifically assessed mTORC1 activation in NSCs, inhibited 
mTORC1 activity after TBI by rapamycin and evaluated subsequent NSC 
proliferation. My results demonstrated that mTORC1 activation in NSCs peaks at 
24 h and maintained high to 48 h post-trauma. Systemic inhibition of mTORC1 
signal suppressed TBI-enhanced NSC proliferation in the hippocampus. Thus, I 
proved that mTORC1 is required for TBI-enhanced NSC proliferation. 
NSCs in the hippocampus consists of radial glia-like cells (RGLs), the 
putative NSCs, and immediate progenitor cells (IPCs), the neuronal lineage 
committed NPCs (Bond et al., 2015). The RGL NSCs are able to self-renew and 
commit neuronal or astrocytic differentiation in the adult hippocampus (Bonaguidi 
et al., 2011, Sierra et al., 2015), while the NPCs have limited proliferative 
capacity and are mainly committed to neuronal differentiation (Daniel A. Berg, 
2015). A previous study suggested that TBI primarily activates RGL NSC rather 
than NPC proliferation (Gao et al., 2009a). I hypothesized that mTORC1 
activation is mediating the differential responses of RGL NSCs and NPCs. To 
test the hypothesis, I distinguished RGL NSC proliferation from NPC proliferation, 
evaluated mTORC1 activation in RGL NSCs versus NPCs, and assessed RGL 
NSC and NPC proliferation after TBI in the presence of mTORC1 inhibition. My 
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results confirmed TBI primarily activates RGL NSC but NPC proliferation, 
mTORC1 is activated in majority of RGL NSCs but only in a small proportion of 
NPCs, inhibition of mTORC1 mainly affects RGL NSC proliferation and has less 
of an influence on NPC proliferation. Together, I confirmed that mTORC1 
activation primarily mediates RGL NSC proliferation after TBI. 
NSC proliferation, especially RGL NSC proliferation, is a precisely 
controlled process, in which NSCs exit quiescence and enter cell cycle to 
proliferate, when they become active NSCs. RGL NSCs primarily remain 
quiescence with a small proportion activated to support neurogenesis in normal 
conditions. The delicate balance between quiescence and activation is regulated 
by multiple extrinsic signals within the NSC niche and intrinsic signals within 
NSCs themselves (Cheung and Rando, 2013), and the prerequisite step to 
activation is the exit from quiescence. Based on my data that mTORC1 is 
mediating TBI-enhanced RGL NSC proliferation, I further hypothesized that 
mTORC1 functions through promoting RGL NSC exit from quiescence and 
priming NSCs for possible proliferation. To test the hypothesis, I evaluated the 
status of individual RGL NSCs in terms of their mTORC1 activity and proliferative 
states in sham and TBI animals. My data showed the existence of a large 
proportion of RGL NSCs with mTORC1 signal activation at 24 h after injury, while 
the increase of RGL NSC proliferation at 48 h was not as dramatic as the 
mTORC1 activation. The return back to quiescence was observed in the majority 
of the mTORC1 activated RGL NSCs. Thus, I proposed the existence of a de 
novo state of NSCs between quiescence and activation, featured by mTORC1 
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activation, in which I termed them alert NSCs. I proposed that alert NSCs 
reversibly exit quiescence and are primed to proliferate, while they remain the 
capacity to return back to quiescence.  
 
Materials and methods  
Animal care 
Male mice (n=83) at the age of 8-10 weeks were housed as described in chapter 
2. All procedures were performed under protocols with approval from Indiana 
University Animal Care and Use Committee. 
 
Controlled cortical impact  
Injuries were performed as described in chapter 2. In these experiments, injury 
parameters were set at 3.0 m/s or 3.5 m/s, 1.0 mm, 0.1 s.  
 
Drug administration 
Rapamycin was dissolved in DMSO at a concentration of 25 mg/ml. It was further 
diluted to 1mg/ml in a solution of 5% PEG400/4% ethanol and 5% Tween 80 in 
sterile water. Rapamycin (10mg/kg, i.p.) or vehicle (5% PEG400/4% ethanol and 
5% Tween 80 in sterile water) was injected at 12 h, 24 h, 36 h, and 44 h post-
trauma. BrdU was given right after the final dose of rapamycin at 44 h after TBI 
(100 mg/kg in saline, i.p.).  
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Immunoblotting 
To evaluate mTORC1 activity in the hippocampus after injury, mice were 
transcardially perfused with cold saline after CCI injury at 4 h, 24 h, 48 h, 72 h, 
and 1 week or after sham surgery. The ipsilateral hippocampi were freshly 
harvested and homogenized in ice-cold Triton lysis buffer (1% Triton, 20 mM 
Tris-HCL, 5 mM EGTA, 10 mM EDTA, 150 mM NaCl, and protease inhibitor 
cocktail [Roche, Basel, Schweiz]). Samples were centrifuged for 30 min 14000 
rpm at 4 °C and subjected to protein concentration determination by a modified 
Lowry assay (Bio-rad, Hercules, CA). For every sample, the same amount of 
protein was loaded for SDS/PAGE and electrotransferred to nitrocellulose 
membranes at 30 V at 4 °C overnight. The membrane was blocked by 5% non-
fat milk in PBS for 1 h at room temperature, followed by incubation with primary 
antibodies at 4 °C overnight. Primary antibodies used were listed in Table 2. 
Secondary antibodies were applied with a dilution at 1:5000. The membrane was 
washed 3 times and rinsed in TBST. Protein blots were detected with ECL 
substrates (Bio-rad), imaged for colorimetric detection. 
 
Immunohistochemistry and cell counting 
Brains were collected and processed to immunostaining as described in chapter 
2. Target cells were counted by the same method as described in chapter 2. To 
quantify mTORC1 activation in total NSCs, every sixth brain sections covering 
the whole hippocampus were immunostained against NSC marker and pS6. The 
number of double positive cells were counted in all the sections, and NSCs were 
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counted in three epicentral sections. The cell density was calculated by dividing 
cell number by the volume of GCL. To quantify mTORC1 activation in total 
proliferating NSCs, every sixth brain sections covering the whole hippocampus 
were immunostained against BrdU, NSC marker, and pS6. The numbers of triple 
positive cells, and BrdU and NSC marker double positive cells were counted 
respectively. The cell density was calculated by dividing cell number by the 
volume of GCL. To evaluate the status of individual RGL NSCs, every sixth brain 
sections covering the whole hippocampus were immunostained against BrdU, 
GFP, and pS6. The numbers of GFP+ pS6-BrdU-, GFP+pS6+BrdU-, 
GFP+pS6+BrdU+, and GFP+pS6-BrdU+ were counted respectively, and the 
percentage of each cell type was calculated by dividing cell number by the 
number of total GFP+ cells.  
 
Statistical analysis 
Quantification of target cells was shown as average ± standard deviation. Data 
were analyzed via the appropriate type of analysis of variance (ANOVA) followed 
by Fisher’s least significant difference (LSD) test. Statistical analysis was 
conducted via SPSS software (IBM Corporation, Armonk, NY). Significance was 
set at p<0.05. 
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Results 
mTORC1 signaling is activated in the hippocampus after TBI 
NSCs have been widely reported to respond to various types of brain injuries, 
including stroke, seizure, and TBI (Dash et al., 2001, Kernie et al., 2001, Braun et 
al., 2002, Chirumamilla et al., 2002, Rice et al., 2003, Ramaswamy et al., 2005, 
Gao et al., 2009a, Zheng et al., 2013, Sun et al., 2005, Parent et al., 1997, Yagita 
et al., 2001, Parent et al., 2002, Yamashita et al., 2006). Following TBI, 
enhanced NSC proliferation in the hippocampus has been consistently observed 
regardless of animal model and injury model (Dash et al., 2001, Kernie et al., 
2001, Braun et al., 2002, Chirumamilla et al., 2002, Rice et al., 2003, 
Ramaswamy et al., 2005, Gao et al., 2009a, Zheng et al., 2013, Sun et al., 
2005). It was further demonstrated that quiescent NSC is the subgroup that is 
mainly activated by TBI (Gao et al., 2009a). However, the molecular mechanism 
of the phenomenon remains elusive, impeding the development of interventions 
aimed at promoting neurogenesis by further enhancing NSC proliferation post-
trauma. Mammalian target of rapamycin (mTOR) signaling pathway, especially 
mTOR complex 1 (mTORC1), is known to be indispensable in NSC activity 
regulation in embryonic (Magri et al., 2011), neonatal (Hartman et al., 2013), 
adult (Paliouras et al., 2012), and aging rodents (Romine et al., 2015, Paliouras 
et al., 2012), its activation has also been reported post-trauma in the 
hippocampus (Chen et al., 2007, Park et al., 2012), so I proposed that mTORC1 
signaling mediates TBI-enhanced NSC proliferation.  
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To demonstrate this hypothesis, I induced moderate TBI in adult mice by a 
CCI injury model and began with evaluation on mTORC1 signal activation in the 
whole hippocampus at different time points post-injury. Adult mice were 
sacrificed after sham surgery or at 4 h, 24 h, 48 h, 72 h, and 1 week after CCI. 
Ipsilateral hippocampi were subjected to immunoblotting. The total amount of 
ribosomal protein S6 (S6, a widely-used marker for mTORC1 activation (Laplante 
and Sabatini, 2012), Figure 3.1 A), and its phosphorylated form were examined, 
respectively. After trauma, the total S6 was elevated rapid at 4 h post-injury, 
reached the peak at 24 h, and maintained at a high level at 48 h and 72 h, while 
returned back to normal level at 1 week after injury (Figure 3.1 B). Meanwhile, 
the amount of activated S6, phosphorylation level (pS6), was dramatically 
increased at 4 h, further elevated at 24 h, maintained at high level at 48 h, 
remained slightly higher than sham level at 72 h and returned back comparable 
to baseline at 1 week (Figure 3.1 C). Together, the data suggested mTORC1 
signal was activated in the hippocampus mainly at 4 h, 24 h, and 48 h after TBI. 
 
mTORC1 signaling is activated in the hippocampal dentate gyrus after TBI 
To assess the temporal-spatial profile of mTORC1 activation in the hippocampal 
dentate gyrus (HDG), adult mice were sacrificed after sham surgery or at 4 h, 24 
h, 48 h, 72 h, and 1 week after CCI. The epicentral section from each animal was 
subjected to immunostaining against pS6. A limited number of pS6-positive cells 
were observed in sham animals, mainly in the granule cell layer (GCL) and few in 
the hilus, indicating a baseline of mTORC1 activity in the HDG (Figure 3.2 A).  
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Figure 3.1: TBI activates mTORC1 signaling in the hippocampus.  
Mice received a moderate controlled cortical impact (CCI) at the age of 9 weeks 
and were sacrificed after sham injury or at 4 h, 24 h, 48 h, 72 h, and 1 week after 
injury (n=3 for each group). (A) Immunoblotting with antibodies against phosphor-
ribosomal protein S6 (pS6), ribosomal protein S6 (S6), and β-actin shows 
mTORC1 signaling activation in the hippocampus. (B, C) Quantification of blots 
shown in panel A (* p<0.05, ** p<0.01). Data contributed by Dr. Lin Xu in Chen 
lab.  
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Figure 3.2: TBI activates mTORC1 signaling in different subregions of the 
hippocampus.  
Mice received a moderate controlled cortical impact (CCI) at the age of 9 weeks 
and were sacrificed after sham injury or at 4 h, 24 h, 48 h, 72 h, and 1 week after 
injury (n=3 for each group). (A-L) Immunostaining against pS6 (red) shows 
mTORC1 signaling activation in the hippocampal dentate gyrus after sham 
surgery (A), and 4 h (C), 24 h (E), 48 h (G), 72 h (I), and 1 week (K) after CCI, 
and in the subgranular zone at corresponding time points (B, D, F, H, J, L, 
respectively. DAPI staining shows the structure of hippocampal dentate gyrus.  
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Following TBI, I observed a wave of mTORC1 activation in the HDG starting no 
later than 4 h and maintaining a high level of activation at least until 72 h, while 
returning to sham level at 1 week post-injury (Figure 3.2 C, E, G, I, K).  
Meanwhile, mTORC1 activation showed different patterns in terms of 
signal location in each HDG subregions at different time points. At 4 h post-
trauma, increased pS6-positive cells were predominantly restricted in the GCL 
(Figure 3.2 C), indicating a rapid response in granule neurons to the initial insult. 
At 24 h post-trauma, the pS6-positive cells further accumulated not only in the 
GCL but also vastly extended to the molecular layer (ML) and hilus (Figure 3.2 
E). At 48 h following CCI, the pS6 signal reached the peak, and positive cells 
were mainly detected in the ML and hilus but few in the GCL (Figure 3.2 G), 
implying strong mTORC1 activation in reactive glia, highly likely reactive 
microglia, at this time point (unpublished data). At 72 h post-trauma, mTORC1 
activation started decreasing, and the remaining positive cells were mostly in the 
ML (Figure 3.2 I), which were largely attributed to reactive astrocytes based on 
unpublished data. At 1 week after TBI, the pS6 signal was back to sham level 
and again showed sporadic activation mainly in the GCL (Figure 3.2 K). 
Collectively, I detected a time-dependent and location-shift mTORC1 activation 
pattern in the HDG following TBI, indicating mTORC1 involvement in diverse 
responses to CCI in multiple cell types. 
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Time-course of mTORC1 signaling activation in the SGZ after TBI 
To further examine whether mTORC1 is activated in the NSCs after TBI, I 
focused on pS6 signal in the SGZ, where adult NSCs reside in the hippocampus 
(Faigle and Song, 2013). In sham animals, I again observed pS6-positive cells 
were rare and mainly located in the GCL (Figure 3.2 B). At 4 h post-trauma, 
increased pS6 signal was seen primarily in the GCL but not SGZ (Figure 3.2 D). 
At 24 h post injury, a dramatic increase of pS6-positive cells showed up in the 
SGZ (Figure 3.2 F), as well as in the ML and hilus. At 48 h following CCI, pS6-
positive cells in the SGZ decreased compared with 24 h, but was still more than 
sham level (Figure 3.2 H). At 72 h and 1 week post-trauma, mTORC1 activation 
in the SGZ was limited and comparable to sham animals (Figure 3.2 J, L). Taken 
together, my data enabled me to narrow down activation of mTORC1 in the SGZ 
predominantly to 24 h and 48 h after initial injury, suggesting the potential time 
course of mTORC1 activation in the NSCs. The period of mTORC1 activation 
correlates with TBI-enhanced NSC proliferation (Gao et al., 2009a), indicating 
possible involvement of mTORC1 activity in TBI-enhanced NSC proliferation. 
 
TBI activates mTORC1 signaling in the NSCs 
To accurately evaluate whether mTORC1 is activated in the NSCs, I co-labeled 
pS6 with NSC marker. Additionally, I took advantage of a Nestin-GFP transgenic 
mouse, in which NSCs ectopically express green fluorescent protein (GFP) (Gao 
et al., 2009a, Mignone et al., 2004). I hardly observed NSCs co-staining with an 
antibody to pS6 in the SGZ of sham-treated animals (Figure 3.3 A-C).   
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Figure 3.3: TBI activates mTORC1 signaling in NSCs. 
Mice received a moderate controlled cortical impact (CCI) at the age of 9 weeks 
and were sacrificed at 24 h, 48 h after injury as well as after sham injury (n=5 for 
each group). (A-I) Immunostaining with antibodies against GFP (green) and 
phosphor-ribosomal protein S6 (pS6, red) shows mTORC1 signaling activation in 
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neural stem cells (indicated by white arrows) after sham surgery (A-C), 24 h (D-
F), and 48 h (G-I) after CCI in the subgranular zone. (J) Quantification of total 
pS6-positive NSCs after sham surgery, and 24 h and 48 h after CCI, 
respectively. (K) Quantification of ratio of pS6-positive NSCs in the epicenter 
after sham surgery, and 24 h and 48 h after CCI, respectively (*p<0.05, **p<0.01, 
***p<0.001). 
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Quantification illustrated that 2.6 ± 2.1% of NSCs were pS6 positive at the 
epicenter (Figure 3.3 J). When I further examined NSCs across the whole 
hippocampus, there were only 1,096 ± 805 /mm3 of total NSCs in the whole 
hippocampus co-labeled with pS6 (Figure 3.3 K). These results confirmed my 
prior notion that basal mTORC1 activity in the NSCs is very low in the sham 
animals. 
At 24 h after injury, the number of pS6-positive cells in the SGZ were 
dramatically increased (Figure 3.3 E) and largely labeled NSCs (Figure 3.3 D-F, 
indicated by white arrows). Quantification showed mTORC1 is active in 60.7 ± 
6.8% of total NSCs in the epicenter (Figure 3.3 J). Totally, mTORC1 signaling is 
active in 15,750 ± 4,620/mm3 NSCs across the whole hippocampus (Figure 3.3 
K), indicating a dramatic 15-fold increase compared to the sham animals.  
At 48 h after TBI, the number of pS6-positive cells was still very high 
(Figure 3.3 H), while labeling in NSCs decreased (Figure 3.3 G-I, indicated by 
white arrows). At the epicenter, the percentage of mTORC1 positive NSCs also 
dropped to 17.7 ± 10.4% (p<0.001 vs. 24 h, p=0.017 vs. sham, Figure 3.3 J). The 
number of NSCs with active mTORC1 in the whole hippocampus rapidly 
decreased to 5,987 ± 1,348/mm3 (p<0.001 vs. 24 h), but was still much higher 
than basal level (p=0.044 vs. sham, Figure 3.3 K). Collectively, I observed a rapid 
and robust activation of mTORC1 in NSCs at 24 h after TBI and lasted at least 
48 h following trauma.  
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TBI activates mTORC1 signaling in the proliferating NSCs 
Previously, my colleagues illustrated that TBI transiently promoted NSCs 
proliferation at around 24-48 h post-injury (Gao and Chen, 2013). The molecular 
mechanisms of TBI-enhanced NSC proliferation are largely elusive. The period of 
mTORC1 signaling activation correlates well with NSC proliferation after TBI, a 
strong indication that mTORC1 signaling activation is involved in TBI-induced 
NSC proliferation. Thus, I further assessed whether mTORC1 signaling is 
activated in the proliferating NSCs. A dose of BrdU injection (i.p., 100 mg/kg) was 
given at 4 h prior to sacrifice (Figure 3.4 A), pulse-labeled the proliferating cells 
during this 4 h period. A series of every sixth section were processed for triple 
immunostaining to assess the mTORC1 activity in proliferating NSCs. 
In sham-treated animals, only 2,320 ± 513/mm3 NSCs are proliferating, 
pulse-labeled by BrdU (Figure 3.4 B, C, E, indicated by white arrowheads, and 
Figure 3.4 N). Among the proliferating NSCs, only 49 ± 40/mm3 are pS6 positive 
(Figure 3.4 O), representing merely 1.9 ± 1.2% of total proliferating NSCs that 
were pS6 positive (Figure 3.4 Q). These data indicate that only a small proportion 
of NSCs are proliferating in the hippocampus of mice receiving sham-surgery, 
and the activity of mTORC1 signaling at these proliferating NSCs is extremely 
low.  
At 24 h after moderate CCI injury, 3,070 ± 658/mm3 NSCs were 
proliferating in the hippocampus (Figure 3.4 F, G, I, indicated by both white 
arrowhead and arrow, and Figure 3.4 N). However, TBI significantly activated 
mTORC1 signaling in the hippocampus (Figure 3.4 H). Of the proliferated NSCs,  
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Figure 3.4: TBI activates mTORC1 signaling in proliferating NSCs. 
Mice received a moderate controlled cortical impact (CCI) at the age of 9 weeks 
and were sacrificed at 24 h, 48 h after injury as well as after sham injury (n=5 for 
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each group). A dose of 5-bromo-2'-deoxyuridine (BrdU) was administered 4 h 
prior to perfusion. (A) Schematic shows experimental strategy. (B-M) 
Immunostaining against GFP (green), BrdU (cyan) and phosphor-ribosomal 
protein S6 (pS6, red) shows proliferating neural stem cells with (indicated by 
white arrows) or without (indicated by arrowheads) mTORC1 signaling activation 
in sham animals (B-E), 24 h (F-I), and 48 h (J-M) after CCI in the subgranular 
zone. (N-P) Quantification of total proliferating NSCs (N) total pS6-positive 
proliferating NSCs (O) and total pS6-negative proliferating NSCs (P) after sham 
surgery, and 24 h and 48 h, respectively. (Q) Percentage of pS6-positive 
proliferating NSCs after sham surgery, and 24 h and 48 h after CCI, respectively 
(*p<0.05, **p<0.01, ***p<0.001). 
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649 ± 229/mm3 or 24.7 ± 6.2% were pS6 positive (Figure 3.4 F-I, pointed out by 
white arrow, and Figure 3.4 O and Q), while the rest of the proliferating NSCs 
were pS6-negative (Figure 3.4 F-I, pointed out by white arrowhead). These 
results suggest that TBI did not dramatically alter NSC proliferation at 24 h 
compared with sham animals (p=0.328, Figure 3.4 N), consistent with previous 
report (Gao and Chen, 2013). In contrast, TBI promoted a 13-fold increase of 
mTORC1 activation in the proliferating NSCs at 24 h after TBI (p=0.001, Figure 
3.4 Q).  
At 48 h after receiving moderate CCI injury, there are 5,396 ± 1,092/mm3 
NSCs were proliferating in the hippocampus (Figure 3.4 J, K, M, indicated by 
both arrowheads and arrows, and Figure 3.4 N). TBI dramatically increased NSC 
proliferation in the hippocampus at this time point (p<0.001), agreeing with 
previous report that TBI transiently promoted NSC proliferation at 48 hours after 
TBI (Gao and Chen, 2013). TBI also significantly promoted the mTORC1 
signaling in the proliferating NSCs (1,260 ± 798/mm3, p=0.005 vs. sham, Figure 
3.4 J-M, pointed out by white arrows, and Figure 3.4 O). These data indicated 
that TBI significantly promotes NSC proliferation (Figure 3.4 N) and enhanced 
mTORC1 activity in the proliferating NSCs at 48 h after injury (Figure 3.4 O, Q). 
Together, I observed a dramatically increased level of mTORC1 activation in 
proliferating NSCs at 24 h and 48 h after TBI, while TBI transiently promotes 
NSC proliferation beginning at 48 hours after TBI. The sequence of mTORC1 
activation and increased NSC proliferation strongly indicate the possible 
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involvement of the mTORC1 signaling activation in TBI-enhanced NSC 
proliferation. 
 
Inhibition of mTORC1 signaling eliminates TBI-enhanced NSC proliferation 
To further confirm mTORC1 activation is required for TBI-enhanced NSC 
proliferation, I treated TBI injured animals with rapamycin, a well-established 
mTORC1 inhibitor and then evaluated NSC proliferation at 48 h after TBI. To fully 
block mTORC1 activity, 4 rapamycin (i.p., 10 mg/kg) or vehicle injections were 
given at 12 h, 24 h, 36 h, and 44 h after TBI or sham surgery. Right after the last 
rapamycin injection, a dose of BrdU (i.p.,100 mg/kg) was delivered to label cell 
proliferation, and then animals were perfused at 48 h after injury (Figure 3.5 A).  
To evaluate mTORC1 inhibition, the epicentral section from each animal 
was subjected to pS6 staining. The low level of mTORC1 activation in sham 
animals was not apparently affected by rapamycin (Figure 3.5 B, D), while the 
originally strong mTORC1 activation in the HDG was dramatically abolished in 
TBI injured animals at 48 h after surgery (Figure 3.5 C, E). The pS6 staining 
demonstrated successful mTORC1 inhibition in the HDG post-trauma. To assess 
overall cell proliferation, the epicentral section from each animal was processed 
to BrdU staining. An obvious decrease of BrdU positive cells in the HDG was 
observed in both rapamycin-treated sham and TBI animals compared with 
vehicle-treated groups (Figure 3.5 F-I). These data suggest that inhibition of 
mTORC1 dramatically reduced cell proliferation in the hippocampus.  
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Figure 3.5: Rapamycin treatment inhibits mTORC1 signaling and cell 
proliferation in the hippocampus following TBI. 
(A) Schematic shows experimental strategy. (B-E) Immunostaining with antibody 
against phosphor-ribosomal protein S6 (pS6, red) shows mTORC1 signaling 
activity after rapamycin or vehicle in sham animals or 48 h after CCI. (F-I) 
Immunostaining against BrdU (red) shows cell proliferation in the hippocampal 
dentate gyrus after rapamycin or vehicle treatment in sham animals or after CCI. 
DAPI staining shows the structure of hippocampal dentate gyrus. 
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There are different types of cells, including glia and NSCs, that are 
proliferating following TBI. To further determine if inhibition on mTORC1 affects 
NSC proliferation, double immunostaining with NSC markers was performed 
(Figure 3.6). In sham animals treated with vehicle, there were 1,925 ± 313/mm3 
NSCs proliferating (Figure 3.6 A-C, indicated by arrows, and Figure 3.6 M), which 
was slightly decreased by rapamycin treatment to 1,436 ± 519/mm3 without 
significant difference (p=0.956, Figure 3.6 D-F, and M). After injury, NSC 
proliferation was dramatically increased to 4,260 ± 1,251/mm3 (p=0.001 vs. sham 
+ vehicle, Figure 3.6 G-I, and M), while rapamycin treatment abolished the 
enhanced effect on NSC proliferation (2,375 ± 920/mm3, p=0.018 vs. TBI + 
vehicle, Figure 3.6 J-L, and M). Together, my data suggested inhibition on 
mTORC1 signaling ablates TBI-enhanced NSC proliferation, suggesting that 
mTORC1 pathway activation is required for TBI-enhanced NSC proliferation.  
 
TBI primarily promotes RGL NSC proliferation but not NPC proliferation 
As mentioned earlier, NSCs are the combination of RGLs, the putative 
multipotent NSCs, and IPCs, the unipotent NPCs (Bond et al., 2015). The two 
populations are both labeled by GFP expression in the Nestin-GFP transgenic 
mice, but display distinct morphologies (Mignone et al., 2004). The RGL NSCs 
hold long radial processes growing through GCL towards ML (Figure 3.7, 
indicated by white arrow), while NPCs lose their radial processes showing round 
cell morphologies (Figure 3.7, indicated by white arrowhead) (Mignone et al., 
2004). By the morphological differences, I am able to distinguish RGL NSCs from 
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Figure 3.6: Inhibition of mTORC1 signaling ablates TBI-enhanced NSC 
proliferation. 
Mice were treated with the same procedure as shown in Figure 3.5 A (n=5 for 
each group). (A-L) Immunostaining against GFP (green) and BrdU (red) shows 
NSC proliferation (indicated by white arrows) in the subgranular zone after 
rapamycin or vehicle treatment in sham animals and 48 h after CCI. (M) 
Quantification of NSC proliferation in the subgranular zone after rapamycin or 
vehicle treatment in sham animals and 48 h after CCI (*p<0.05, **p<0.01, 
***p<0.001). 
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Figure 3.7: Morphological differences of RGL NSCs and NPCs in Nestin-GFP 
transgenic mouse SGZ. 
RGL NSCs show long radial processes growing through GCL towards ML 
(indicated by white arrow). NPCs show non-radial round morphology without 
processes (indicated by white arrowhead). 
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NPCs and study their differences in response to TBI, and the roles mTORC1 
might play in it.  
I first separated RGL NSC proliferation from NPC proliferation in sham 
and injured animals at 24 h and 48 h post-trauma (Figure 3.8). In sham animals, 
the majority of BrdU and GFP double positive cells showed the round cell 
morphologies without radial processes demonstrating higher baseline of NPC 
proliferation (Figure 3.8 A-C, indicated by white arrowheads, 1935 ± 178 
cells/mm3, Figure 3.8 J) than RGL NSC proliferation (Figure 3.8 A-C, indicated by 
white arrow, 456 ± 114 cells/mm3, Figure 3.8 J), consistent with their regular 
contributions to adult neurogenesis. At 24 h after TBI, I observed a slight but not 
significant increase of NPC proliferation (Figure 3.8 D-F, indicated by white 
arrowheads, 3138 ± 979 cells/mm3, Figure 3.8 J), and similar phenomenon was 
also observed for RGL NSC proliferation (Figure 3.8 D-F, indicated by white 
arrow, 548 ± 122 cells/mm3, Figure 3.8 J). At 48 h after TBI, I again observed 
comparable level of NPC proliferation (Figure 3.8 G-I, indicated by white 
arrowheads, 3161 ± 1032 cells/mm3, Figure 3.8 J), while the RGL NSC 
proliferation was dramatically increased to 1346 ± 68 cells/mm3, 3.0-fold increase 
compared to sham animals (Figure 3.8 G-I, indicated by white arrows, p<0.001 
vs. sham, Figure 3.8 J). Together, the data is consistent with a previous study 
(Gao et al., 2009a), and again proved that it is the RGL NSCs who robustly 
respond to TBI by increasing their proliferation. 
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Figure 3.8: TBI primarily promotes RGL NSC proliferation other than NPC 
proliferation. 
Mice received a moderate controlled cortical impact (CCI) and were sacrificed at 
24 h, 48 h after injury as well as after sham injury (n=5 for sham, n=3 for 24 h 
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and 48 h). A dose of 5-bromo-2'-deoxyuridine (BrdU) was administered 4 h prior 
to perfusion. (A-I) Immunostaining against GFP (green) and BrdU (red) shows 
proliferating RGL NSCs (indicated by white arrows) and proliferating NPCs 
(indicated by white arrowheads) in sham animals (A-C), 24 h (D-F), and 48 h (G-
I) after CCI in the subgranular zone. (J) Quantification of proliferating RGL NSCs 
and NPCs after sham surgery, and 24 h and 48 h (***p<0.001, n.s. stands for not 
significant). 
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mTORC1 is required primarily for RGL NSC proliferation after TBI 
Furthermore, I wondered if mTORC1 activation is mediating the different 
responses of RGL NSCs and NPCs, and is required primarily for RGL NSCs to 
proliferate after TBI. By the same strategy of separating RGL NSCs from NPCs 
via morphological differences, I evaluated mTORC1 activity in RGL NSCs and 
NPCs, respectively (Figure 3.9). In sham animals, I again rarely detected 
mTORC1 activation in either RGL NSCs or NPCs. There were totally 2.0% ± 
1.6% of all RGL NSCs having mTORC1 activation, and the ratio of mTORC1 
active NPCs was even smaller (0.9% ± 0.7%, Figure 3.9 A-C, and J). At 24 h 
after TBI, I again observed dramatic elevation of mTORC1 activity in Nestin-GFP 
positive cells. The activation of mTORC1 in RGL NSCs was significantly 
increased to 56.9% ± 5.6% of all RGL NSCs in the hippocampus (Figure 3.9 D-F, 
pointed by white arrows, p<0.001 vs. sham, Figure 3.9 J). For the NPCs, 
mTORC1 was dramatically activated in 29.0% ± 2.0% of total NPCs in the 
hippocampus (Figure 3.9 D-F, pointed by white arrowheads, p<0.001 vs. sham, 
Figure 3.9 J), but the level of mTORC1 activation in NPCs is significantly lowered 
than in RGL NSCs (p<0.001, Figure 3.9 J). At 48 h after injury, the mTORC1 
activation was again decreased in Nestin-GFP positive cells but still higher 
compared to sham animals. While the pattern of mTORC1 activation in RGL 
NSCs versus NPCs was similar with 24 h, in which a larger proportion of RGL 
NSCs (13.2% ± 4.2%) were still active for mTORC1 activity compared to NPCs 
(4.7% ± 2.6%, p=0.002 vs. RGL NSCs, Figure 3.9 J). Together, my data 
demonstrated that although mTORC1 was activated in both NSCs and NPCs  
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Figure 3.9: TBI primarily activates mTORC1 signaling in RGL NSCs other than 
in NPCs. 
Mice received a moderate controlled cortical impact (CCI) and were sacrificed at 
24 h, 48 h after injury as well as after sham injury (n=4 for each group). (A-I) 
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Immunostaining against GFP (green) and pS6 (red) shows mTORC1 active RGL 
NSCs (indicated by white arrows) and NPCs (indicated by white arrowheads) in 
sham animals (A-C), 24 h (D-F), and 48 h (G-I) after CCI in the subgranular 
zone. (J) Quantification of mTORC1 activation in RGL NSCs and NPCs after 
sham surgery, and 24 h and 48 h (*p<0.05, **p<0.01, ***p<0.001). 
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after TBI, the level of mTORC1 activation is significantly greater in RGL NSCs 
than in NPCs.  
To investigate if the differential mTORC1 activation is largely required for 
TBI-enhanced RGL NSC proliferation but less for NPC proliferation, I assessed 
how mTORC1 inhibition after TBI affects RGL NSC proliferation and NPC 
proliferation, respectively. With the same strategy of mTORC1 inhibition by 
rapamycin administration (Figure 3.5), I detected the baseline of RGL NSC 
proliferation (Figure 3.10 A-C, indicated by white arrow, 289 ± 73 cells/mm3, 
Figure 3.10 J) and NPC proliferation (Figure 3.10 A-C, indicated by white 
arrowheads, 4680 ± 1444 cells/mm3, Figure 3.10 J) in sham animals with vehicle 
treatment. At 48 h after TBI, I again detected a significant increase of RGL NSC 
proliferation to 1152 ± 118 cells/mm3 (p<0.001 vs. sham + vehicle, Figure 3.10 
M), a 3.98-fold increase compared to sham. Whereas, the effects of TBI on RGL 
NSC proliferation was largely eliminated with mTORC1 inhibition, shown as the 
RGL NSC proliferation in injured animals with rapamycin treatment is 
dramatically decreased compared to vehicle treated injury cohorts (448 ± 109 
cells/mm3 vs. 1152 ± 118 cells/mm3, p<0.001, Figure 3.10 J-L, and M), but was 
still larger than sham controls (448 ± 109 cells/mm3 vs. 289 ± 73 cells/mm3, 
p=0.026, Figure 3.10 M). While RGL NSC proliferation in sham animals was not 
affected by rapamycin (303 ± 76 cells/mm3, p=0.831 vs. sham + vehicle). On the 
contrary, although the NPC proliferation showed fluctuations, neither TBI insult 
nor rapamycin treatment significantly altered NPC proliferation (p=0.054 for 
injury, and p=0.090 for rapamycin treatment, Figure 3.10 M). Together, the data   
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Figure 3.10: Inhibition of mTORC1 signaling primarily ablates TBI-enhanced 
RGL NSC proliferation other than NPC proliferation. 
Mice were treated with the same procedure as shown in Figure 3.5 A (n=5 for 
sham+vehicle, n=4 for sham+rapamycin, TBI+vehicle, and TBI+rapamycin). (A-L) 
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Immunostaining against GFP (green) and BrdU (red) shows RGL NSC 
proliferation (indicated by white arrows) and NPC proliferation (indicated by white 
arrowheads) in the SGZ after rapamycin or vehicle treatment in sham animals 
and 48 h after CCI. (M) Quantification of RGL NSC proliferation and NPC 
proliferation in the SGZ with rapamycin or vehicle treatment after sham surgery 
and 48 h after CCI (*p<0.05, **p<0.01, ***p<0.001). 
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demonstrated that mTORC1 is primarily required for TBI-enhanced RGL NSC 
proliferation. 
 
mTORC1 primes quiescent RGL NSCs to facilitate proliferation and 
features a de novo alert state of NSCs 
As discussed earlier, RGL NSCs mainly remain quiescent, and only a small 
proportion is constantly proliferating (Bond et al., 2015). The delicate balance 
between quiescence and proliferation featured activation is precisely controlled 
by extrinsic and intrinsic signals, primarily at the step of exit from quiescence 
(Figure 3.11). My data demonstrated that mTORC1 is primarily mediating TBI-
enhanced RGL NSC proliferation, so I wondered how mTORC1 promotes 
quiescent RGL NSCs to exit quiescence and enter proliferation. To answer the 
question, I evaluated the status of individual RGL NSCs in sham and injured 
animals in terms of their mTORC1 activity and proliferative status.  
I again combined the Nestin-GFP expression and radial glial morphology 
to identify each individual RGL NSCs, used pS6 as a marker to assess mTORC1 
activity and BrdU label as an indicator of proliferation. In sham animals, I 
observed that 94.8% ± 0.7% of RGL NSCs were negative for either pS6 or BrdU 
(Figure 3.12 A-D, indicated by white arrowhead), indicating they are quiescent 
NSCs (qNSCs), which is consistent with the roles of NSCs to maintain a 
regenerative reservoir. A small proportion of RGL NSCs were positive for 
mTORC1 signal but negative for BrdU labeling (Figure 3.12 E-H, indicated by 
white arrowhead, 2.4% ± 1.1%, Figure 3.12 Q), differentiating them from 
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Figure 3.11: Quiescence and activation balance of RGL NSCs and mechanism 
of the balance. 
(A) RGL NSCs in the SGZ maintains a delicate balance between quiescence and 
activation. The quiescence maintenance is critical for preserving a regenerative 
pool of RGL NSCs for lifelong tissue homeostasis and injury repair. The 
activation is essential for sustaining neurogenesis to support normal cognitive 
functions, especially learning and memory and emotion regulation. (B) Various 
extracellular signals together control quiescence and activation balance.  
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Figure 3.12: Activation of mTORC1 signaling features a distinct population of 
RGL NSCs different from quiescence and BrdU labeled activation. 
Mice received a moderate controlled cortical impact (CCI) and were sacrificed at 
24 h, 48 h after injury as well as after sham injury (n=3 for each group). A dose of 
5-bromo-2'-deoxyuridine (BrdU) was administered 4 h prior to perfusion. (A-P) 
Immunostaining with antibodies against GFP (green), pS6 (red), and BrdU (cyan) 
shows quiescent RGL NSCs (A-D, indicated by white arrow), alert RGL NSCs (E-
H, indicated by white arrow), transition RGL NSCs (I-L, indicated by white arrow), 
and activation RGL NSCs (M-P, indicated by white arrow). (O) Quantification of 
RGL NSCs in different statuses after sham surgery, and 24 h and 48 h (*p<0.05, 
**p<0.01, ***p<0.001, compared to sham. #p<0.05, ##p<0.01, ###p<0.001, 
compared to 24 h). 
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quiescent state although they were not proliferating, in which I termed them alert 
NSCs (alNSCs). Very rare RGL NSCs were seen positive for both mTORC1 
activity and BrdU labeling (Figure 3.12 I-L, indicated by white arrowhead, 0.1% ± 
0.1%, Figure 3.12 Q), indicating a transient state in which NSCs were activated 
by starting proliferation and mTORC1 activity was not turned off yet, in which I 
named them transition NSCs (tNSCs). A small proportion of RGL NSCs were 
negative for mTORC1 activity and solely positive for BrdU labeling (Figure 3.12 
M-P, indicated by white arrowhead, 2.7% ± 1.0%, Figure 3.12 Q), representing a 
state in which NSCs were actively proliferating when mTORC1 activity is no 
longer needed for maintaining proliferation. This is the pure proliferation state, 
which corresponds to active NSCs (aNSCs), who supports learning and memory 
function through normal neurogenesis (Bond et al., 2015). 
At 24 h after injury, I was still able to observe RGL NSCs in these four 
categories. However, they underwent a dramatic shift between different statuses. 
The qNSCs ratio dramatically decreased to 34.8% ± 6.7% (p<0.001 vs sham, 
Figure 3.12 Q), in a result, a significant increase was observed for alNSCs (2.4% 
± 1.1% in sham to 61.5% ± 6.5% in 24 h, p<0.001, Figure 3.12 Q), consistent 
with previously detected peak of mTORC1 activity in RGL NSCs. Whereas, the 
percentage of tNSCs was merely increased from 0.1% ± 0.1% to 2.0% ± 0.7% 
(p=0.014, Figure 3.12 Q), and aNSCs were not significantly changed yet 
(p=0.138 vs. sham, Figure 3.12 Q). At 48 h after TBI, I observed that the alNSCs 
ratio dramatically decreased to 16.7% ± 5.2%, only a quarter of the ratio at 24 h 
(p<0.001 vs. 24 h, Figure 3.12 Q), while the proliferating tNSCs and aNSCs 
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combination only increased from 2.8% ± 1.1% to 8.4% ± 1.1% (p=0.001 sham vs. 
48 h, Figure 3.12 Q). Correspondingly, the qNSC ratio restored to 74.9% ± 5.7% 
(p<0.001 vs. 24 h, Figure 3.12 Q), indicating the majority of alNSCs returned 
back to quiescence.  
It is well known that BrdU is rapidly metabolized after its introduction into 
the mouse system and labels proliferating cells in S phase of cell cycle for 
approximately 4 h (Hayes and Nowakowski, 2000), so I further validated 
individual RGL NSC status by an endogenous cell cycle maker, MCM2, to more 
accurately reflect proliferation status. Similarly, I was able to observe RGL NSCs 
in four different statuses (Figure 3.13 A-P). In sham animals, I detected majority 
but a slightly less proportion of NSCs were quiescent (88.9% ± 4.6%, Figure 3.13 
Q) as detected by BrdU (94.8% ± 0.7%, Figure 3.12 Q), showing negative 
expressions for either pS6 or MCM2 (Figure 3.13 A-D, indicated by white 
arrowhead), and relatively same ratio of alNSCs were detected (2.0% ± 1.6%). 
As a result, a higher ratio of proliferating tNSCs and aNSCs (9.1% ± 3.8%) were 
observed with the endogenous cell cycle maker MCM2 labeling as I expected. 
However, the pattern of RGL NSC status distribution was consistent as BrdU 
labeling, which was shown as majority of qNSC (88.9% ± 4.6%), rare alNSCs 
(2.0% ± 1.6%), nearly undetectable tNSCs (0.03% ± 0.05%) and small proportion 
of aNSCs (9.1% ± 3.8%). At 24 h after injury, I again observed a significant 
decrease of qNSCs ratio (35.4% ± 4.3%, p<0.001 vs. sham, Figure 3.13 Q), 
along with a dramatic increase of alNSCs proportion (52.5% ± 4.5%, p<0.001 vs.  
sham, Figure 3.13Q) and slightly increased tNSCs (4.4% ± 1.5%, p=0.002 vs.   
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Figure 3.13: Activation of mTORC1 signaling features a distinct population of 
RGL NSCs different from quiescence and MCM2 labeled activation. 
Mice received a moderate controlled cortical impact (CCI) and were sacrificed at 
24 h, 48 h after injury as well as after sham injury (n=4 for each group). (A-P) 
Immunostaining with antibodies against GFP (green), pS6 (red), and MCM2 
(cyan) shows quiescent RGL NSCs (A-D, indicated by white arrow), alert RGL 
NSCs (E-H, indicated by white arrow), transition RGL NSCs (I-L, indicated by 
white arrow), and activation RGL NSCs (M-P, indicated by white arrow). (O) 
Quantification of RGL NSCs in different statuses after sham surgery, and 24 h 
and 48 h (*p<0.05, **p<0.01, ***p<0.001, compared to sham. #p<0.05, ##p<0.01, 
###p<0.001, compared to 24 h). 
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sham) and unchanged aNSCs (7.7% ± 2.1%, p=0.628 vs. sham). At 48 h after 
TBI, a similar result was observed as a dramatic decrease of alNSCs (9.9% ± 
2.5%, p<0.001 vs. 24h), with a significant but small increase of proliferating tNSC 
and aNSC together (20.2% ± 7.1%, p=0.010 vs. sham) and great restoration of 
qNSC proportion (69.9% ± 8.2%, p<0.001 vs. 24 h).  
Collectively, my data with exogenous and endogenous cell cycle markers 
illustrated the existence of a noteworthy population of NSCs that are mTORC1 
active but not proliferating, which was termed alert NSCs (alNSCs) and was 
dramatically increased by injury transiently at 24 h after injury. The alNSCs 
showed the capacities to either enter proliferation or return back to quiescence, 
presumably depending on extra signals. I hypothesized that alNSCs is a de novo 
state of NSCs, different from the classically known quiescence and 
activation/proliferation, featured by mTORC1 activation. In the alert state, NSCs 
activate mTORC1 pathway to reversibly exit quiescence and prepare for potential 
proliferation for tissue homeostasis or injury repair, possibly by elevating overall 
protein synthesis, cellular metabolism, and/or macromolecule biogenesis 
(Laplante and Sabatini, 2012). Whereas, they are not guaranteed to necessarily 
enter proliferation and maintain the option to return to quiescence. Further 
characterizations on the protein synthesis level, cellular metabolism status, 
transcriptional activities, and/or gene expression patterns would help distinguish 
alNSCs from qNSCs and aNSCs and validate its existence as a de novo state 
between quiescence and activation/proliferation.  
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Discussion 
TBI causes tremendous hippocampal cell death, resulting in vast disconnections 
of neurocircuitries and subsequent neurobehavioral dysfunctions. To date, no 
FDA-approved drug against neuronal loss caused by TBI is available, and 
effective neuroprotective or alternatively neural repair approaches are urgently 
needed. Neural stem/progenitor cells (NSC) in the hippocampus resemble the 
potential of neuroregeneration in the adult brain and hold great promise for 
neuronal replenishment post-trauma (Kuhn et al., 1996, Shapiro and Ribak, 
2005, Ming and Song, 2005, Zhao et al., 2006). NSC proliferation has been 
widely reported to increase following TBI (Dash et al., 2001, Kernie et al., 2001, 
Braun et al., 2002, Chirumamilla et al., 2002, Rice et al., 2003, Ramaswamy et 
al., 2005, Gao et al., 2009a, Zheng et al., 2013, Sun et al., 2005), the same as 
generation of mature neurons in some circumstances (Sun et al., 2005, Sun et 
al., 2007, Wang et al., 2016b). This phenomenon shows the regenerative 
potential of the adult brain by the neurogenic response of NSCs after TBI. 
However, the increased NSC proliferation not always results in enhanced 
neurogenesis (Gao and Chen, 2013, Wang et al., 2016b). Therefore, the innate 
response is not always adequate to fully compensate for neuronal loss in some 
cases, which requires approaches to further promote NSC proliferation post-
trauma. Unfortunately, the molecular mechanisms of TBI-enhanced NSC 
proliferation are currently unknown, largely impeding its application.  
As a fundamental pathway in all cell types, mTOR signaling is involved in 
various important cellular events, including cell cycle progression, cell survival, 
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cell metabolism, and cell growth (Laplante and Sabatini, 2012). Especially in the 
nervous system, particularly in NSCs, mTOR signaling, specifically mTORC1, is 
significant for balancing differentiation and self-renewal. It has been reported that 
in the embryonic stage, constitutive mTORC1 signaling hyperactivity is 
responsible for deregulated NSCs activity and leads to the development of 
tuberous sclerosis (Magri et al., 2011). In the postnatal development, mTORC1 
activity is also required for NSCs, particularly in the maintenance of the transit 
amplifying neural progenitor pool (Paliouras et al., 2012). The decline of NSC 
proliferation in aging rodents can also be restored by activating mTORC1 activity 
(Romine et al., 2015). Collectively, mTORC1 plays significant roles in regulating 
NSCs activity, particularly in regulating NSC proliferation. In the current study, I 
demonstrated that mTORC1 activation is primarily mediating TBI-enhanced RGL 
NSC proliferation by driving qNSCs out of quiescence and priming them to a de 
novo alert state, and inhibition of mTORC1 activation primarily eliminated injury 
promoted RGL NSC proliferation. Thus, I identified a molecular target to 
potentially promote post-traumatic NSC proliferation and subsequent 
endogenous neurogenesis. 
Before I proved its role in mediating post-traumatic NSC proliferation in the 
current study, activation of mTORC1 signaling in the ipsilateral cortex and 
hippocampus has been noticed for a while (Chen et al., 2007, Park et al., 2012). 
In initial studies, mTORC1 was shown to mediate apoptotic neuronal death within 
hours after TBI, and early inhibition of mTORC1 signaling by rapamycin pre-
treatment has been shown to alleviate motor deficits and cognitive impairments 
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at 3 days post-trauma (Park et al., 2012, Ding et al., 2015). Later on, mTORC1 
activation in astrocytes and microglia post-injury was also documented, which 
supported the idea that the role of mTORC1 in TBI pathogenesis included 
inducing neuroinflammation and promoting astrogliosis, which could be reversed 
by rapamycin administration (Ding et al., 2014, Nikolaeva et al., 2015). In 
addition, the genetic activation of mTORC1 by inactivating upstream negative 
regulator worsens cognitive performances after TBI in rodents (Rozas et al., 
2015). Butler and colleagues additionally pointed out a regulatory role of 
mTORC1 in post-traumatic neurogenesis and synaptic reorganization, which was 
potentially involved in post-traumatic epileptogenesis (Butler et al., 2015). The 
studies supported the idea that mTORC1 activation was considered a deleterious 
event after TBI.  
However, another study instead demonstrated that rapamycin treatment 
worsened cognitive deficits (Zhu et al., 2014). My colleague’s unpublished data 
also indicates that mTORC1 activation is required for survival of spared neurons 
in the injured cortex. The exact roles of mTOR in TBI pathophysiology has yet to 
be determined. In the present study, I focused on the regulatory role of mTORC1 
in NSC proliferation after moderate TBI using a CCI model in mice. I illustrated 
that mTORC1 activation in NSCs in the hippocampus was delayed to after 24 h 
to 48 h of initial injury compared with 4 h post-trauma in mature neurons as 
previously reported (Chen et al., 2007, Ding et al., 2015). Inhibition of mTOR by 
rapamycin abolished TBI-enhanced NSC proliferation in the hippocampus at 48 h 
in a model of moderate CCI. My study demonstrated a beneficial role of 
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mTORC1 in neuroplasticity by mediating NSC proliferation after TBI. Although 
some studies described above indicate that inhibition of mTORC1 activity by 
rapamycin treatment pre- or post-injury improved motor functions and cognitive 
outcomes at the acute phase after TBI, my results suggest that the use of 
rapamycin may come at the expense of compromising neuroregeneration in a 
long-term manner. On the contrary, enhancing mTORC1 activation may increase 
neurogenesis and have a beneficial effect in improving learning and memory 
functions in the long term.  
Besides its therapeutic potential as a neural repair treatment after TBI, the 
role of mTORC1 in NSC activity regulation also sheds light on the principle 
question of how NSCs maintain balance between quiescence and 
activation/proliferation. There are at least 2 subtypes of NSCs that can be 
categorized in the adult hippocampal dentate gyrus. They can be distinguished 
from each other based on their radial vs. non-radial morphologies, protein 
marker, such as GFAP expression, and asymmetric vs. symmetric division 
modes (Seri and Garcia-Verdugo, 2001, Filippov et al., 2003, Bull and Bartlett, 
2005, Seaberg and van der Kooy, 2002, Mignone et al., 2004, Encinas et al., 
2006, Encinas et al., 2008, Encinas and Enikolopov, 2008). Radial glia-like (RGL) 
cells are the putative neural stem cells (NSCs). Only a small fraction (1.73 % to 
2.81 %) of them can be labeled by BrdU after a 4 hours pulse ((Gao et al., 
2009a) and Figure 3.12), implying that they mainly remain quiescent (Mignone et 
al., 2004, Encinas et al., 2006). Thus, RGL NSCs are consisted of a majority of 
quiescent neural stem cells (qNSC) and sparse active neural stem cells (aNSCs) 
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that are proliferating. Functionally, qNSCs maintain stem cell pool, while aNSCs 
asymmetrically divide to generate small round or oval shape neural progenitor 
cells (NPCs) (Seri et al., 2001, Bonaguidi et al., 2011). These progeny cells 
undergo limited rounds of symmetric divisions to generate neuroblasts. They can 
be labeled by BrdU in high frequency, approximately 14.99% (Gao et al., 2009a). 
Hence, they are termed as amplifying neural progenitor cells (NPCs) (Mignone et 
al., 2004, Encinas et al., 2006). My colleagues have previously proved that TBI 
mainly activates qNSCs (Gao et al., 2009a), and the observation has been again 
confirmed in the current study (Figure 3.8). The RGL NSCs dramatically 
increased their proliferation by 3.0-fold at 48 h post-trauma, whereas NPCs 
slightly but not significantly increase their proliferation at either 24 h or 48 h, 
indicating the therapeutic potential of specifically RGL NSCs in neuronal 
replacement represented neural repair. The difference in proliferative responses 
was further proved to be attributed to mTORC1 signal activation, as the inhibition 
of mTORC1 signal after TBI primarily eliminates RGL NSC proliferation while left 
NPC proliferation only marginally affected (Figure 3.10). This leads to the 
hypothesis that mTORC1 regulates quiescence and activation/proliferation 
balance of RGL NSCs. 
The RGL NSCs differ from NPCs in proliferative profiles partially shown as 
their unique ability to maintain quiescence. Cellular quiescence is a non-
proliferating state in which RGL NSCs are actively and reversibly restrained in 
the G0 phase of the cell cycle (Coller, 2011). The maintenance of quiescence, 
exit from quiescence and initiation of proliferation, and return back to quiescence 
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of RGL NSCs are tightly regulated to preserve normal tissue homeostasis while 
also support normal functions (Figure 3.11) (Bond et al., 2015). After TBI, I 
observed a noticeable population of RGL NSCs featured by mTORC1 signal 
activation that peaked at 24 h, representing 52.5% ± 4.5% of total NSCs, and I 
termed them alert NSCs (alNSCs). Whereas, the activation of mTORC1 signal in 
proliferating NSCs constantly maintained at a low level with no larger than 4.4% 
± 1.5% of total RGL NSCs, and I termed them transition NSCs (tNSCs) (Figure 
3.13). Despite the large proportion of alNSCs emerged after TBI, the percentage 
of proliferating tNSCs and aNSCs was only increased from 9.1% ± 3.8% to 
20.2% ± 7.1% at 48 h after injury, and qNSCs population exhibited a restoration 
from 35.4% ± 4.3% to 69.9% ± 8.2% (Figure 3.13). The disparity between 
alNSCs and proliferating tNSCs / aNSCs populations suggests mTORC1 
activation does not directly initiate the proliferation program. The separate time 
courses and limited overlap between mTORC1 signal and proliferation marker 
indicate involvement of mTORC1 in cellular events before cell cycle entry. The 
restoration of qNSCs proportion indicates mTORC1 activation features a 
reversible state different from quiescence. Collectively, I proposed a model of 
mTORC1 featured de novo state of NSCs, in which mTORC1 activation 
reversibly drives NSCs out of quiescence into an alert state (Figure 3.14). The 
alert NSCs can either enter cell cycle or return back to quiescence, possibly both 
depending on extra regulatory mechanisms. In the alert state, NSCs are different 
from quiescent and primed by mTORC1 activation, possibly by elevating overall 
cellular activities, to be prepared for potential proliferation.  
  
 142 
 
Figure 3.14: Alert RGL NSCs featured by mTORC1 signaling activation. 
Activation of mTORC1 features a de novo state of NSCs, in which I termed alert 
NSCs. The alert NSCs can either return back to quiescence or initiate 
proliferation, possibly depending on extra signals.  
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The alert state between quiescence and activation/proliferation provides a 
fine-tuning regulatory node for NSCs to modulate their activities to fit the dynamic 
changes in the environment. The existence of an alert state is supported by 
single cell transcriptomics studies. Single NSCs from the naïve adult 
hippocampus and injured SVZ were analyzed and a group of cells showed 
distinct gene expression profile different from qNSCs and aNSCs (Shin et al., 
2015, Llorens-Bobadilla et al., 2015). My study suggests that the distinct NSC 
state detected in single cell transcriptomic studies corresponds to the alert state I 
proposed. And the alert state is featured and can be identified by mTORC1 
activation. Further characterizations on alNSCs in terms of their protein synthesis 
rate, cellular metabolism activities, macromolecule biogenesis level, and 
transcriptional profiles would help define them as a distinct state by 
characterizing molecular differences such as single cell transcriptomics in qNSCs 
and aNSCs.  
The role of mTORC1 in regulating the transition of stem cell quiescence to 
activation/proliferation is not limited to the nervous system. It has also been 
reported in hematopoietic stem cells and muscle stem cells (Yilmaz et al., 2006, 
Rodgers et al., 2014). The regulation of protein synthesis rate is one of the 
shared mechanisms of how mTORC1 controls the transition of quiescence to 
activation/proliferation in different types of stem cells (Signer et al., 2014, 
Rodgers et al., 2014). Together, mTORC1 might serve as a fundamental 
regulator of stem cell quiescence and activation/proliferation transition across 
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different systems. Further characterizations on alNSCs would also shed light on 
potential mechanisms regulating stem cell activities in other organs. 
In conclusion, the body of my works in chapter 3 demonstrated that TBI 
enhances primarily RGL NSC proliferation by activating mTORC1 signal mainly 
in RGL NSCs. And mTORC1 promotes RGL NSC proliferation by reversibly 
driving RGL NSCs out from quiescence to an alert state. This conclusion 
provides a molecular target that can be potentially utilized to increase post-
traumatic NSC proliferation and possibly concomitant post-traumatic 
neurogenesis. Thus, in chapter 4, I evaluated the effects of a pharmacological 
approach targeting mTORC1 signaling on cognitive function recovery after TBI 
and assessed if it functions through activating mTORC1 in NSCs and 
subsequently increasing post-traumatic neurogenesis. 
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CHAPTER 4 
ASSESSMENT ON EFFECTS OF A PHARMACOLOGICAL APPROACH 
TARGETING MTORC1 SIGNALING PATHWAY ON COGNITIVE FUNCTION 
IMPROVEMENT  
 
Hypotheses 
1) Ketamine treatment improves spatial learning and memory function after TBI, 
2) ketamine treatment enhances mTORC1 signaling in NSCs after TBI, and 3) 
ketamine treatment promotes post-traumatic neurogenesis. 
 
Introduction 
The results in chapter 3 demonstrated that mTORC1 signaling is mediating TBI-
enhanced NSC proliferation. Thus, I further tested if a pharmacological approach 
that targets mTORC1 signaling can promote NSC proliferation after TBI. This 
would thus enhance post-traumatic neurogenesis and improve cognitive function 
recovery. Although mTOR, especially mTORC1, has been recognized as a 
fundamental pathway regulating cell growth, proliferation, migration and survival, 
development of pharmacological approach mainly focused on its inhibition, 
mainly because of its active involvement in cancer progression (Laplante and 
Sabatini, 2012). Activation of mTORC1 is usually achieved by genetic 
modifications on its upstream negative regulator PTEN and/or TSC1/2 in animal 
studies (Magri et al., 2011, Park et al., 2008, Liu et al., 2010), which is not 
translatable to human studies. Although some small molecule inhibitors of PTEN 
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and combination of growth factors are able to activate mTORC1 activity (Walker 
et al., 2012, Walker et al., 2019, Liu et al., 2017), they are either not FDA-
approved or not able to cross the blood-brain barrier with peripheral delivery. To 
probe an FDA-approved blood-brain barrier permeable pharmacological 
approach activating mTORC1, I have chosen to test a sub-anesthetic dose of 
ketamine treatment in TBI model. 
Ketamine was initially synthesized as an NMDA receptor channel blocker 
in 1962. It has been widely used in clinics for anesthesia and pain management 
since its FDA approval in 1970. In the past two decades, ketamine has emerged 
as a therapeutic with rapid anti-depressant effects when used at a sub-anesthetic 
dose (0.5mg/kg in anti-depressant versus 1-4.5mg/kg in anesthesia) (Berman et 
al., 2000, Zarate et al., 2006). Mechanistic investigations demonstrated that 
ketamine dose-dependently activates mTORC1 signaling in the prefrontal cortex 
in rats, which is required for the rapid anti-depressant effect (Li et al., 2010). The 
activation of mTORC1 by ketamine only happens at the sub-anesthetic and not 
the anesthetic dose. This was the first proof of a sub-anesthetic dose of ketamine 
acting as an mTORC1 activator. My colleagues have used ketamine to activate 
mTORC1 signaling in aging NSCs. I demonstrated that ketamine promoted the 
proliferation of NSCs and enhanced neurogenesis in the aging mouse 
hippocampus (Romine et al., 2015). Thus, I hypothesized that ketamine can 
activate mTORC1 signaling in NSCs after TBI in young adult mice, which would 
subsequently enhance post-traumatic neurogenesis, and improve cognitive 
function recovery. To test the hypothesis, I treated animals with a sub-anesthetic 
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dose of ketamine at 10mg/kg, and tested spatial learning and memory function of 
injured and sham animals with or without ketamine treatment. My data 
demonstrated that ketamine treatment benefited spatial learning but not memory 
function recovery after TBI. Further histological assessments demonstrated that 
ketamine treatment can promote mTORC1 signaling in NSCs after TBI. However, 
the ketamine treatment did not enhance the level of post-traumatic neurogenesis, 
but instead showed some potential in promoting functional recruitment of post-
injury born neurons. Further studies are needed to illustrate the alternative 
mechanisms underlying the beneficial effects of ketamine on spatial learning 
function improvement post-trauma. 
 
Materials and methods 
Animal care 
Male C57BL/6 mice (n=110) at the age of 8 weeks were purchased from The 
Jackson Laboratory and were housed and cared as described in chapter 2. All 
procedures were approved by Indiana University Animal Care and Use 
Committee.  
 
Controlled cortical impact 
Mice were subjected to sham or CCI injuries at the age of 8 weeks, and surgeries 
were performed as described in chapter 2. Injury parameters were set at 3.5 m/s, 
1.0 mm, and 0.1 s.  
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Drug administration 
Ketamine was given 3 times daily at 4 h apart (10mg/kg in sterile water i.p.) for 2 
weeks after injury starting at 24 h after injury (n=30, Figure 4.1 A). Delayed 
paradigm was given with similar strategy except the first 2 doses were skipped, 
so the treatment started at 32 h after injury and also lasted for 2 weeks (n=20, 
Figure 4.2 A). BrdU (50mg/kg in sterile water, i.p.) was given once per day with 
the third ketamine injection for 2 weeks after injury (n=40).  
 
Morris water maze test 
Spatial learning and memory function was tested via Morris water maze test 
followed the protocol described by Vorhees and Williams (Vorhees and Williams, 
2006). Briefly, a 103 cm diameter circular water tank with a 10 cm diameter 
circular platform was used in the experiments. The water was colored opaque by 
a non-toxic soluble white paint, and the platform was submerged 1 cm 
underwater. Water temperature was adjusted to 18 °C. Mice in the water tank 
was recorded, and their routes were traced and analyzed by a TopScan software 
(CleverSys Inc.). The test consisted of 5 days training and probe trial 1 day after 
last training. In each day of training, every mouse was subjected to 4 successive 
trials with pseudo random start positions listed in Table 3, and the inter-trial 
interval was 1 min. For each trial, the mouse was released at designated start 
position facing the water tank wall. When the mouse located the platform and 
stayed on the platform for 3 s successively within 60 s of the test, it was 
considered escaped. If the mouse did not locate the platform within 60 s, the test  
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Table 3: Start positions for Morris water maze test. 
 Day1 Day2 Day3 Day4 Day5 
Trial 1 N SE NW E N 
Trial 2 E N SE NW SE 
Trial 3 SE NW E N E 
Trial 4 NW E N SE NW 
Adapted from Table 1 (Vorhees and Williams, 2006).  
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was stopped, and the mouse was guided to the platform and left on the platform 
for 15 s. After each trial, the mouse was put in a cage provided with towels, 
placed on a heating pad, and left in the cage for 1 min before the next trial. After 
all 4 trials, the mouse was left in a warm cage until its fur was dry and was placed 
back to the home cage. On the sixth day, the platform was removed from the 
water tank, and each mouse was released at the same novel start position (NE). 
They were tested in the water maze for 60 s, with their routes tracked and 
analyzed. The average time to find the platform was calculated from 4 trials each 
day of each mouse. The escape time on day 1 to day 5 was plotted to represent 
spatial learning function. The time spent in each quadrant on day 6 was 
calculated, time spent in the target quadrant was compared to the other three 
quadrants to show spatial memory function. Data were shown as average   
standard error. 
 
Immunohistochemistry and cell counting 
Brain tissues were collected and processed to immunostaining as described in 
chapter 2. To quantify mTOR activity in NSCs after TBI, 3 epicentral sections 
were processed to immunostaining against Sox2 and pS6. Sox2 positive cells in 
the SGZ and Sox2 pS6 double positive cells in the SGZ were counted. The ratio 
of double positive cells in the Sox2 single positive cells was calculated. Activation 
of mTOR in NSCs were expressed as ration of mTOR active NSCs in total NSCs. 
To quantify post-traumatic neurogenesis, neuronal activity, and active post-injury 
born neurons, every sixth section covering the whole hippocampus were 
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subjected to immunostaining against BrdU, NeuN, and c-fos. The numbers of 
BrdU NeuN double positive cells, c-fos NeuN double positive cells, and BrdU c-
fos NeuN triple positive cells were counted. Contours of GCL were drawn, and 
the area of GCL was measured. The cell density of post-injury born neurons 
were calculated by dividing the total number of BrdU NeuN double positive cells 
by the volume of GCL and expressed as cells/mm3. The numbers of c-fos NeuN 
and BrdU c-fos NeuN positive cells were calculated by multiplying the counted 
number by 6 and shown as total cells per dentate gyrus. 
 
Statistical analysis 
Behavioral data were analyzed by SPSS via repeated measures ANOVA 
followed by post hoc test. Histological data were analyzed by SPSS via two-way 
ANOVA followed by post hoc test. Significance was set at p<0.05. 
 
Results 
Ketamine treatment improved spatial learning function at long-term time 
point 
To assess if ketamine treatment can improve cognitive function recovery after 
TBI, I treated sham and TBI animals with a sub-anesthetic dose of ketamine 
(10mg/kg, i.p.) with a strategy of 3 doses every day, 4 h apart, for 14 days 
starting at 24 h after injury. I assessed the spatial learning and memory function 
of the mice 5 days and 33 days after the treatment (19 days and 47 days after 
injury) in Morris water maze (Figure 4.1 A).  
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Figure 4.1: Ketamine treatment improves long-term spatial learning function 
recovery. 
(A) A schematic shows the experimental design. Ketamine treatment starts at 24 
h after injury. (B-C) Spatial learning function tested by a 5-day training paradigm 
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in Morris water maze test at 3 weeks (B, n=21 for sham, n=15 for 
sham+ketamine, n=14 for TBI, n=10 for TBI+ketamine) and 7 weeks (C, n=23 for 
sham, n=15 for sham+ketamine and TBI, n=12 for TBI+ketamine) after sham or 
TBI surgery with or without ketamine treatment (*p<0.05, **p<0.01, ***p<0.001 
vs. sham. #p<0.05, ##p<0.01, ###p<0.001 vs. TBI. &p<0.05, &&p<0.01, 
&&&p<0.001 vs. sham+ketamine). (D-E) Spatial memory function in a probe test 
24 h after last training session in Morris water maze test at 3 weeks (D) and 7 
weeks (E) after sham or TBI surgery with or without ketamine treatment (*p<0.05, 
**p<0.01, ***p<0.001 vs. target quadrant).  
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In the 5-day session of spatial learning, all groups exhibited spatial 
learning ability, shown as mice spent less and less time to locate the hidden 
platform regardless of their groups (Figure 4.1 B, C). Whereas, the performances 
differed among the four groups. At 3 weeks after injury, sham animals spent 52.5 
s  1.7 s learning to find the hidden platform on the first day, gradually 
progressed, and ended the training session within 26.0 s  3.0 s on the fifth day 
(Figure 4.1 B). Compared to sham animals, CCI injured animals showed spatial 
learning functional deficits, as they started the training at similar level on the first 
day (52.0 s  2.9 s, p=0.890 vs. sham), gradually progressed but in a slower 
manner, and spent more time learning to locate the hidden platform than sham 
animals, especially on day 4 (38.2 s  4.6 s in TBI vs. 25.7 s  1.8 s in sham, 
p=0.013) and day 5 (39.3 s  4.9 s in TBI vs. 26.0 s  3.0 s in sham, p=0.019) 
(Figure 4.1 B). At 7 weeks after injury, animals were tested in the MWM again, 
and they exhibited memory of the test by locating the platform faster at the first 
day of training session compared to the first day of the previous training session. 
Meanwhile, sham animals continued to progress in the test by spending 33.6 s  
2.9 s finding the hidden platform on the first day and ending the training session 
within 19.2 s  2.2 s on the fifth day (Figure 4.1 C). Whereas spatial learning 
functional deficits in TBI animals persisted, thus they still performed worse than 
sham animals throughout the five-day session by starting slower on the first day 
(38.2 s  1.9 s) and ending slower on the fifth day (24.8 s  3.8 s), although the 
difference was not statistically significant. With ketamine treatment, sham 
animals performed consistently comparable to their non-treated counterparts 
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either in a short-term (Figure 4.1 B) or long-term (Figure 4.1 C) period after 
treatment. Whereas, ketamine treatment in TBI animals showed a transient 
adverse effect in a short-term period, as they performed even worse than TBI 
non-treated cohorts throughout the five-day training session, especially on day 4 
(50.5 s  4.7 s in TBI + ketamine vs. 38.2 s  4.6 s in TBI, p=0.039, Figure 4.1 B). 
In a long-term period after treatment, however, ketamine treatment instead 
improves spatial learning function in injured animals, as treated animals 
performed consistently better than their non-treated TBI cohorts, significantly 
faster on day 3 (18.1 s  2.5 s in TBI + ketamine vs. 32.3 s  3.6 s in TBI, 
p=0.011, Figure 4.1 C). 
In the 60 s probe test, sham animals showed spatial memory by spending 
much more time in the target quadrant, in which the hidden platform used to be, 
than in the other quadrants (Figure 4.1 D, E). Whereas, the TBI injured animals 
showed spatial memory functional deficits and failed to show preference for the 
target quadrant over the other quadrants in the probe test short-termly after injury 
(3 weeks, Figure 4. 1 D) or long-termly after injury (7 weeks, Figure 4.1 E). With 
ketamine treatment, sham animals exhibited a transient short-term spatial 
memory function defect, as they also failed to display preference for the target 
quadrant (Figure 4.1 D), which was spontaneously resolved in a long-term period 
(Figure 4.1 E). Whereas, for the TBI animals, ketamine treatment did not exhibit 
beneficial effects on spatial memory function, shown as the animals consistently 
spent comparable time in each quadrant and failed to show preference for target 
quadrant (Figure 4.1 D, E). 
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Collectively, TBI injured animals showed functional deficits in spatial 
learning and memory tests, and ketamine treatment improves spatial learning 
function recovery in a long-term manner while left spatial memory function 
unaffected. 
 
Delayed ketamine treatment maintained long-term beneficial effect and 
eliminated short-term adverse effect 
Although ketamine treatment showed a beneficial effect on spatial learning 
function recovery in a long-term manner, a transient adverse effect was observed 
shortly after treatment (Figure 4.1 B, D). I wondered if it is possible to sustain the 
beneficial long-term effects while minimizing the short-term adverse effects by 
modifying the treatment paradigm.  
As previously mentioned in chapter 3, mTORC1 signaling is activated not 
only in NSCs after TBI. It is also activated in microglia and peaked at 24 h after 
injury, the time point I started ketamine treatment. The ketamine treatment might 
also exaggerate microglia reactivation, which may contribute to the adverse 
effect. To minimize the adverse effect, I applied a delayed treatment strategy as 
an alternative, in which I removed the initial 2 doses and started the treatment at 
around 32 h after injury (Figure 4.2 A). By the delayed treatment, ketamine 
treatment no longer exhibited adverse effect, but contrarily, treated animals 
showed better performances than non-treated TBI cohorts both short-termly and 
long-termly after injury (Figure 4.2 B, C), although statistical significance was 
only detected on day 1 (45.0 s  2.5 s in TBI + ketamine vs. 56.8 s  1.7 s in TBI,  
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Figure 4.2: Delayed ketamine treatment alleviates short-term adverse effect on 
spatial learning function. 
(A) A schematic shows the experimental design. Ketamine treatment starts at 32 
h after injury. (B-C) Spatial learning function tested by a 5-day training paradigm 
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in Morris water maze test at 3 weeks (B, n=21 for sham, n=10 for 
sham+ketamine, n=8 for TBI, n=10 for TBI+ketamine) and 7 weeks (C, n=23 for 
sham, n=9 for sham+ketamine, n=10 for TBI, n=9 for TBI+ketamine) after sham 
or TBI surgery with or without delayed ketamine treatment (*p<0.05, **p<0.01, 
***p<0.001 vs. sham. #p<0.05, ##p<0.01, ###p<0.001 vs. TBI. &p<0.05, 
&&p<0.01, &&&p<0.001 vs. sham+ketamine). (D-E) Spatial memory function in a 
probe test 24 h after last training session in Morris water maze test at 3 weeks 
(D) and 7 weeks (E) after sham or TBI surgery with or without delayed ketamine 
treatment (*p<0.05, **p<0.01, ***p<0.001 vs. target quadrant).  
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p=0.002, Figure 4.2 B), and day 2 (38.6 s  5.5 s in TBI + ketamine vs. 52.6 s  
1.8 s in TBI, p=0.013, Figure 4.2 B) at 3 weeks after injury. In the probe test, 
delayed ketamine treatment was not able to improve spatial memory function 
recovery either in a short-term or long-term period as the previous paradigm, and 
injured animals still failed to display preference for target quadrant over other 
quadrants (Figure 4.2 D, E). Collectively, delayed ketamine treatment was able to 
remove the transient adverse effect on spatial learning function in injured animals 
while sustaining beneficial effects on spatial learning recovery after injury in a 
long-term period.  
 
Ketamine treatment activated mTOR activity in NSCs after TBI 
Since ketamine treatment was given systemically, it can target various 
mechanisms in the brain that may contribute to spatial learning recovery. I 
wondered if ketamine treatment benefits spatial learning function by activating 
mTORC1 signaling, and thus assessed mTORC1 activity in NSCs after TBI with 
ketamine treatment. I treated TBI injured animals with an intensive paradigm of 
ketamine treatment as a proof-of-concept, in which animals received ketamine 
injections (10mg/kg, i.p.) every 2 h for 24 h after injury (Figure 4.3 A).  
By immunostaining against Sox2 and pS6, I quantified mTORC1 activation 
in NSCs after TBI. As previously described in chapter 3, mTORC1 activation in 
sham animals is low and mainly locates in the mature neurons (Figure 3.2 A and 
B, Figure 4.3 B). The activation of mTORC1 in NSCs is very limited, as only 2.6% 
± 2.9% of Sox2 positive cells in the SGZ are also positive for pS6 (Figure 4.3 B,  
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Figure 4.3: Ketamine treatment increases mTORC1 signaling activation in NSCs 
after TBI. 
(A) A schematic shows the experimental design. (B-D) Immunostaining against 
pS6 (red) and Sox2 (green) shows mTORC1 activation in NSCs (indicated by 
white arrowheads) in sham (B), TBI (C), and TBI with ketamine treatment (D) 
animals. 4′,6-diamidino-2-phenylindole (DAPI) staining of nuclei shows GCL 
structure. (E) Percentage of pS6 and Sox2 double positive cells in total Sox2 
positive cells in the SGZ (n=3 for sham and TBI+ketamine, n=4 for TBI, *p<0.05, 
**p<0.01, ***p<0.001).  
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E). At 24 h after TBI, I again observed dramatic increase of mTORC1 activity in 
the SGZ, and specific activation of mTORC1 in NSCs was significantly increased 
(indicated by white arrowheads, Figure 4.3 C), as 63.2% ± 4.7% of Sox2 positive 
cells in the SGZ were co-labeled with pS6 (p<0.001 vs. sham, Figure 4.3 E). 
Moreover, after ketamine treatment, mTORC1 activity was further promoted in 
the SGZ and specifically in NSCs (indicated by white arrowheads, Figure 4.3 D), 
leading to 85.2% ± 7.4% of mTORC1 positive cells in total Sox2 positive cells in 
the SGZ (p=0.001 vs. TBI, Figure 4.3 E). This data serves as a proof-of-concept 
that ketamine treatment can further promote mTORC1 activation in NSCs after 
TBI.  
 
Ketamine treatment did not enhance post-traumatic neurogenesis nor 
alleviate post-injury born neuron mismigration 
Since ketamine treatment was able to further promote mTORC1 activation in 
NSCs after TBI, it is potentially able to enhance post-traumatic NSC proliferation 
and subsequent neurogenesis, which may underlie the spatial memory function 
improvement long-termly after injury. To evaluate if ketamine treatment benefits 
spatial learning function by enhancing post-traumatic neurogenesis, I labeled cell 
proliferation with BrdU along with the delayed ketamine treatment and 
determined post-traumatic neurogenesis after Morris water test (Figure 4.4 A). 
By immunostaining against BrdU and NeuN, post-traumatic neurogenesis 
was evaluated in each group (Figure 4.4 B-E).  In sham animals, I again 
observed BrdU positive cells mainly in the GCL, and largely co-labeled with  
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Figure 4.4: Ketamine treatment does not increase post-traumatic neurogenesis. 
(A) A schematic shows the experimental design. (B-E) Immunostaining against 
BrdU (green) and NeuN (red) shows post-traumatic neurogenesis in sham (B), 
sham with ketamine treatment (C), TBI (D), and TBI with ketamine treatment (E) 
animals. (F) Quantification of BrdU and NeuN double positive cells in the GCL 
(n=8 for sham and TBI, n=9 for sham+ketamine and TBI+ketamine, *p<0.05, 
**p<0.01, ***p<0.001). 
 163 
NeuN (Figure 4.4 B). The baseline of neurogenesis was 6177 ± 1082 cell/mm3 
(Figure 4.4 F). At 7 weeks after TBI, I again observed a dramatic increase of 
BrdU positive cells throughout the hippocampal dentate gyrus, including a large 
proportion in the ML, which were not co-labeled with NeuN, corresponding to 
robust glial response (Figure 4.4 D). BrdU and NeuN double positive cells 
primarily located in the GCL, and neurogenesis was significantly elevated to 
11532 ± 2662 cell/mm3 by severe injuries (p<0.001 vs. sham, Figure 4.4 F). With 
ketamine treatment, I observed a similar pattern of BrdU labeling, mainly in the 
GCL in sham animals (Figure 4.4 C) and throughout the hippocampal dentate 
gyrus in TBI animals (Figure 4.4 E). In the GCL, with NeuN co-labeling, post-
traumatic neurogenesis was assessed. Ketamine treatment did not change post-
traumatic neurogenesis in either sham (6229 ± 1043 cell/mm3 in sham + 
ketamine vs. 6177 ± 1082 cell/mm3 in sham, p=0.957, Figure 4.4 F) or TBI 
animals (9709 ± 2532 cell/mm3 in TBI + ketamine vs. 11532 ± 2662 cell/mm3 in 
TBI, p=0.068, Figure 4.4 F).  
Except for influences post-traumatic neurogenesis on the cell number 
level, ketamine might work through ameliorating abnormalities of post-injury born 
neurons to improve spatial learning function recovery. One of the issues reported 
on post-injury born neurons is their ectopic migration, as adult-born granule 
neurons are supposed to migrate from SGZ to inner GCL, but are observed to 
mismigrate to outer GCL and ML after injury (Ibrahim et al., 2016, Wang et al., 
2016a). To assess if ketamine amends mismigration issue of post-injury born 
neurons, I further evaluated the localization of post-injury born neurons in the 
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GCL. In sham animals, majority of post-injury born neurons migrated from SGZ 
to inner GCL (indicated by white arrows, Figure 4.5 A), the baseline of post-injury 
born neurons located in the outer GCL is around 13.1% ± 2.6% (Figure 4.5 E). 
After injury, some post-injury born neurons migrated to and stopped in the inner 
GCL (indicated by white arrows), while a large number of them migrated to outer 
GCL (indicated by white arrowheads, Figure 4.5 C). The rate of misplaced post-
injury born neurons in the outer GCL was dramatically increased to 32.1% ± 
11.4% (p<0.001 vs. sham, Figure 4.5 E). However, ketamine treatment did not 
alter baseline of mismigration rate in sham animals (Figure 4.5 B, 12.6% ± 2.6% 
in sham + ketamine vs. 13.1% ± 2.6% in sham, p=0.852, Figure 4.5 E) or 
alleviate the mismigration issue in TBI animals (Figure 4.5 D, 27.8% ± 5.0% in 
TBI + ketamine vs. 32.1% ± 11.4% in TBI, p=0.176, Figure 4.5 E). Collectively, 
ketamine treatment did not increase post-traumatic neurogenesis or alleviate 
mismigration of post-injury born neurons.  
 
Ketamine treatment potentially promotes activity of post-injury born 
neurons 
To benefit functional recovery, not only an adequate number of neurons is 
needed, but also normal neuronal activity is required for any neurons to be 
recruited to the network. As an NMDAR antagonist, ketamine might benefit 
functional recovery by regulating neuronal activity in the hippocampus, so I 
evaluated neuronal activity both overall in the hippocampal dentate gyrus and 
specifically in post-injury born neurons after injury or sham surgery with or  
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Figure 4.5: Ketamine treatment does not alleviate post-injury born neuron 
mismigration after TBI. 
(A-D) Immunostaining against BrdU (green) and NeuN (red) shows post-injury 
born neurons with normal migration to the inner one third of GCL (indicated by 
white arrows) and with ectopic migration to the outer two thirds of GCL (indicated 
by white arrowheads) in sham (A), sham with ketamine treatment (B), TBI (C), 
and TBI with ketamine treatment (D) animals. (E) Percentage of mismigrated 
post-injury born neurons. (n=8 for sham and TBI, n=9 for sham+ketamine and 
TBI+ketamine, *p<0.05, **p<0.01, ***p<0.001) 
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without ketamine treatment. By immunostaining against c-fos and NeuN, I first 
evaluated overall neuronal activity in the hippocampal dentate gyrus 45 min after 
MWM probe test. In all groups, I observed that c-fos positive cells primarily 
located in the GCL, and greatly co-labeled with NeuN, indicating neuronal 
specific c-fos expression (Figure 4.6 A-D). This is consistent with the roles of c-
fos as a functional marker for granule neurons in memory formation (Reijmers et 
al., 2007, Garner et al., 2012, Ramirez et al., 2013). By quantification, I found 
that the baseline of c-fos positive active neurons was 2940 ± 602 cells per 
dentate gyrus in sham animals (Figure 4.6 A, E). And the number was not altered 
either after injury (2799 ± 625 cells per dentate gyrus in TBI, p=0.778 vs. sham, 
Figure 4.6 E) or by ketamine treatment (3069 ± 759 cells per dentate gyrus in 
sham + ketamine, p=0.797 vs. sham, Figure 4.6 E). Not surprisingly, ketamine 
treatment did not change overall neuronal activity in the hippocampal dentate 
gyrus after injury either (3461 ± 766 cells per dentate gyrus in TBI + ketamine vs. 
2799 ± 625 cells per dentate gyrus in TBI, p=0.201, Figure 4.6 E).  
Since adult-born neurons undergo a process of morphological and 
functional maturation after birth, which can take up to months (Zhao et al., 2006), 
and ketamine treatment has been proved to promote immature neuron 
maturation at specific stage (Ma et al., 2017), I wondered if ketamine treatment 
possibly shapes newborn neuron maturation and thus enhances functional 
recruitment specifically of post-injury born neurons. By immunostaining against 
BrdU, c-fos, and NeuN, I then selectively assessed neuronal activity of post-
injury born neurons. In sham animals, I detected a limited number of triple 
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Figure 4.6: Ketamine treatment does not alter overall neuronal activity in the 
GCL. 
(A-D) Immunostaining against c-fos (cyan) and NeuN (red) shows overall 
neuronal activity in the GCL in sham (A), sham with ketamine treatment (B), TBI 
(C), and TBI with ketamine treatment (D) animals. (E) Quantification of c-fos and 
NeuN double positive cells in the GCL (n=4 for each group, n.s.=no significance). 
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positive cells (indicated by white arrowheads, Figure 4.7 A-C, 14 ± 8 cells per 
dentate gyrus, Figure 4.7 M), consistent with functional integration of adult-born 
granule neurons in spatial network (Kee et al., 2007). With ketamine treatment, I 
detected a similar number of triple positive cells in sham animals (indicated by 
white arrowheads, Figure 4.7 D-F, 12 ± 6 cells per dentate gyrus in sham + 
ketamine, p=0.872 vs. sham, Figure 4.7 M). After injury, I found a slight but not 
significant increase of post-injury born neuron activation (indicated by white 
arrowheads, Figure 4.7 G-I, 18 ± 2 cells per dentate gyrus in TBI, p=0.631 vs. 
sham, Figure 4.7 M). With ketamine treatment, the number of triple positive cells 
was further increased and thus suggested a potential promotion in functional 
recruitment of post-injury born neurons (indicated by white arrowheads, Figure 
4.7 J-L, 32 ± 10 cells per dentate gyrus in TBI + ketamine, p=0.165 vs. TBI, 
Figure 4.7 M). The numbers of triple positive cells in animals of all groups were 
very limited, which impeded the power of statistical analysis. Thus, further 
investigations on the activation of post-injury born neurons are needed to validate 
if injury itself with or without ketamine treatment indeed influences the functional 
recruitment of post-injury born neurons or not. Moreover, it would be interesting 
to study whether the functional recruitment of post-injury born neurons is 
regulated by hippocampal dependent behavior tasks or not. 
 
Discussion 
In order to take advantage of the molecular mechanism, namely mTORC1 
mediated post-traumatic NSC proliferation, that I have demonstrated in chapter  
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Figure 4.7: Ketamine treatment shows a trend of promoting functional 
recruitment of post-injury born neurons. 
(A-L) Immunostaining against BrdU (green), c-fos (cyan), and NeuN (red) shows 
active post-injury born neurons (indicated by white arrowheads) in sham (A-C), 
sham with ketamine treatment (D-F), TBI (G-I), and TBI with ketamine treatment 
(J-L) animals. (M) Quantification of BrdU, c-fos, and NeuN triple positive cells in 
the GCL (n=4 for each group). 
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3, sub-anesthetic anti-depressant dose of ketamine was used as an mTORC1 
activator. Although ketamine has been used in the clinics since the 1970s for 
anesthesia and analgesia treatments as an NMDAR channel blocker, its role as a 
potent mTORC1 activator at sub-anesthetic dose was not discovered until the 
2000s. Since its anti-depressant effect first reported in a small human study 
(Berman et al., 2000), more studies with larger patient group sizes confirmed the 
use of low-dose ketamine (0.5mg/kg) infusion as a rapid anti-depressant therapy 
to treatment-resistant depression patients either as single dose treatment (Zarate 
et al., 2006), or as repeated-dose (aan het Rot et al., 2010). Although the rapid 
onset of anti-depressant effects within hours is largely attributed to its direct 
regulatory roles in glutamatergic neurotransmission, the sustained influence up to 
a week after a single dose has suggested involvement of synaptic plasticity 
(Duman et al., 2019). Following mechanistic studies revealed that dose-
dependent activation of mTORC1 signaling and activity-dependent BDNF release 
are required for ketamine induced synaptogenesis mediated rapid and sustained 
anti-depressant effect (Li et al., 2010, Liu et al., 2012).  
In the current study, I took advantage of the mTORC1 activator role of 
ketamine and demonstrated that a sub-anesthetic dose of ketamine treatment is 
beneficial for post-traumatic spatial learning functional improvement in mice 
(Figure 4.1, 4.2). This beneficial effect was correlated to mTORC1 signal 
activation in NSCs after TBI as expected (Figure 4.3). However, it did not 
increase post-traumatic neurogenesis (Figure 4.4) or alleviate post-injury born 
neuron mismigration (Figure 4.5). Noteworthily, a trend was observed in which 
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there was an increase in functional recruitment of post-injury born neurons and a 
further increase by ketamine treatment (Figure 4.7), potentially contributing to the 
functional improvement. 
Interestingly, in my assessment of spatial learning and memory functions, 
I observed a preferential improvement of spatial learning but not memory 
performance after ketamine treatment (Figure 4.1 and 4.2). In set-up of the MWM 
test, the spatial learning function in the 5-day training period is more likely 
representing memory acquisition or formation process, whereas the spatial 
memory function assessed by the probe test 24 h after the training period is 
closely symbolizing the memory retrieval process (Nakazawa et al., 2004). 
Classically, it has been considered that environmental stimuli activate neurons in 
the EC and hippocampus through the circuit of entorhinal cortex layer II (EC II) → 
DG → CA3 → CA1 → entorhinal cortex layer V (EC V) to initiate memory 
formation, and the reactivation of neurons in the same circuit facilitates memory 
retrieval (Nakazawa et al., 2004). Recent studies have increased current 
understandings on the circuit and demonstrated that circuits for memory 
formation and memory retrieval largely converge while slightly diverge. A place-
learning dependent neuronal activity pattern along the EC II → DG projection 
was demonstrated essential for memory formation in visually guided navigation, 
and also required for memory retrieval (Qin et al., 2018), proving EC II and DG 
as essential and shared hubs for the memory circuits. Whereas, by cell-specific 
optogenetic inhibition, a study has pointed out that the CA1 → EC V projection is 
selectively indispensable for memory formation, whereas successful memory 
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retrieval requires an additional hippocampal sub-region, dorsal subiculum (dSub), 
and exclusively depends on CA1 → dSub → EC V pathway (Roy et al., 2017). In 
the model of TBI, the EC is remote from the injury site and my colleagues and I 
have not detected obvious cell death or tissue alteration in this region, whereas 
the hippocampus is largely damaged with dramatic mature and immature 
neuronal death in the DG, and sparse CA1 and CA3 pyramidal neuron death 
(Zhou et al., 2012, Gao et al., 2008, Wang et al., 2016a). I have not selectively 
assessed the damage of the subiculum in the TBI model. Collectively, damage of 
the shared nodes in memory functions including DG → CA3 → CA1 is possibly 
contributing to both aspects of the memory function deficits after TBI, whereas I 
cannot rule out the possibility that disruption in the subiculum also occurs and it 
possibly contributes to memory retrieval issues. These studies together bring 
about the possibility that in the TBI model, ketamine treatment might only 
alleviate damages in shared circuit components, like DG, CA3 and/or CA1, but 
neglect retrieval components, the subiculum. Thus beneficial effects were only 
observed in the spatial learning, the memory formation aspect, but not the 
memory retrieval aspect of the MMW test. Additionally, to fulfill the goal of 
escaping water maze task, the EC-hippocampus circuit is an essential core 
element in the full network, while more brain regions are required, like the 
superior colliculus, posterior cingulate cortex, and caudate nucleus (Garthe and 
Kempermann, 2013). It has been recently described that an analysis of the 
heterogeneous strategies used by mice instead of simple analysis on the escape 
time can help determine if a defect in the MWM task is hippocampus-dependent 
 174 
or not (Garthe and Kempermann, 2013). Thus, further detailed analysis of my 
behavior data by categorizing searching strategies might help us understand if 
ketamine benefits spatial learning function likely in a hippocampal circuit 
dependent manner or not. 
Although I observed increased activation of mTORC1 signaling in NSCs 
by ketamine treatment after TBI, post-traumatic neurogenesis was not 
correspondingly increased. This can result from unchanged NSC proliferation 
and/or newborn immature neuron survival issue. As discussed in chapter 3, 
mTORC1 is required for TBI-enhanced NSC proliferation. However, it works by 
driving RGL NSCs out of quiescence to alert state, but not directly initiate 
proliferation. The entrance of proliferation potentially depends on secondary 
signals. It is possible that ketamine promoted mTORC1 signal is able to keep 
RGL NSCs at the alert state for a prolonged period, but the lack of stimulatory 
signal and/or existence of inhibitory signal impedes the further enhancement on 
proliferation. Although NSC proliferation is the first step to initiate neurogenesis, 
the survival of immature neurons is another step affecting neurogenesis. More 
than 75% of newborn neurons would not survive in basal conditions (van Praag 
et al., 1999, Tashiro et al., 2006), while the survival rate of newborn neurons can 
be increased in an enriched environment (van Praag et al., 1999). Survival of 
newborn neurons depends on NMDA receptor mediated circuit integration, and it 
is locally controlled by astrocytes (Tashiro et al., 2006, Sultan et al., 2015). 
Additionally, microglia also play critical roles in newborn neuron integration and 
survival, depending on their modes of activation (Ekdahl, 2012). Although my 
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colleagues’ and my previous studies and others did not observe significant 
change on survival rate of newborn neurons after TBI (Wang et al., 2016a, Chen 
et al., 2016), I cannot rule out the possibility that ketamine treatment may also 
decrease newborn neuron survival by altering astrocyte and/or microglia 
activities, which may contradict the potential enhancement on NSC proliferation 
and lead to the unchanged neurogenesis. 
Noteworthily, the beneficial effect I observed in spatial learning tests is 
most prominent around 5 weeks after the ketamine treatment, indicating the 
involvement of a delayed mechanism. It roughly matches the time needed for 
proliferated NSCs to differentiate and become mature neurons (Bond et al., 
2015). This supports the potential contribution of post-injury born neurons to 
functional recovery. Correspondingly, I observed a trend of increased recruitment 
of post-injury born neurons with ketamine treatment (Figure 4.7), consistent with 
others’ observations (Soumier et al., 2016). Collectively, the data suggests that 
low dose ketamine might partially function to promote post-injury born neuron 
recruitment to enhance functional recovery. 
As discussed in chapter 3, mTORC1 signal is not only activated in NSCs 
after TBI. Instead, spared mature neurons, microglia and astrocytes all have 
mTORC1 activation at different time points post-trauma. By the systemic 
introduction of ketamine, I am highly likely boosting mTORC1 activation in 
various cell types, and any of them may positively or negatively participate in 
cognitive function recovery. Moreover, as an anti-depressant treatment, a sub-
anesthetic dose of ketamine has been reported to activate various mechanisms 
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besides mTORC1 signal (Duman et al., 2019). Among them, enhanced BDNF 
release and synaptogenesis are also applicable mechanisms in the case of post-
traumatic functional improvement with ketamine treatment. Further investigations 
with specific silencing of post-injury born via optogenetic or chemical genetic 
tools would help determine if post-traumatic neurogenesis is required for spatial 
learning and memory function recovery after injury, and if the beneficial effects of 
ketamine on the recovery depends on post-traumatic neurogenesis or not. 
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CHAPTER 5 
CONCLUSIONS 
 
Summary 
Traumatic brain injury patients suffer from cognitive dysfunctions, especially 
learning and memory impairments (Salmond and Sahakian, 2005). Hippocampal 
neuronal loss largely contributes to the problem (Wolf and Koch, 2016). The 
discovery of adult NSCs in the hippocampus provides great promise of utilizing 
the neuroregenerative approach to compensate cell loss. The work in current 
studies emphasizes research directed toward improving cognitive function 
recovery after TBI by taking advantage of endogenous adult hippocampal NSCs 
mediated neurogenesis to achieve neuronal replacement.   
Although it is widely agreed that NSCs respond to TBI by increasing 
proliferation (Chirumamilla et al., 2002, Braun et al., 2002, Ramaswamy et al., 
2005, Sun et al., 2005, Gao et al., 2009a), it is not consistently reported on 
whether TBI affects neurogenesis. The results in chapter 2 have depicted the 
baseline of post-traumatic NSC proliferation, immature neurons survival, and 
post-traumatic mature neuron generation after different severities of TBI. My 
results demonstrated that mild TBI does not change NSC proliferation, immature 
neuron number, or mature neuron generation. Moderate TBI increases NSC 
proliferation, but not immature neuron, or newborn mature neuron number. 
Severe TBI further increases NSC proliferation, increases immature neuron 
number, and promotes post-injury mature neuron generation. I speculated the 
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difference originated from the different cell death patterns induced by varying 
injury severities. This part of the work partially explains the pre-existing 
controversy in the field and sets the foundation for utilizing the process for 
neuronal replacement. 
Despite morphological and electrophysiological studies on individual post-
injury born neurons’ properties (Villasana et al., 2015, Sun et al., 2007, Emery et 
al., 2005), their anatomical and functional integration has not been well 
documented. In chapter 2, I used a pseudorabies viruses based neurocircuitry 
tracing system to assess if the injury environment alters the anatomical 
integration pattern of post-injury born neurons. The results demonstrated that 
post-injury born neurons not only receive signals from the well-known projections 
but also make connections with neurons in brain regions that have not been 
previously discovered innervating dentate gyrus. Additionally, post-injury born 
neurons have been recruited to function on its neurocircuit with neuronal activity 
in a standard housing condition and during spatial learning and memory behavior 
task. This part of work demonstrates the capacity of post-injury born neurons in 
network integration and supporting behavioral performances. 
One of the obstacles impeding the application of endogenous adult NSC 
mediated post-traumatic neurogenesis is the lack of a molecular target. In 
chapter 3, the current study demonstrated that mTORC1 is required for TBI-
enhanced post-traumatic NSC proliferation, and proved that mTORC1 is primarily 
required for TBI-enhanced RGL NSC proliferation. MTORC1 has been proposed 
to prime RGL NSCs to a de novo alert state, in which RGL NSCs are reversibly 
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released from quiescence, prepared for proliferation, but maintaining the ability to 
return to quiescence. This part of work provides a molecular target for utilizing 
endogenous NSCs mediated neurogenesis to compensate cell loss, and 
deepens current understandings on RGL NSC dynamics. 
Several clinical trials have been targeting post-traumatic neurogenesis to 
seek cognitive function improvement, yet none have succeeded. In chapter 4, a 
sub-anesthetic dose of ketamine treatment, an FDA-approved widely used drug, 
has been applied and proved beneficial for spatial learning function recovery. 
Furthermore, ketamine treatment has shown an effect on mTORC1 pathway 
activation in NSCs post-trauma without increasing post-traumatic neurogenesis. 
Ketamine treatment can also potentially increase the functional recruitment of 
post-injury born neurons. This part of work suggests the potential of ketamine as 
a treatment against post-traumatic cognitive impairments and reveals potential 
mechanisms through activating mTORC1 in NSCs and/or increasing functional 
recruitment of post-injury born neurons. 
Overall, the body of this thesis work proves the feasibility of compensating 
for neuronal loss in the hippocampus by functional post-injury born neurons. This 
work provides a potential molecular target to enhance endogenous 
neuroregenerative machinery and reveals the therapeutic effect of an FDA-
approved drug in cognitive function improvement post-trauma.  
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Future directions 
Although post-traumatic neurogenesis has been correlated to functional recovery 
(Lu et al., 2005, Kleindienst et al., 2005, Lu et al., 2003), no evidence has directly 
proven the essential roles of post-injury born neurons in the functional recovery. 
It is of great interest to further assess functional outcomes with optogenetic 
and/or chemical genetic silence on post-injury born neurons to prove the cause-
and-effect relationship between post-traumatic neurogenesis and functional 
improvement. Moreover, hippocampal neuronal loss is not the only mechanism 
underlying cognitive functional deficits, for axonal injury and dendritic and/or 
synaptic degeneration also contribute (Wolf and Koch, 2016). Thus, post-
traumatic neurogenesis is not the sole approach for functional recovery, axonal 
sprouting and dendritic and/or synaptic regeneration mediated network 
reorganization may also participate in functional restoration. It would also be 
important to determine to what degree post-traumatic neurogenesis contributes 
to behavioral restoration.  
Since I have demonstrated the essential role of mTORC1 signaling in the 
TBI-enhanced NSC proliferation, it would be critical to investigate the 
extracellular signals that selectively activate the mTORC1 pathway in NSCs. This 
might benefit NSC specific treatment while minimizing effects on other cell types 
that also have activated mTORC1 after injury, which would help to avoid 
potentially converse influences. Additionally, the proposed alert NSCs features a 
de novo node of NSC activity regulation. Further investigations on their cellular 
metabolism level, transcriptional and translational statuses, and epigenetic 
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profiling would help better distinguish alert NSCs from quiescent and active 
NSCs. Moreover, the fate decision mechanism at alert state controlling their 
return to quiescence or initiation of proliferation would be of great interest, since 
this could bring about new therapeutic targets on neuroregeneration, as well as 
on regenerative medicine in other organs. 
Although I chose ketamine as a pharmacological approach to target 
mTORC1 signaling in NSCs, there are other mechanisms that are potentially 
undergoing parallel activations. For instance, the neuroprotection and 
synaptogenesis actions of ketamine might also contribute to the functional 
improvement (Duman et al., 2019, Wang et al., 2017). Further investigations on 
the mechanisms of ketamine improved cognitive function recovery might benefit 
the therapeutic applications of ketamine on TBI patients. Since ketamine 
successfully activates mTORC1 in NSCs after TBI, it is of great interest to 
delineate the reason why neurogenesis is not subsequently enhanced. It would 
be helpful to study if ketamine failed to increase post-traumatic NSC proliferation, 
or the enhanced NSC proliferation is counteracted by survival issue, thus leads 
to unchanged post-traumatic neurogenesis.  
Besides ketamine, there are other reagents proved to be capable of 
activating mTORC1 pathway. Although they are not FDA-approved drugs yet, it 
is worth testing them in animal research to provide alternative avenues. For 
example, the combination of IGF-1 and osteopontin (Liu et al., 2017), the small 
molecule PTEN inhibitor bpv (Walker et al., 2019), and a new small molecule NV-
5138 in clinical trial led by Navitor Pharmaceuticals (Sengupta et al., 2019, 
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Walker et al., 2019) are good candidates as mTORC1 activators. Since mTORC1 
is implicated in neuroregeneration not only in regard to NSC proliferation but also 
in terms of axonal regeneration (Liu et al., 2010, Park et al., 2008), treatments 
aiming on mTORC1 can possibly hit multiple targets. Assessments on these 
different aspects would benefit the evaluation of treatment efficacy. 
Additionally, NSC proliferation is only the initial step of neurogenesis, 
while there are other critical steps of neurogenesis that worth targeting, like the 
survival of newborn neurons. As mentioned earlier, more than 75% of newborn 
neurons die after birth (Tashiro et al., 2006, van Praag et al., 1999), makes this 
step another target with great potential. It has been proved that a small molecule 
mimicking BDNF is effective in promoting newborn neuron survival after TBI 
(Zhao et al., 2016). A combinational approach targeting NSC proliferation and 
newborn neuron survival would be expected to amplify the benefits of post-
traumatic neurogenesis. 
 
Clinical translation 
My current study provides a potential target for utilizing endogenous hippocampal 
neurogenesis to seek cognitive functional improvement post-trauma; however, it 
is not close to clinical translation yet. TBIs in animals are studied in a precisely 
controlled manner, in which injuries are delivered by the exact same parameters 
at the same injury site to animals at the same age, with the same gender and 
genetic background who are raised in the same environment. However, human 
TBI cases are largely heterogeneous. Several animal models have recapitulated 
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some key differences in human TBIs, such as diffusive versus focal injury, 
closed-head versus penetrating injury, blast wave versus contusion injury, and 
single hit versus repetitive injuries, roughly represented the diversity of injury 
patterns in human (Hajiaghamemar et al., 2019). My result shows that even 
different severities of injuries generated by the same injury model can produce 
different effects on post-traumatic neurogenesis, it would not be surprising if 
different injury mechanisms differently influence the process.  
In addition to injury mechanisms, patient’s age may also complicate injury 
progression and recovery. In clinical observances, young children are more likely 
to suffer from neurological complications after TBI (Giza and Prins, 2006, 
Maxwell, 2012). While the elderly population shows relatively inferior functional 
outcomes under similar injury severities (Stocchetti et al., 2012). Although the 
difference may be attributed to increase of some age-dependent cellular 
mechanisms, such as apoptosis, oxidative stress, and inflammation, an extra 
contributor may be the age-dependent regenerative capacity decline (Fan et al., 
2003, Timaru-Kast et al., 2012, Sun et al., 2013). As mentioned in chapter 1, age 
itself negatively regulates neurogenesis. Juvenile animals have a higher 
neurogenesis baseline compared to adults, while aged animals show a drastic 
decline in neurogenesis (Sun et al., 2005, Jinno, 2011). However, how age 
affects injury progression and post-traumatic neurogenesis has not been widely 
studied. Most current studies on post-traumatic neurogenesis were conducted in 
adult animals, and few have focused on pediatric or geriatric TBIs. TBI happens 
to immature brains, including in childhood and adolescence; this can cause 
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profound issues in neural network development that may result in long-lasting 
complicated neurological and cognitive dysfunctions. Thus it is essential to 
extend studies on post-traumatic neurogenesis to pediatric settings and exploit 
selective strategy to target development rescue. A pediatric TBI study in rodents 
compared post-traumatic SVZ neurogenesis when injury happened at different 
developmental stages, and reported that post-traumatic cell proliferation in the 
SVZ increased in immature brains, but the response sharply declines as age 
(Covey et al., 2010). Sun and colleagues have similarly detected a greater post-
traumatic cell proliferation increase in the SGZ in juvenile rats compared to adults 
after a moderate FPI trauma (Sun et al., 2005). While the Nobel-Haeusslein 
group reported a decease in post-traumatic cell proliferation and neuronal 
differentiation at relatively same age in juvenile animals sub-acutely after injury 
(Potts et al., 2009). Collectively, current data suggests that immature brains 
respond to TBI robustly in the acute phase, but may suffer from sustained 
neurogenesis impairment chronically, potentially contributing to the profound 
neurological and cognitive dysfunctions after pediatric TBI. While for geriatric 
TBI, despite the remarkable prevalence of TBI in the elderly population, much 
less efforts were made to study how NSCs react to brain injuries in aged 
subjects. In other types of brain injuries, like stroke, even elderly patients 
exhibited increased NSC proliferation (Macas et al., 2006). TBI is highly likely 
able to stimulate NSC proliferation in elderly subjects, although the injury 
mechanisms vary. More endeavors should be made towards understanding how 
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NSC responses to TBI in the elderly group, and whether neuronal differentiation 
and survival happen.  
In line with current attentions with gender differences, a few studies have 
also reported differences in post-traumatic neurogenesis in males versus female 
animals (Cahill et al., 2018, Brydges et al., 2018). Collectively, by precisely 
assessing the effects of age and gender on post-traumatic neurogenesis, it would 
be possible to develop more specified treatment strategies targeting individual 
situations to enhance neural repair and approach personalized medicine in the 
future. 
More importantly, neuronal loss is not the only issue after TBI, and 
regeneration is not the only key to a cure to TBI. Although cognitive dysfunction 
is one of the most commonly complained symptoms post-trauma, other physical 
and neurobehavioral deficits are also widely reported and can persist chronically 
after injury. While these deficits are not discussed in the current study, they are 
also urgent problems in TBI research. There would not be a single silver bullet for 
TBI treatment, and combinational therapy is anticipated to provide the optimal 
strategy. For example, once a TBI patient get access to medical help, after or 
simultaneously with stabilization of intracranial pressure and hemorrhage, 
neuroprotective efforts might be considered as the first line of defense against 
neuronal loss and axonal and/or dendritic degeneration. Subsequently, 
neuroregenerative approaches might be considered as reinforcements to repair 
the inevitable damages and restore the functional network. Together potentially 
with neurotrophic and angiogenic endeavors, the injured tissue would be 
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replenished with newborn mature neurons that can properly function and 
adequately perfused by new neurovascular structure. Additionally, anti-
inflammatory interventions should be expected accordingly. Extra approaches, 
like hypothermia, aimed at extending the therapeutic window for neuroprotection, 
will be beneficial for the remedy as well. Only if there is a comprehensive 
understanding on the temporal profile of events occurring after TBI and their 
specific roles in the pathophysiology of TBI, a guide can be developed to operate 
therapeutic interventions in an appropriate manner. It is a long journey to achieve 
the current understanding of TBI. It is urgently needed to carry on the studies and 
elucidate the detailed mechanisms behind pathophysiological events. Only by 
these means, will it be feasible o develop better strategies to precisely target the 
mechanisms, ameliorate the issues, and restore normal functions in the brain.  
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Below are the statements regarding permissions from journals to use my 
first-author published manuscripts in my thesis: 
Part of content in chapter 2 was reprinted with permission from JOURNAL 
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Part of content in chapter 3 was reprinted with permission from eNeuro, 
published by the Society of Neuroscience. 
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